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PROLOGUE 
 
 
 
 
 
 
 
 
 
 
“Despite the difficulties which exist, the outlook for eventual control of acute pediatric 
respiratory disease is encouraging…. Thus, it would appear that most of the ingredients for 
successful immunoprophylaxis are now available and await only synthesis into an effective 
program for disease prevention”— Robert Chanock and Robert Parrott, 1965 
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ABSTRACT 
 
Human respiratory syncytial virus (RSV) is the primary cause of respiratory illnesses in infants, 
young children, elderly and immunocompromised individuals. Supportive care is the mainstay of 
RSV treatment. Currently no licensed vaccine against RSV is available. We have developed a 
subunit RSV vaccine candidate (ΔF/TriAdj) consisting of a truncated version of the RSVfusion 
protein (ΔF) formulated with a combination adjuvant (TriAdj) comprised of low molecular 
weight (LMW) polyinosinic:polycytidylic acid [poly(I:C)], an innate defense regulator (IDR) 
peptide and poly[di(sodium carboxylatoethylphenoxy)]-phosphazene (PCEP). We previously 
demonstrated the safety and protective efficacy of ΔF/TriAdj in several animal models. The 
overall objective of this thesis was to elucidate the mechanism of action of ΔF/TriAdj in BALB/c 
mice. First, we determined that ΔF/TriAdj when delivered intranasally plays a crucial role in 
stimulating innate immune responses in both upper and lower respiratory tracts of immunized 
mice as demonstrated by local production of cytokines, chemokines and interferons, as well as 
infiltration and activation of immune cells. Innate activation subsequently led to robustadaptive 
immunity and protection against RSV. Next, we elucidated the mechanisms of action of 
ΔF/TriAdj at the cell-signaling level in macrophages.Macrophages responded directly to in vitro 
stimulation with ΔF/TriAdj with induction of both endosomal and cytosolic pattern recognition 
receptors (PRRs). Based on inhibition studies, we determined that multiple signal transduction 
pathways are involved in ΔF/TriAdj-mediated activation of macrophages. Finally, we conducted 
a comprehensive chemical isotope labeling liquid chromatography-mass spectrometry (CIL LC-
MS) analysis of the lung tissues from vaccinated and unvaccinated, RSV-infected mice as well as 
healthy controls, to understand the underlying mechanisms of action of ΔF/TriAdj at the further 
downstream metabolomic level. Metabolomic profiling revealed alterations of tryptophan 
metabolism (including kynurenine pathway), biosynthesis of amino acids (including arginine 
biosynthesis), urea cycle and tyrosine metabolism due to RSV infection. Interestingly, ΔF/TriAdj 
was found to a play a critical role in modulating alterations in the concentrations of the 
metabolites of the above-mentioned pathways in response to RSV infection. 
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Ultimately, information on the mechanism of action of this RSV vaccine candidate may serve to 
identify potential biomarkers for immunogenicity and protective efficacy of ΔF/TriAdj in future. 
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CHAPTER 1 
1                          INTRODUCTION AND LITERATURE REVIEW 
 
1.1 Introduction of human respiratory syncytial virus  
In 1955, scientists working at the Walter Reed Army Institute of Research, United States isolated 
a virus from the nasal discharge of young chimpanzees with respiratory illnesses such as 
sneezing, coughing and mucopurulent rhinorrhea [1]. Initially named as chimpanzee coryza agent 
(CCA), Robert Chanock isolated CCA from two infants in 1956. One of them was suffering from 
bronchiolitis and the other one from pneumonia. Since the CCA in cell culture system produced 
characteristic multinucleated giant cells with formation of syncytia, Chanock proposed a new 
name for CCA, which was ‘respiratory syncytial virus’ (RSV) [2]. RSV formerly belonged to the 
subfamily of Pneumoviridae within the Paramyxoviridae. However, according to the latest virus 
taxonomy nomenclature by the International Committee on Taxonomy of Viruses (ICTV) in 
2016, Pneumoviridae itself is reclassified as a family with two genera, Orthopneumovirus and 
Metapneumovirus. Human RSV now belongs to the family Pneumoviridae and genus 
Orthopneumovirus and consists of subgroups such as A1, A2, B1 and B2 [3]. The genus 
Orthopneumovirus also includes viruses that infect bovines (bovine respiratory syncytial virus or 
BRSV) and rodents (pneumonia virus of mice or PVM). The genus Metapneumovirus contains 
human metapneumovirus and avian metapneumovirus.  
 
1.1.1 Epidemiology of RSV: Cited as the leading cause of acute lower respiratory tract infections 
(LRTIs) in children, RSV affects 60-70% of children by the age of one year with 2-3% requiring 
hospitalization and by the age of two years, RSV infects almost all children at least once [4]. A 
worldwide estimate of approximately 33.8 million new cases of acute LRTIs due to RSV are 
reported annually in children aged less than 5 years. Among them 3.2 million patients are 
reportedly hospitalised with an in-hospital death of 59,600 children in 2015 [5]. Overall, RSV is 
responsible for more than one million pediatric deaths annually, which is 10 times higher than the 
mortality rate due to influenza in infants less than one year of age [2]. 
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Reportedly, 99% of the deaths are in the developing world [6]. An estimated $700 million cost is 
incurred per year due to RSV-borne hospitalization of infants with bronchiolitis [2]. RSV is also 
a significant threat to infants with congenital heart diseases (CHDs) and causes aggravated 
complications in infants requiring surgery during an ongoing RSV infection [7]. RSV poses 
greater challenge to special populations such as children with neuromuscular diseases, infants 
with Down syndrome, cystic fibrosis and aboriginal children. RSV is a seasonal virus. In the 
temperate climate, annual outbreaks of RSV occur during the winter season, while in the tropical 
climate RSV infection prevails mostly during the monsoon season [8]. The onset of RSV wave 
was reported between March and June in the countries in the Southern hemisphere and between 
September and December in countries in the Northern hemisphere [5]. The RSV season lasts for 
5-6 months in most countries in both hemispheres.   
 
1.1.2 Clinical symptoms: RSV first infects the upper respiratory tract (URT) and then may also 
traverse down to infect the lower respiratory tract (LRT). Symptoms of the URT due to RSV 
infection include rhinitis, cough and coryza, as well as low-grade fever as manifested by the 
majority of RSV-infected children. On the other hand, symptoms of the LRT due to RSV 
infection include dyspnoea, subcostal recession and feeding difficulties. RSV infection in severe 
cases causes bronchiolitis that may lead to respiratory failure, bronchospasm and hypoxia [8]. 
RSV infection in early life predisposes a child to the development of recurrent wheezing, asthma 
and other pulmonary disorders later in the life. Premature infants are at increased risk of 
developing severe RSV disease and require intensive care unit (ICU) admissions and ventilation 
support. 
 
1.1.3. Pathogenesis of RSV: Environmental and social factors such as household smoking, 
presence of young siblings in the family, daycare attendance, nosocomial infection and traffic-
born pollution may increasethe risk of exposure to RSV [9, 10]. In addition, viral and host factors 
also contribute to RSV pathogenesis. 
Viral factors: Despite being not a highly cytopathic virus, several features of RSV have been 
linked to disease severity and pathogenesis. These include: (a) high infectivity, (b) non-
cytopathic or invasive nature, (c) limited antigenic and strain diversity, (d) very early infection in 
life, (e) reinfection, (f) tissue tropism, (g) characteristics of RSV proteins [such as non-structural 
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(NS1, NS2) proteins, attachment (G) protein and fusion (F) protein] and (h) effects on 
macrophages and DCs[10]. Being one of the most contagious viruses, RSV can infect 90% of 
infants and children in a daycare setting and is responsible for yearly epidemics. RSV is not very 
cytopathic or invasive within the epithelium and during a long replication cycle of 30-48h, there 
is only a modest decrease in total cellular DNA, RNA and protein synthesis without any gross 
histological effect on the infected cells. RSV causes infections, very early in life which greatly 
increases disease severity and risk because of characteristic underdeveloped features (such as 
narrower airways and hence greater susceptibility to RSV-induced airway obstruction), 
immunosuppression due to maternally derived antibodies, an immature immune systemand Th2 
biased immune responses in infants that can affect the quality of primary and memory responses. 
The ability of RSV to reinfect throughout life results in severe disease in infants, elderly and 
immunocompromised individuals.The ability of RSV to cause multiple reinfections greatly 
increases the risk of viral transmission to these susceptible populations. In terms of tissue 
tropism, RSV is mainly restricted to the superficial luminal cells of the respiratory airway tract. 
Since local immunoglobulin (Ig)As are short-lived, serum antibodies are required to gain access 
to the respiratory lumen by transudation, which is inefficient [11]. Moreover, RSV-specific 
cytotoxic T lymphocytes (CTLs) get functionally impaired after recruitment to the lungairways 
due to reduced content of granzyme B [10, 12]. RSV attenuates production of IFN-α/β by 
myeloid DCs (mDCs) and maturation of plasmacytoid DCs (pDCs). RSV also alters the cytokine 
secretion profile of macrophages and DCs, such as decreased production of IL-12 and increased 
secretion of IL-10, IL-11and prostaglandin E2 (PGE2), which impairs T cell activation and skews 
towards a T helper (Th)2 response. RSV inhibits upregulation of CCR7 on DCs known to be 
crucial in DC migration to LNs in response to CCL19 and as such, RSV impairs induction of 
adaptive immune responses. RSV also targets bone marrow stromal cells (BMSCs), which results 
in alteration of chemokine/cytokine induction, disruption of cytoskeletal filaments and 
impairment of B cell stimulation and maturation [9, 10]. 
Host factors: Host factors such as premature birth (<35 weeks of gestation), young age (<6 
months), low birth weight, bronchopulmonary dysplasia, congenital heart and chronic lung 
disease, developmental defects (unusually narrow airways), damage or hyperactivity of the 
airway, lack of breastfeeding, immunodeficiency or immunosuppression, low titres of RSV-
specific maternally derived antibodies and vitamin D deficiency in the cord blood of healthy 
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neonates, as well as male gender, all contribute to RSV pathogenesis [2, 9, 10]. In addition, 
genetic polymorphisms in genes involved in innate defense such as surfactant protein A (SP-A, 
SP-B, SP-C and SP-D), host cell receptor or intracellular signaling molecules [toll-like receptor 
(TLR)4, CD14, IL-4R, CX3CR1, CCR5], neutrophil and Th1/Th2 response genes (IL-4, IL-8, 
IL-10, IL-13, CCL5) and other gene effectors of adaptive immunity are contributing factors to 
RSV disease severity [9, 10]. Host response to RSV infection such as induction of IL-8 by 
epithelial cells and macrophages leads to influx of neutrophils and is linked to RSV-induced 
immunopathogenesis. Similarly, RSV-specific Th2+CD4+ T cells as well as CD8+ T cells are also 
implicated in RSV-induced immunopathogenesis. The host response to RSV infection involve 
elevated lung chemokines and cytokines such as IFN gamma-induced protein (IP-10), monocyte 
chemoattractant protein (MCP)-1, macrophage inflammatory protein (MIP-1)α, MIP-1β, 
regulated on activation, normal T cell expressed and secreted (RANTES), tumor necrosis factor 
(TNF)-α, IL-1, IL-6, IL-8, IL-17, IL-23 and IFNα/β [13].  
 
1.1.4 Management and Prevention of RSV: More than 60 years have passed since the discovery 
of RSV. However, RSV disease management is mainly restricted to supportive care. Although 
there is still no effective prophylaxis against RSV, there are several safe and effective passive 
pharmacological interventions that are able to ameliorate the disease outcome in high-risk and 
vulnerable patients. RSV is usually a self-limiting infection and does not always require medical 
interventions [14]. However, symptoms such as difficulty in feeding, respiratory distress or 
oxygen supplementation require urgent treatment and monitoring. Supportive care mainly 
involves adequate fluid intake, proper nutrition and mechanical ventilation support. 
Pharmacological interventions include bronchodilator, corticosteroids, antivirals, surfactants and 
anti-leukotrienes. Bronchodilators such as β-agonists, epinephrine and anti-cholinergic agents are 
used in infants suffering from wheezing due to RSV-induced LRT infections. However, their 
routine use is not supported [2]. Like bronchodilators, systemic corticosteroids are not 
recommended for routine treatment of bronchiolitis. Ribavirin, a synthetic nucleoside analog is 
the only licensed antiviral virustatic compound licensed for treatment of severe RSV infections. 
Routine use of ribavirin is not recommended as it is teratogenic and expensive. Furthermore the 
classical signs of bronchiolitis usually appear towards the end of viral replication in the lung. 
This is the timewhen immunopathology outcompetes RSV pathogenesis and hence, ribavirin does 
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not prove to be that effective. Exogenous administration of surfactants to infants with serious 
bronchiolitis-induced respiratory failure has been found to improve gaseous exchange of the 
airways. Since leukotrienes are released during RSV infection and plays significant role in airway 
inflammation and hyperactivity, administration of anti-leukotrienes is another strategy. However, 
the evidence in favor or against the use of anti-leukotrienes is not conclusive [2]. Hand washing, 
avoidance of tobacco smoking and breastfeeding to transfer maternal antibodies are some 
effective measures to prevent spread or contraction of RSV. In addition, immunoprophylaxis 
measures are also available (discussed in section 1.9.2).  
1.2 Composition of RSV  
The RSV virion consists of a nucleocapsid that is surrounded by a lipid envelope derived from 
the plasma membrane from the host cell. In cell culture, the virions appear as spherical particles 
measuring 100-350 nm in diameter and also as long filaments measuring upto 10 μm in length 
[10]. The virus is mostly associated with the cell surface. 
1.2.1 The genome of RSV: The RSV genome consists of a negative-sense, single-stranded, non-
segmented RNA of 15,000 nucleotides. A complementary copy of the genome called the 
antigenome is involved in RSV replication. Both the genome and the antigenome lack 5’caps or 
3’polyA tails with conserved promoter elements present in the first 24-26 nucleotides at the 
3’ends of the genome and the antigenome. Furthermore, both the genome and the antigenome are 
encapsidated by the nucleoprotein N and packaged in the form of a nucleocapsid. The 
nucleocapsid forms the template for RNA synthesis and serves to protect RNA from degradation. 
Italso helps the virus to evade recognition by the host cell’s pattern recognition receptors (PRRs).  
The genome of RSV encodes 10 transcription units that are sequentially transcribed to produce 
11 proteins in the following order (NS1>NS2>N>P>M>SH>G>F>M2-1>M2-2>L)[15]. The 
mRNAs are post-transcriptionally modified by methylated 5’caps and 3’polyA tails. Among all 
the transcriptional units, only that for M2 consists of two separate open reading frames that 
encode M2-1 and M2-2 proteins. At the 3’end of the genome, a 44-nucleotide long extragenic 
leader region is present preceding the NS1 gene. At the 5’end of the genome and following the L 
gene, a 155-nucleotide extragenic trailer sequence is present. 
1.2.2 RSV proteins: The RSV lipid envelope contains two transmembrane glycoproteins: F and 
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G, as well as a small hydrophobic (SH) protein [16]. The glycoproteins form separate homo-
oligomers distributed as spikes of short length (11-16 nm). The inner face of the envelope is lined 
by non-glycosylated matrix (M) protein. No neuraminidase or hemagglutinin activity is found in 
RSV. In addition to the surface glycoproteins and matrix protein, RSV contains four additional 
proteins, the nucleoprotein N, phosphoprotein P, transcription processivity factor M2-1 and the 
large polymerase subunit L protein [10]. The F and G glycoproteins are the only proteins that 
induce neutralizingantibodies and therefore, act as protective antigens.  
F protein: The F protein is 574-amino acids long and is responsible for viral penetration via host 
cellular membrane fusion and also for syncytium formation [17, 18]. Synthesized as an inactive 
F0 precursor, three such F0 monomers are assembled into a trimer. In the Golgi apparatus, the 
monomers are activated by cellular furin-like endoprotease and cleaved at two sites to produce 
three polypeptides, the N-terminal smaller F2 subunit, the intervening 27 amino acid peptide 
(pep27) and the C-terminal larger F1 subunit. The two subunits are linked to each other by two 
disulfide bonds. A single N-linked glycan in the F1 fragment is crucial for the F protein to cause 
fusion with the cellular membrane [19, 20]. On the virion membrane, the functional F protein 
trimers are present in a metastable pre-fusion conformation and during virus entry it rapidly 
undergoes refolding to change its conformation to the highly stable post-fusion state. The amino 
acid sequence identities of the F protein in both subgroups of RSV is 90% or higher. The RSV F 
protein also acts as a ligand for several cell surface proteins such as TLR4, intercellular adhesion 
molecule 1 (ICAM-1) and Nucleolin. Interactions of F protein with these receptors play 
important roles in attachment of virions to the host cellular membrane, triggering F protein to 
change its conformation from pre- to post-F and also in the activation of the innate immunity 
[18]. 
G protein: The G protein is 298-amino acids long and is the major virus attachment protein [21]. 
Replication of RSV takes place in some cell lines in the absence of G protein with equal 
efficiency as wild-type RSV. The G protein is the most variable protein between the two 
subgroups with only 53% amino acid identity and 1-7% antigenic relatedness. The G protein is a 
highly glycosylated protein with an extensive sheath of sugar side chains to shield the 
polypeptide backbone, thereby favoring immune escape from neutralizing antibodies. The 
receptors for G protein are identified to be CX3CR1, SP-A and Annexin II, while G protein has 
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also been demonstrated to interact with the lectins, DC-SIGN and L-SIGN on DCs [18]. The G 
protein has a CX3C motif in its sequence that mimics the CX3C chemokine fractalkine and thus 
impedes the infiltration of immune cells into the lungs of RSV-infected mice. The G protein also 
mimics the TNF-α receptor, thus preventing the anti-viral effects of TNF-α. Furthermore, the G 
protein acts on human DCs by interacting with its receptor DC-SIGN to alter antigen-
presentation pathways. In addition, activation of several TLRs (including TLR4) is inhibited by 
the central conserved domain of the G protein to counteract the activity of the F protein [10]. 
RSV infection also produces a truncated and secreted version of the G protein (sG) that acts as a 
decoy. The sG protein binds RSV-specific antibodies to decrease the availability of antibodies 
required for virus neutralization, as well as inhibits cell-mediated RSV neutralization by Fc 
receptor-positive cells. The sG protein also acts as a TLR antagonist and down-regulates 
inflammatory responses mediated by TLR2, TLR4 and TLR9 pathways. 
SH protein: The transmembrane SH protein is 64-amino acids long and anchored to the 
membrane at its N-terminus while the C-terminus is located extracellularly. Different 
glycosylated and non-glycosylated forms of SH protein are found in different strains of RSV 
[22]. For instance, RSV strain A2 contains four isoforms of SH protein, the full-length 
unmodified non-glycosylated (SH0), N-linked glycosylated form (SHg), polylactosaminoglycan-
modified form (SHp) and a truncated form of SH0 (SHt). Although the functions of SH proteins 
are not well understood, it is implicated that the primary role of SH protein is to act as a viroporin 
by forming pentameric pore-like structures with cation-selective channel-like activity [10]. In this 
way, the SH protein modifies membrane permeability that affects budding and apoptotic 
processes. The SH protein is involved in the survival of RSV in vivo to a certain extent although 
not essential for viral replication in vitro [18]. The SH protein is also known to inhibit the activity 
of the antiviral TNF-α [10]. 
Non-structural proteins and their role in inhibiting multiple members of cellular IFN pathways: 
Two non-structural NS1 and NS2 proteins are encoded by two promoter-proximal genes. Since 
they are encoded from the first two transcription units, the NS1 and NS2 transcripts are abundant 
and produced early in infection.  They are accessory proteins and are not packaged into mature 
virions and expressed only in infected cells [15, 23]. The NS1 and NS2 proteins are known for 
their antagonistic properties against both cellular antiviral responses as well as IFN transcription. 
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The NS proteins subvert the host’s innate immune responses by blocking type I IFN induction as 
well as signaling at various steps [23]. 
While the NS1 protein co-localizes with the downstream adaptor protein IFN-beta 
promoter stimulator 1(IPS-1) to inhibit retinoic acid-inducible gene I (RIG-I)/IPS-1 interaction 
required for type I IFN signaling via the transcription factor, IFN regulatory factor (IRF)3, the 
NS2 protein itself interacts with RIG-1 to antagonize type I IFN induction. Thus both NS1 and 
NS2 inhibit RIG-I/IPS-1 signaling [24], with RSV NS2 targeting both IFN induction (blocking 
RIG-I activation) and IFN signaling pathways (inhibiting IRF3 activation).  
The TNFreceptor-associated factor 3 (TRAF3) serves as a strategic point of signaling 
where both RIG-I and TLR signal transduction pathways converge to trigger type I IFN 
induction. Both NS1 and NS2 proteins inhibit TRAF3, with NS1 being more efficient in reducing 
the levels of TRAF3 via a non-proteasomal mechanism. The NS1 protein also decreases IRF3 
kinase, [IκB kinase (IKK)ε] involved in induction of type I IFNs. Furthermore, the NS1 protein 
acts as an ubiquitin E3 ligase to degrade STAT2 [24-26].Both NS1 and NS2 promote 
ubiquitination of STAT2. Degradation of STAT2 leads to inhibition of type I IFN signaling. Thus 
RSV NS1/NS2 proteins target at least three critical signaling molecules of type I IFN induction 
pathways i.e. TRAF3, IKKε and STAT2. Loss of IKKε further decreases downstream type I IFN 
signaling, while loss of STAT2 altogether results in abrogation of the cell’s response to IFN due 
to blockade of JAK-STAT signaling [25]. 
Suppressor of cytokine signaling (SOCS) acts as a negative feedback loop to block the 
JAK-STAT signaling pathway and inhibit type I IFN induction in the host [24, 26]. RSV NS1 
and NS2 upregulate both SOCS1 and SOCS3 leading to loss of STAT2 and STAT1/2 
phosphorylation, while NS2 induces upregulation of only SOCS1. This upregulation of SOCS 
proteins takes place at an early stage of infection before the activation of endogenous IFN 
signaling. Thus, RSV activates a potent mechanism to attenuate innate antiviral responses before 
the endocrine IFN could get activated. This upregulation of SOCS1 and SOCS2 by NS proteins 
suppresses the induction of type 1 IFNs, IFN-stimulated genes (ISGs) and TLR3-dependent 
chemokines responses [24]. Therefore, RSV replication can continue successfully in the absence 
of any antiviral signaling [26]. Furthermore, NS1 protein inhibits the proliferation and activation 
of protective CD8+ T cells and Th17 cells via monoubiquitination of interacting proteins and 
promotes proliferation and activation of RSV disease-enhancing Th2 cells. While NS2 promotes 
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induction of regulatory T cells (Tregs), NS1 suppresses the production of Tregs. Absence of 
Tregs is implicated in immunopathology and enhanced RSV disease [23].  
Other proteins:The M protein consists of 256amino acidsand plays an important role in virion 
morphogenesis [27]. Detection of M protein in the nucleus earlier during infection suggests a role 
of this protein in inhibiting host transcription while detection of M protein later in the 
cytoplasmic viral inclusion bodies and plasma membrane suggests a role of M protein in viral 
RNA synthesis and virion formation, respectively. M protein is also required in the transport of 
nucleocapsids from viral inclusion bodies to the plasma membrane. The N protein is 391-amino 
acids long and both the genome and antigenome are tightly bound by N protein to form helical 
nucleocapsids that serve as the template for RNA synthesis [28]. The function of N protein is to 
antagonize the host’s innate immunity by binding to double stranded (ds) RNA-inducible protein 
kinase R (PKR), thereby preventing eukaryotic initiation factor (eIF)-2α phosphorylation and 
subsequent translation. The P protein is another RSV protein, which is 241-amino acids long and 
is the major phosphorylated RSV protein [10]. It serves as an essential polymerase co-factor. The 
P protein binds to N, M2-1 and L protein mediating interactions in the nucleocapsid/polymerase 
complex. Binding of P protein to free N protein precursors prevents self-aggregation of N protein 
or binding of N protein to non-viral RNA. The RSV genome also encodes the L protein, which is 
2165-amino acids long and represents polymerization-related catalytic domains. Finally, the M2-
1 is 194-amino acid long and is an essential transcription processivity factor. Interaction of M2-1 
protein with RNA or the P protein is required for the ability of M2-1 to support RNA synthesis. 
The M2-2 protein is 88 or 90-amino acids long and may be involved in regulation of RNA 
synthesis [29]. 
 
1.3 Animal models of RSV  
 
An ideal animal model that can mimic human RSV disease in vivo is an indispensable 
requirement not only for understanding RSV pathogenesis, but also for the development of novel 
prophylactic or therapeutic treatments against RSV. It is very difficult to identify an appropriate 
animal model for RSV. Most of RSV infections in healthy adults are resolved by itself with 
display of only mild symptoms and therefore, no medical intervention is required and hence, no 
samples are collected. Furthermore, in the case of severe infections that primarily involve the 
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LRT, collection of specimens mostly includes peripheral blood cells, nasal washes and lung 
aspirates, as direct sampling from the LRT is unethical and not feasible [9].  
 
1.3.1 Heterologous animal models 
Chimpanzee: As mentioned earlier, the chimpanzee was the animal species from which RSV was 
first isolated in 1956 [1]. Chimpanzees support RSV replication and allow monitoring of URT 
disease symptoms such as rhinorrhea, coughing and sneezing. There is some evidence that acute 
respiratory distress symptom such as fatal bronchopneumonia and extensive histopathological 
changes (such as neutrophil infiltration and edema) can occur in chimpanzees upon RSV 
infection. Other advantages with this model include genetic and anatomical similarity to that in 
humans. However, there are a number of obvious logistical, economical, emotional and ethical 
concerns that greatly limit working with this animal model [30].  
 
Sheep: Sheep are susceptible to both ovine and bovine RSV, while lambs can also be infected 
with RSV to develop both upper (ex. coughing) and lower respiratory tract (ex. bronchiolitis, 
apoptotic changes in the airway alveolar walls) disease. Other advantages of working with sheep 
and lamb models include similar structural features of the respiratory tract such as the size and 
organization of lymphoid tissues. However, high cost, limited availability of reagents and 
handling/housing makes it challengingto work with this model [30]. Newborn lambs have airway 
structuresand functions that are similar to that in human infants. In terms of pathology, the 
features are quite similar between lambs and humans in terms of development of bronchiolitis 
with the characteristic degeneration and sloughing of epithelial cells, intraluminal infiltration of 
neutrophils and peribronchiolar infiltration of lymphocytes and plasma cells. Therefore, lamb 
model is considered as an attractive model to examine RSV pathogenesis [9].  
 
Cotton rat: Cotton rats (Sigmodon hispidus) belong to the order Rodentia and are considered as 
the standard animal model to study RSV pathogenesis, drug testingand evaluation of vaccines. 
This is due to the fact that the pulmonary pathology induced by RSV in cotton rats is similar to 
those in humans. The cotton rat is a semi-permissive model for RSV replication and supports 
~100-fold more replication than that inbred mice [30, 31]. Upon intranasal inoculation with RSV 
in cotton rats, virions can be detected in both upper and lower respiratory tracts with viral 
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replication predominantly occurring in the lower respiratory tract. Disadvantages of working with 
this model include limited availability of reagents, unavailability of transgenic or knockout 
strains of cotton rat as well as special handling [30]. 
Mouse: Considered as the most popular animal model, the inbred mouse is a semi-permissive 
host for RSV, with BALB/c being more susceptible than other strains. However, a very high 
intranasal inoculum is required for detection of LRT disease symptoms and other signs of general 
illness. Moreover, different strains of RSV (ex. RSV A2, long strain and clinical isolates such as 
Line 19, RSV 2-20) have different effects on mice [32-34]. Like in humans, RSV infection in 
young mice causes increased airway hyperactivity, mucus production, influx of eosinophils and 
Th2 responses upon reinfection later in life. The mouse model has several advantages such as 
easy availability of reagents and knockout strains, availability of molecular tools and easy 
handling/housing. However, the mouse is not a natural host for RSV and replication of RSV is 
not robust in this model. The anatomy of the lung in the mouse is very different from that in 
humans. Furthermore, there are differences in the innate and adaptive immune responses to RSV 
in mice when compared to humans in terms of induction of cytokines/chemokines, PRR signaling 
and cell surface expression of immune markers on leukocytes and lymphocytes [30]. 
 
1.3.2 Cognate host-Pneumovirus models 
Cattle-BRSV: Comparisons of pathogenesis between BRSV in cattle and RSV in humans reveal 
many similar characteristics such age-dependency in the development of disease (ex. BRSV 
infection is most severe in calves than adults, similar to RSV which is also most severe in 
neonates than in adults) as well as clinical signs and symptoms involving both the URT and LRT. 
Furthermore, bovine and human RSV are antigenically similar. Like RSV in humans, BRSV is a 
natural pathogen in cattle. However, there are several logistical issues associated with working on 
this model such as the high cost, limited availability of reagents and housing/handling. Moreover, 
co-infection of natural BRSV with bacterial pathogens such as Mannheimia haemolytica, 
Pasteurella multocida or Haemophilus somnusis a distinguishable feature from that of natural 
RSV infection in humans [30, 35, 36]. 
Mouse-PVM: In contrast toRSV infection in inbred mice,PVM replicates to a high titre with a 
minimum amount of viral challenge inoculum, in the lung of BALB/c mouse [37, 38]. PVM 
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infection in mice induces clinical signs and symptoms of severe LRT disease with a marked 
weight loss and a potentially high mortality rate. Similar to RSV infections in humans, PVM in 
mice is greatly dependent on the age of the animals with respect to disease pathogenesis. The 
PVM model serves as an attractive strategy in the development of prophylactic and therapeutic 
treatments against RSV. Disadvantages of this model include the obvious antigenic differences 
between RSV and PVM [30]. 
 
1.4 Intrinsic and innate immune responses against RSV  
 
Intrinsic and innate immune responses play an important role in controlling RSV infection in the 
initial stages of infection [39]. Innate immunity is a critical determinant of the outcome of RSV 
infection as well as the adaptive immune responses that ensue RSV infection [40]. 
 
1.4.1 Intrinsic factors: Pulmonary surfactant is known to provide the first line of defense against 
RSV. It consists of a layer of phospholipids (lecithin and sphingomyelin) in combination with 
surfactant proteins. Surfactants decrease the surface tension in alveoli and bronchioles [2]. A 
decrease in surfactant A, B and D concentrations have been reported in the bronchioalveolar 
lavage fluids (BALFs) from RSV-infected infants under ventilation. The function of surfactant 
proteins involves binding to surface oligosaccharides on pathogens to mediate opsonization and 
complement activation [8]. Surfactant D promotes production of free radicals by alveolar 
macrophages [2]. 
 
1.4.2 Innate components: Accounting for 93% of cells in the upper airway and 76% in the lower 
airway of RSV-infected neonates, neutrophils (phagocytic cells) are clearly the most important 
and major cell type involved in the innate immune response against RSV and also involved in 
RSV pathogenesis and bronchiolitis [41]. Macrophages and respiratory epithelial cells are the 
two cell types that first encounterRSV in the airway [42]. These cells produce cytokines such as 
TNF-α and chemokine IL-8, which is responsible for the chemotaxis of neutrophils. These 
cytokines and chemokines also play an important role in increasing vascular permeability and 
result in recruitment and activation of lymphocytes, neutrophils and natural killer (NK) cells to 
the site of infection. The secretion of IL-8 in the nasopharyngeal aspirates and BALFs from 
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infants suffering from RSV-induced bronchiolitis reveals significant correlation with disease 
severity [8]. 
The role of eosinophils in immune responses against RSV is debatable. Eosinophil 
chemoattractants, such as CCL3 and CCL5, are upregulated by RSV-infected respiratory 
epithelial cells. There are reports of eosinophil degranulation in both nasopharynx and lung 
parenchyma and elevated levels of blood eosinophil cationic protein (ECP) observed in infants 
with RSV bronchiolitis [43, 44]. However, eosinophils constitute only up to 8% cellular 
infiltrates in the airway lavages from asthma patients. Interestingly, eosinophils have not been 
identified in RSV-infected lung during primary RSV infection in both human and murine studies.   
Accumulation of NK cells occurs in the first few days of infection. NK cells are activated 
by TNF-α, IL-12 and IFN-β [44]. NK cells are the major producers of IFN-γ early during 
infection. The decrease in MHC-I expression in virus-infected cells is used as an identification 
feature by the NK cells to recognize these cells and destroy them by cytotoxic actions [8].  
Innate immune sensors such as PRRs including TLRs, RIG-I-like receptors (RLRs) and 
nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs) are all involved in the 
detection of RSV [45]. Among TLRs, TLR2/6 are activated by RSV to induce production of pro-
inflammatory cytokines and chemokines, but not type I IFNs, via the Myeloid differentiation 
(MyD)88-dependent signaling pathway [45]. Induction of CD14 and TLR4 by RSV F protein via 
MyD88 and TIR-domain-containing adapter-inducing IFN-β (TRIF) is another mechanism of 
activation of the innate immune system by RSV [46]. The endosomal TLR3 is activated by RSV 
dsRNA (an RSV replication intermediate) via the TRIF-dependent signaling pathway to induce 
type I IFN production, while the endosomal TLR7 is activated by the RSV single stranded (ss) 
RNA genome to induce production of both type I IFNs and pro-inflammatory cytokines via the 
MyD88-dependent signaling pathway [45]. The cytosolic RLR sensors such as RIG-I and 
melanoma differentiation-associated protein 5 (MDA5) are activated by RSV dsRNA or 5’-
triphosphorylated uncapped RSV RNA. This leads to interaction with IPS-1, an adaptor protein, 
and ultimately results in induction of type I IFNs and pro-inflammatory cytokines via IRF3 and 
NF-κB-dependent signaling pathways. RSV single-stranded RNA is also recognized by the 
cytosolic Nod2 receptor and participates in induction of IFN-β via the IPS-1-mediated signaling 
pathway. RSV can also activate the NLRP3 inflammasome receptor to induce production of IL-
1β [45]. 
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1.5 Adaptive immune responses against RSV  
 
Adaptive immune responses against RSVare characterized by immunological memory and clonal 
expansion of lymphocytes with antigen-specific receptors. 
 
1.5.1 Humoral immunity against RSV: Humans develop antibodies to most RSV proteins. 
However, only the F and G proteins induce production of potent protective neutralizing 
antibodies [47, 48]. Newborn babies acquire RSV neutralizing maternal antibodies through 
transplacental transfer and colostrum. The maternal RSV-specific antibodies are protective 
against severe RSV-associated illnesses [49, 50]. However, the half-life of these antibodies is 
only approximatelyone month (also reported as 2.5 months elsewhere). Following birth, the 
maternal antibodies decline rapidly and by 6 months of age, their number is too low to confer 
protection [49, 50]. Extension of this period of protection in an infant against RSV is possible by 
the presence of higher level of antibodies in the mother. This can greatly reduce RSV-induced 
morbidity and mortality in early infancy [49]. Maternal immunization can boost maternal 
antibody levels (discussed in section 1.9.1). RSV infection also leads to the production of 
antibodies in the serum, with infants developing lower antibody titres than older children and 
adults. IgM is the first antibody isotype that is generated within a few days of primary RSV 
infection and can be detected in the serum for 1-2 weeks before the IgG isotype appears in the 
second week, reaches a maximal level in the fourth week and then declines after 1-2 months. A 
high titre (>1/100) of RSV neutralizing antibodies in the serum is more likely to protect children 
from RSV-induced bronchiolitis than a low titre [8]. Domachowske et al also reported that 
children with RSV-neutralizing antibody titres greater than 1:100 manifested significantly lower 
RSV-induced LRT infections than infants with lower titres [51]. RSV infection also elicits 
secretory antibody response of IgA and IgG isotypes that confer protection from RSV infection in 
the URT and LRT [52]. The levels of all antibody isotypes increase upon reinfection. The IgE 
isotype is implicated in immunopathogenesis as infants with high IgE levels manifest symptoms 
such as recurrent wheezing and acute bronchiolitis [8]. 
 
1.5.2 Cell-mediated immunity (CMI) against RSV: CMI is required to combat an infection that 
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has already been established and mediateselimination of the virus-infected cells. Children with 
deficient CMI against RSV shed virus for months in contrast to healthy children who clear the 
virus within weeks. Both CD8+ CTLs and CD4+ Th cells are thought to have both antiviral and 
immunopathogenic functions. The CTLs have been found to promote viral clearance from lungs, 
but can also causelung injury in mice. This indicates that a strong,but not excessive CD8+ T cell 
response helps in recovery from viral infection without causing any harm to the host [53]. A 
positive correlation has been observed between RSV-specific CTL levels and IFN-γ [8]. 
Although RSV-induced bronchiolitis has primarily been associated with a Th2 response, limited 
evidence existsfor the role of Th2 cytokines in RSV-induced bronchiolitis. According to some 
reports, a higher IL-4/IFN-γ ratio was observed in stimulated peripheral blood mononuclear cells 
(PBMCs) isolated from children with RSV bronchiolitis compared to PBMCs isolated from 
healthy children [8, 54]. However, according to other studies, an increased concentration of IFN-
γ was observed in nasopharyngeal secretions from RSV-infected infants. Furthermore, the 
predominant cytokines in RSV patients irrespective of disease severity were indicative of a Th1 
response [8, 55, 56]. Factors such as the cytokine milieu present at the time of antigen priming as 
well as immunomodulatory cells such as CTLs may play important roles in determining or 
controlling the Th1/Th2 cytokine responses in humans during RSV infection [8]. 
 
1.6 Hurdles in the development of RSV vaccines  
 
1.6.1 Immune evasion: RSV has evolved various strategies to escape host immune responses. 
RSV selectively infects the superficial airway epithelial cells, ciliated cells of small bronchioles 
and pneumocytes lining the alveoli [57]. Thus, the antigen-sensing cells usually located in the 
underlying basal epithelium never get the chance to scan the viral particles and fail to initiate any 
immune response. While RSV flips rapidly from pre-F to post-F conformation to mediate fusion 
with the host cellular membrane, the pre-F neutralizing epitopes are shielded in this process. This 
leads to avoidance of any pre-F-specific neutralizing antibody by RSV [58]. In addition, RSV 
interferes with the host anti-viral type I IFN responses using its non-structural (NS1 and NS2) 
proteins, or alters DC signaling with the help of G protein [23, 59].  
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1.6.2 Early and late age of infection: RSV targets people of two extreme age groups, the infants 
and the elderly, who represent the two most susceptible high-risk populations. The infant 
population, especially the neonates, present the greatest challenges for RSV vaccine 
development. As the immune system of infants is underdeveloped or immature with no capacity 
for affinity maturation and somatichypermutation of their antibodies until 4-5 months of age, they 
do not respond well to a vaccine and may demonstrate only a limited B cell repertoire. Children 
aged between 6 months and 2 years are still at risk for vaccine-enhanced disease since they may 
be still RSV naïve [60]. Moreover, the maternal antibodies in newborns and infants <6 months of 
age provide partial protection, but may also reduce antibody production after vaccination. In the 
elderly population, the presence of pre-existing immunity may make it very challenging to 
provide a further boost by vaccination [60]. The presence of pre-existing antibodies from 
previous natural infections may neutralize the vaccine and hence are often associated with 
decreased responses to vaccination in the older adults. Other risk factors include underlying old-
age-associated disease conditions such as chronic pulmonary and cardiac diseases, and 
immunosenescence that might contribute to a reduction in the number of antibodysecreting cells 
(ASC), and antigen-specific effector memory CD4+ and CD8+ T cells.  
 
1.6.3 Identification of the relevant vaccine antigen: As discussed earlier, the lipid envelope of 
RSV contains F, G and SH proteins. The G protein is a subject of debate, whether to use it in 
clinical trials or not, due to its role in virus-induced enhanced disease [61]. The SH protein is 
currently in a phase-1 clinical trial conducted by ImmunoVaccine Technologies. The F protein is 
considered as a potentially better vaccine candidate as it can elicit broadly neutralizing 
antibodies. Moreover, the efficacy of Palivizumab, a monoclonal antibody directed against F 
protein, is already established. In 2013, the structure determination of F protein revealed two 
distinct conformations, the metastable pre-F and the highly stable post-F [62]. The post-F protein 
has been historically used as the main protective antigen. This is due to the instability of the F 
protein in its pre-fusion conformation, which converts easily into the stable post-F conformation 
both in solution and on the surface of the virion [63]. The pre- and post-F conformations of the F 
protein share the common antigenic sites II and IV. However, the crystal structure of pre-F 
revealed three additional unique antigenic sites (φ, III and V) that are highly neutralization 
sensitive, φ in particular. A subset of highly neutralizing antibodies (5C4, AM22 and D25) binds 
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specifically to the pre-fusion antigenic site φ, while two other neutralizing antibodies (AM14 and 
MPE8) bind very efficiently to pre-F via antigenic sites III and V [62]. These three antigenic sites 
(φ, III and V) are absent in post-F. The antigenic site that is only unique to post-F is the site I. 
However, the antibodies generated against post-F antigenic site I have weak or no neutralizing 
activity. Hence, pre-F is now considered by some as a better vaccine antigen [64]. Palivizumab 
can recognize both post- and pre-fusion structures. In the context of real life infection, RSV 
undergoes a conformational rearrangement from pre-F to post-F and both versions of the F 
protein are present on the infectious virion. In order to achieve significant neutralizing activity, 
RSV F-specific antibodies have to recognize and disrupt pre-F functions. Post-F based subunit 
vaccines may not elicit high enough neutralizing antibodies or the right type of antibodies to 
confer protection for the entire duration of a RSV season. 
 
1.6.4 Failure of natural infection to induce immunity that prevents reinfection: Nearly all 
children are infected with RSV during their first two years of life. Children and adults get 
reinfected with the virus every 3-10 years [65].Thus, natural RSV infection only provides limited 
protection from reinfection and subsequent disease. Primary infection leads toboth antibody and 
T cell responses with effective clearance of the virus, yet reinfection occurs again and again 
during the lifetime of an individual. There may be several reasons for the inability of natural RSV 
infection to induce sufficient immunity to prevent reinfection. Initial RSV infection might alter 
the characteristics of adaptive immune effectors and memory immune cells, thus making the 
immune system more vulnerable to reinfection [65]. For instance, RSV when directly infecting 
DCs, causes dysregulation of antigen presentation functions. This leads to impaired T cell 
activation and induction of memory response [66]. Secondly, the antibody and T cell responses to 
primary or natural infection may be of poor quality, functionality or durability, thus rendering 
ineffective prevention of reinfection. Furthermore, the evasion of local and innate immunity by 
RSV may contribute to the inability of the host to prevent RSV infection [65]. 
 
1.6.5 Legacy of vaccine-associated enhanced respiratory disease (ERD):RSV vaccine 
development met with a huge set-back in 1966 when a clinical trial with a formalin-inactivated 
alum-precipitated RSV vaccine (FI-RSV) resulted in hospitalization of 80% of the vaccine 
recipients including and the death of two children, 14 and 16 months in age [67, 68]. Priming 
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with FI-RSV led to vaccine associated ERD upon subsequent RSV infection. Poor functional 
antibody responses with low neutralizing and fusion-inhibiting activity, immune complex 
deposition and complement activation in small airways, blood eosinophilia and strong Th2 
immune responses were associated with the FI-RSV-primed disease outcome [65]. Natural RSV 
infection post FI-RSV immunization also contributed to exaggerated peribronchiolar 
inflammation and infiltration of neutrophils and eosinophils into airways. Thus, safety concerns 
about subunit vaccines are particularly high in seronegative (i.e. antigen-naïve) infants because of 
vaccine induced ERD. Although RSV vaccine development came to a standstill for several 
decades after this disastrous trial, substantial research activities in the interim finally identified 
the reason for FI-RSV vaccine failure. FI-RSV-induced ERD resulted due to destruction of virus 
neutralizing epitopes due to formalin treatment that resulted in poor TLR activation. This led to 
non-protective antibody responses. CD4+ T cells were primed in the absence of any CTLs, which 
in turn, resulted in pathogenic Th2 memory responses, eosinophilia and immune complex 
deposition in the lung upon exposure to natural RSV exposure [69]. Since this failed trial, RSV 
vaccine development primarily started to focus on live-attenuated or vector-based vaccines in 
infants [61]. 
 
1.6.6 Identification of the correlates of protection: In order to determine the mechanisms by 
which the immune system mounts a protective response, it is important to define the correlates of 
protection (i.e. the immunological parameters associated with protection against subsequent 
infection) against RSV. Knowledge of the correlate of protection is required to obtain RSV 
vaccine licensure [70]. Antigen-specific antibody titres are usually considered as reliable 
correlates of protection for many vaccines. However, an emerging body of evidence suggests that 
this is not true for all vaccines. The T cell responses serve as an important correlate of protection 
for many current vaccines such as those that are being tested against HIV, tuberculosis (TB) and 
malaria [71]. A study of RSV-infected infant cohorts in the Netherlands revealed that RSV-
specific mucosal IgG but not plasma IgG inversely correlated with the viral load [70]. However, 
such results need to be replicated in larger populations in other parts of the world to come to a 
final conclusion about the identification of correlates of protection against RSV. 
 
1.7 Target populations for RSV vaccination 
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Epidemiology studies reveal that there are at least four distinct target populations for vaccines 
against RSV, with RSV-naïve infants being the target population with the highest priority. Each 
of these target populations poses different safety concerns and requires different vaccination 
strategies. 
 
1.7.1 Neonates and infants (≤6 months of age): Neonates and infants (≤6 months of age) have 
certain immunological features that make them more susceptible to severe RSV infection. Some 
of these features include decline in the titre of the maternal antibodies, immature immune system, 
first exposure to RSV and the risk of vaccine-enhanced disease as witnessed during the earlier 
failed trials of FI-RSV [60, 72]. Further challenges to vaccine development against RSV in the 
neonates include underlying diagnosed or undiagnosed risk factors such as cardiac or lung 
ailments or high susceptibility to RSV. The prevalent approaches to vaccine development in 
infants include live-attenuated RSV and live chimeric virus or vectored vaccines (the vaccination 
strategy in which a bacterial plasmid or virus encoding the vaccine gene of interest is delivered to 
the vaccine recipients) [60, 73]. 
 
1.7.2 Young children (6-24 months of age): The challenges regarding vaccination of young 
children are similar to those in infants but reduced as the chance of responding to vaccines is 
higher due to lower maternal antibody interference. Moreover, the immune system of the young 
children is more mature. Furthermore, the chance of developing adverse respiratory tract 
complications from vaccination with a FI-RSV vaccine is considerably less in young children 
than in infants. Vaccinating young children would reduce transmission of RSV to susceptible 
family members such as infants and adults. Primary approaches to vaccine development for 
young children are similar to those for infants including live-attenuated RSV, live chimeric virus 
andvectored vaccines [60]. 
 
1.7.3 Pregnant women: The primary goal of vaccinating pregnant women or women of 
childbearing age is to induce high titres of neutralizing antibodies in the mother so as to confer 
passive antibody-mediated protection of the neonate or block any virus transmission from the 
mother to the infant [74]. The limiting factors include previous multiple RSV infections in the 
 20  
mother and the need to induce substantially elevated antibody titres in the mother that can protect 
the infant. Live RSV vaccines are not immunogenic in adults and multiple RSV infections in the 
adults ensure much reduced risk of any vaccine-enhanced disease. Primary approaches to vaccine 
development in this target population include subunit vaccines and virus-like particles formulated 
with adjuvants [60]. 
 
1.7.4. Elderly/older adults (>65 years of age): This target population may suffer from serious 
RSV complications and represents a considerable disease burden. Previous multiple RSV 
infections and immunosenescence may impede an effective response to vaccination. Other 
challenges include co-existence of underlying disease conditions and lack of clear indicators 
reflecting RSV disease severity [75]. Since live RSV vaccines are not immunogenic in adults, 
possible vaccine strategies include vectors encoding subunit proteins, virus-like particles and 
subunit proteins formulated with adjuvants [60]. 
1.8. Goals of RSV vaccine development 
Since the past several decades, RSV vaccine research has helped both immunologists and 
vaccinologists to gain immense knowledge, gather new perspectives and take advantage of 
exciting opportunities to drive RSV vaccine development in a successful direction. The following 
list summarizes some of the important considerations for improving or designing new vaccines 
against RSV.  
 
Features that an ideal RSV vaccine should exhibit 
 
a. ARSV vaccine should induce local innate immune responses in the upper and lower 
respiratory tract to set the stage for optimal adaptive immunity. 
b. A RSV vaccine should induce virus neutralizing antibodies in the first place and also generate 
T cell responses. This is because antibodies are the only adaptive effector molecules that act 
as the first line of defense to protect airway epithelial cells. 
c. A RSV vaccine should induce antibodies with high affinity and potent long-term neutralizing 
activity. For RSV, boththe quality and magnitude of antibody responsesare important.  
d. A RSV vaccine should also induce CD8+ T cell responses, which will serve as the second line 
of defense when both innate immunity and antibodies are insufficient to prevent infection. 
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e. However, RSV vaccines should not induce excessive T-cell responses in the host so that there 
is no immune-mediated pathology and no long-term consequences. 
f. These effector mechanisms should be present early after exposure to RSV to facilitate early 
viral clearance.  
g. Timing is critical, especially for infant vaccination. Ideally, RSV vaccine antigen exposure 
should be the first the infants experience. Since there is no evidencefor the existence of 
intermediate host or animal reservoir for RSV, vaccinating an infant with vaccine antigen 
before the infant gets exposed to natural RSV for the first time would alter the ecology of the 
virus in that infant. This would prevent continuous reinfection by RSV in that particular 
infant [65]. Infants need to be immunized as early as possible, but have to wait till the level of 
maternal antibodies is low enough for the vaccine to elicit strong vaccine-induced antibody 
responses. 
 
Features that an ideal RSV vaccine should not exhibit 
a. A RSV vaccine shouldnot elicit non-neutralizing antibodies, especially in seronegative 
individuals. 
b. A RSV vaccine should not induce Th2 responses for several reasons:  
i. CD4+ T cells that produce IL-4 may cause eosinophilia 
ii. History of Th2 responses with FI-RSV 
iii. Increased mucus production, airway hyper-responsiveness and wheezing associated with 
Th2 responses. 
iv. Th2 cytokines like IL-4 and IL-13 cause diminished or altered CD8+ T cell effector 
functions and delayed viral clearance. 
 
1.9 Passive immunization against RSV 
 
1.9.1 Maternal immunization: Due to immunological immaturity, immunization of neonates or 
infants is very challenging. The principle of maternal immunization is to boost protective 
antibody levels in pregnant woman. This way the mother can transfer an increased level of 
maternal antibodies (MtAbs) to the infant both transplacentally and through the colostrum[76]. 
This will help to confer delayed susceptibility of the child to any infection at a time when the 
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immune system of the neonate or infant is at its most immature state. Another advantage of 
maternal immunization is that the mother’s immune system is fully mature, so she will be highly 
vaccine-responsive. This strategy of immunization will not only help to protect the mother 
(protection especially important at the time of pregnancy), but will also allow the mother to 
transfer higher levels of MtAbs to protect the infant, for at least the first 6 months. This approach 
has been found to be safe and immunogenic with tetanus and influenza vaccines. Both GSK and 
Novavax are developing maternal RSV vaccines and are currently in phase I and III clinical 
trials, respectively [61]. However, maternal immunization will only work if antibodies are the 
correlates of protection for a given pathogen and thus, knowledge of the correlates of protection 
as well as the minimum protective titre against RSV is important. It is only after 13 weeks of 
gestation that the IgG transfer from the mother to the child is initiated. Moreover, the expression 
of Fc receptors increases in the third trimester, while the transfer rate of MtAbs is highest during 
the last 4 weeks of pregnancy. In summary, all these factors should be taken into consideration, 
especially while deciding when to perform maternal immunization against RSV. In addition to 
the quantity, the quality of the antibodies elicited by maternal immunization is important. There 
are conflicting reports on whether the maternal antibodies against RSV are protective or not [77]. 
RSV-specific naturally acquired maternal antibodies often have lower affinities resulting in lower 
neutralizing efficacy. Therefore, it is crucial that maternal immunization induces high-affinity 
antibodies in the mother that can be transferred to the infant to protect them from a RSV 
infection.  
 
1.9.2 Immunoprophylaxis: Immunoprophylaxis against RSV includes the administration of RSV-
Intravenous Immunoglobulin (RSV-IVIG), as well as RSV neutralizing monoclonal antibodies. 
 
RSV-IVIG: RSV-IVIG is a hyperimmune pooled polyclonal human immunoglobulin that has 
been purified from donors who develop high RSV-neutralizing antibody titres. This was 
developed by MedImmune to prevent RSV in high-risk pediatric population [61]. During the 
RSV season, RSV-IVIG is usually administered by monthly intravenous infusion and was found 
to significantly decrease the hospitalization and length of hospital stay due to RSV in high-risk 
infants. However, the disadvantages outweighed the benefits. Intravenous injection increases the 
chances of acquiring blood-borne infections. Furthermore, the need for repeated venous access, 
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long infusion time (4-6h) and volume of injection (15ml/kg) that may lead to fluid overload and a 
need for diuretic rescue are the most prominent disadvantages. RSV-IVIG can also potentially 
interfere with live virus vaccines [such as measles, mumps and rubella(MMR) vaccine] and leads 
to increased surgical morbidity and mortality in infants with CHDs [2]. 
 
Palivizumab: Palivizumab is a humanized monoclonal IgG1 antibody in which murine-derived 
sequences complimentary to the A antigenic site of the RSV F protein are inserted into a human 
IgG such that the resultant antibody is minimally immunogenic (>95% being human) and is 
broadly reactive against both strains of RSV [78]. The preparation contains high titre neutralizing 
antibodies and can be administered intramuscularly in a small volume in a home or outpatient 
setting. Monoclonal antibodies do not pose a risk of exerting immunosuppressive effects in 
children. Till date, Palivizumab (Synagis®) developed by MedImmune is the only licensed 
product available for treatment of RSV in any population [61]. However, Palivizumab is 
ineffective in preventing RSV infection of the URT as it can only prevent downward spread to 
the lung [2]. 
 
Motavizumab: To overcome the limitations of Palivizumab, Motavizumab was developed as the 
more potent second generation fully humanized IgG1 monoclonal antibody with a substitution of 
13 amino acid residues in the complimentary-defining regions of Palivizumab, which results in a 
70-fold higher affinity for the RSV F protein and 100-fold higher anti-RSV activity [79]. Unlike 
Palivizumab, Motavizumab is able to inhibit RSV replication in the URT as demonstrated in a 
study with cotton rats [2, 79]. 
 
1.10 Active immunization against RSV  
 
1.10.1 Live-attenuated/chimeric vaccine: Live attenuated vaccines represent many of the safest 
and the most effective vaccines in use today. This is because they closely mimic a live infection 
without causing any disease [80]. Examples areMMR vaccine, 2009 H1N1 influenza nasal spray, 
chickenpox and smallpox vaccine, oral polio vaccine, rotavirus vaccine, rabies and yellow fever 
vaccine. Some of the attenuation strategies in RSV vaccines involve reverse genetics to delete 
genes that are associated with modulation of immune responses or incorporating mutations 
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associated with temperature sensitivity so as to develop a highly attenuated strain with restrictive 
replicative capacity [60]. Other approaches include passaging of the virus at suboptimal 
temperatures or in the presence of mutagen to produce strains with attenuated replicative ability. 
There are several advantages of live attenuated vaccines. The most important advantage is that 
live attenuated RSV vaccines have not been found to cause vaccine-associated enhanced disease 
with a subsequent natural infection with wild-type RSV [61]. Secondly, live attenuated vaccines 
induce local mucosal immunity, which is very important against respiratory pathogens such as 
RSV. Since these vaccines can conveniently be delivered intranasally, attenuated viruses replicate 
in the URT and retain immunogenicity even in the presence of maternally derived serum 
neutralizing antibodies usually present in very young infants. Another advantage is the non-
invasive method of live attenuated vaccine administration. Live attenuated vaccines elicit broad, 
effective and possibly more stimulation of innate, cellular and humoral immunity. Live 
attenuated RSV vaccine is the only type of vaccine that has been demonstrated to be safe in RSV 
naïve infants and children [60, 81, 82]. 
However, live attenuated vaccines have several potential drawbacks that limit their use in 
several situations. Live attenuated vaccines work on the principle that in order to achieve an 
optimal immune response, a low to moderate level of virus replication is necessary. The level of 
replication of live attenuated RSV is generally inversely correlated to the degree of attenuation. 
Hence, the live attenuated RSV vaccines that are optimally attenuated to maintain highly 
restricted replication abilitywas often found to be insufficiently immunogenic to provide effective 
protection against wild-type natural RSV infection. The second disadvantage of live attenuated 
RSV vaccines is the high degree of instability of the virus itself that posesa great challenge in 
terms of developing high-titre stocks, storage and usage in developing countries. Thirdly, live 
attenuated RSV vaccines mayrevert to wild-type and can cause severe complications in 
immunocompromised RSV patients. A number of live attenuated vaccines delivered either 
intramuscularly or intranasally have been tested, but none have progressed to phase 2 or 3 
efficacy trials [61]. 
 
1.10.2. Vectored and nucleic acid-based vaccine: Candidate vaccines such as viral vectors, 
replicons and plasmids that execute similar functions as live vaccines but without the risk of 
under-attenuation are being investigated. Commonly employed vectors include adenovirus and 
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modified vaccinia virus Ankara (MVA). The goal of these vaccines is to stimulate balanced 
immune responses and eliminate the risk of vaccine-enhanced disease [61]. Vaccine-enhanced 
disease in RSV-naïve infants and young children is associated with processing of extracellular 
proteins or particles through MHC class II presentation pathways. Furthermore, vector-based 
vaccines avoid interference by pre-existing immunity or maternal antibodies, and do not cause 
live vaccine-associated problems such as immune evasion and modulation of host immune 
responses[60]. Internal proteins such as N, M and M2-1 are rich in T cell epitopes. Recombinant 
vectors expressing these proteins can be potentially used to promote or enhance T cell mediated 
immunity. However, the potential for development of anti-vector immunity is one disadvantage 
of using viral vector-based vaccines, as anti-vector immunity can limit immune responses to 
subsequent immunizations [61]. DNA vaccines do not cause such problems. 
 
1.10.3 Subunit and particle-based vaccines: Subunit vaccines are considered safer as a specific 
antigen(s) from the pathogen is used rather than the whole virus to induce specific immune 
responses and lower the chances of vaccine-associated enhanced disease. Protein subunit 
vaccines although safe in older children and adults, often show only modest immunogenicity 
when used without adjuvant. Particle-based vaccines such as virus-like particles expressing F 
protein or F protein incorporated into nanoparticles are being tested to elicit protective immune 
responses. Since the G protein is considered to play a role in virus-induced enhanced disease-
causing inflammatory responses, the F protein is the antigenofchoice in most subunit and vector-
based vaccines[83]. Moreover, the F protein is highly conserved between the subgroups (90% 
sequence identity). The F protein induces broadly neutralizing antibodies and is also the target for 
the licensed monoclonal antibody Palivizumab. RSV subunit vaccines with F protein as the 
vaccine antigen follow two approaches, one with the post-fusion form of F and the other one with 
pre-fusion form of F. Both post- and pre-F contain antigenic site II and IV, while post-F contains 
antigenic site I and pre-F contains antigenic site Φ. Importantly, the pre-F protein elicits more 
potent neutralizing antibodies than post-F [61]. Dalhousie University and Immunovaccine 
Technologies is using SH protein as an antigen in phase I clinical trials. 
In subunit vaccines, antigens purified from the pathogen or produced by recombinant 
DNA technology are used. These highly purified antigens often are poorly immunogenic and 
hence fail to directly stimulate the innate immune system. Therefore, adjuvants are often mixed 
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with these antigens to enhance vaccine potency and efficacy. There are only five approved 
subunit or killed viral vaccines in the USA; four of them include an adjuvant. Adjuvants help to 
induce long-lasting antibody responses as reported for HPV 16 and 18 Cervarix (GSK) vaccines 
[84]. When compared to RSV G protein, RSV F is known to induce higher neutralizing 
antibodies, promote enhanced protective immunity and provide better cross-protection against the 
two strains of RSV. In RSV-primed older children and adults, subunit vaccines containing 
purified or expressed proteins are safe [60]. Wyeth developed a purified F vaccine and Sanofi 
developed purified F, G and M vaccines for adults in the 1990s and 2000s respectively, but both 
these vaccines failed when tested in efficacy studies [61]. In a large phase III clinical trial with a 
total of 11,586 elderly subjects aged 60 years or higher, a post-fusion F protein vaccine 
developed by Novavax failed to show any efficacy. Similarly, a post-fusion F protein vaccine 
formulated with glycopyranosyl lipid adjuvant (GLA) in combination with squalene (SE), known 
as GLA-SEdeveloped by MedImmune, also failed to show any efficacy when tested in 1900 
subjects aged 60 years or more. Currently, pre-fusion F protein vaccines formulated with or 
without adjuvants are being tested by Crucell, GSK and other pharmaceutical companies 
targeting maternal and adult population for immunization. A total of 14 vaccines and two 
monoclonal antibodies are in the pipeline in the field of vaccine development [61]. 
 
1.11 Introduction to RSV vaccine candidate (ΔF/TriAdj) 
Previously, we have developed a subunit RSV vaccine candidate (ΔF/TriAdj) that consists of a 
truncated, secreted form of the RSV fusion protein (ΔF) as the main protective antigen. The 
subunit protein is formulated with a combination adjuvant (TriAdj) comprised of LMW 
poly(I:C), the innate defense regulatorpeptide (IDR1002), and a water-soluble polymer (PCEP). 
Poly(I:C) is a synthetic analog of viral dsRNA with immunostimulatory properties and used as 
nucleic acid adjuvant [85]. Poly(I:C) acts as a ligand for endosomal TLR3 and cytosolic RIG-I 
and MDA5. Since TLR3 ligands favour strong cellular Th1-type immune responses, poly(I:C) is 
considered an attractive vaccine adjuvant against viral infections. Synergy between TLR3 and 
MDA5 activation contributes to the superior adjuvant qualities of poly(I:C). TLR3 is required for 
CD8+ T cell activation by cross-priming, while MDA5 stimulation in stromal cells by poly(I:C) is 
responsible for CD8+ memory T cell survival. The major mechanism by which poly(I:C) exerts 
its adjuvanticity is through the induction of CD8+ T cell responses mediated by the action of type 
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I IFNs, including proliferation of CD8+ T cells [86]. Poly(I:C)-induces TLR3-dependent 
increased MHC-I expression and type I IFN-production as well as facilitates antigen cross-
presentation to primed CD8+ T cells. Poly(I:C) also induces IFN-γ production by NK cells and 
boosts NK cell activation [86]. 
Cationic synthetic IDRs are amphipathic peptides. In vitro characterization of a library of 
IDR peptides (derivatives of bactenecin) demonstrated that IDR1002 (VQRWLIVWRIRK) had 
significantly higher potency in inducing chemokines than other IDR peptides [87]. In general, 
host defense peptides (HDPs) are capable of modulating innate immune responses and are 
increasingly being used as therapeutics [88-90]. The mechanism of action of HDP lies in its 
immunomodulatory properties including chemotaxis, by inducing chemokine production, leading 
to recruitment of neutrophils and monocytes, modulation of DC activation and differentiation and 
regulation of apoptosis of neutrophils and epithelial cells [87, 89]. HDPs such as human 
neutrophil defensin, as adjuvant promotes humoral and CMI responses upon intranasal 
administration in mice. Both systemic and mucosal immune responses were induced by a DNA 
vaccine encoding HIV-1 glycoprotein 120 fused with murine β-defensin 2. Murine β-defensin 2 
was used in this DNA vaccine as an adjuvant to promote chemoattraction and pro-inflammatory 
responses [91].  
Polyphosphazenes such as PCEP are high-molecular-weight, water-soluble, synthetic, 
biodegradable polymers consisting of a backbone of alternating phosphorus and nitrogen atoms 
and organic side groups attached to each phosphorus atom [92]. PCEP induces adjuvant core 
response genes encoding cytokines, chemokines, innate immune receptors, IFN-induced proteins, 
adhesion molecules and other proteins involved in antigen presentation [93]. Since PCEP forms 
water-soluble, non-covalent complexes with antigens, it promotes stable and efficient 
presentation of antigens to the immune cells [92, 94, 95]. PCEP also induces immune cell 
recruitment, and thereby helps to establish a local immunocompetent or immunostimulatory 
environment. PCEP does not form a depot at the site of injection to exert its adjuvant activity 
[92]. PCEP is also a potent mucosal adjuvant. Tested via different mucosal routes, such as 
intranasal, oral and intrarectal, PCEP not only enhances the production of secretory IgA at the 
site of delivery, but also at distant mucosal sites via the common mucosal immune system, with 
intranasal delivery being the most effective mucosal route of immunization with PCEP [96]. The 
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adjuvant activity of polyphosphazenes has been demonstrated in vaccine formulations against 
influenza [97, 98], human rotavirus [99], cholera [100] and BRSV [92].  
 It has previously been demonstrated that co-formulation of a truncated bovine RSV fusion 
protein with TLR9 agonist (CpG ODNs), HDP (indolicidin, a bovine HDP) and polyphosphazene 
resulted in humoral and cellular immune responses with induction of protective Th1-type 
immune response in both C57BL/6 and BALB/c strains of mice. No pulmonary IL-4, IL-5, IL-13, 
eotaxin and eosinophilia were observed following BRSV challenge [92]. This study had 
important implications for the development of a RSV vaccine for humans. A combination of CpG 
ODN and IDR peptide HH2 in a pertussis toxoid vaccine also led to the induction of toxoid-
specific cellular and humoral immune responses in mice [101]. Furthermore, intramuscular or 
intranasal administration of RSV ΔF protein co-formulated with CpG ODN, IDR1002 and PCEP 
induced a robust and balanced immune response in mice and cotton rats without signs of 
immunopathology [88]. 
Previously, we demonstrated that when BALB/c mice were intranasally immunized twice 
with ΔF/TriAdj consisting of 1 μg of ΔF, 10 μg of poly(I:C), 20 μg of IDR1002 and 10 μg of 
PCEP, both local mucosal immune responses in the lung and systemic immunity were induced 
[102]. Immunization with ΔF/TriAdj led to induction of RSV ΔF IgG1, IgG2a, IgA and virus 
neutralizing antibodies as well as ΔF-specific CD8+ T cells in the lung and CD8+ central memory 
T cells in the lung dLNs. RSV-specific CD8+ central memory T cells are implicated in protection 
from RSV disease. Formulating ΔF protein with TriAdj also promoted affinity maturation of 
RSV ΔF-specific IgG. Analysis of the IgG2a to IgG1 ratio as well as in vitro measurement of 
IFN-γ to IL-5 production in re-stimulated splenocytes revealed that ΔF/TriAdj promoted Th1-
biased humoral and cellular immune responses. The ability of TriAdj to promote cross-
presentation and cytolytic CD8+ T cell responses was also confirmed. This vaccine was also 
demonstrated to be highly effective and safe in cotton rats, a better replicative model of RSV 
[102]. Most importantly, combining ΔF protein with poly(I:C) alone was not protective against 
RSV in cotton rats, demonstrating the importance of TriAdj as the adjuvant platform in this 
candidate subunit vaccine formulation [102]. Increasing the dose of poly(I:C) is not advisable for 
regulatory and safety reasons. Formulation of ΔF with TriAdj was found to induce sufficient 
immunity to confer complete protection and, importantly, without inducing any pulmonary 
immunopathology. This further highlighted the fact that a combination of poly(I:C), IDR1002 
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and PCEP promotes a balanced and optimal immune response, is safe and efficacious. As 
mentioned earlier about the potential mechanism of action of individual components of the 
combination adjuvant, we believe that while poly(I:C) in the vaccine formulation is involved in 
PRR signaling, the role of IDR1002 is to augment CMI and control and modulate excessive 
consequences of PRR signaling (owing to its immunomodulatory properties), while PCEP 
facilitates formation of non-covalent complexes with the antigen that serves to enhance antigen-
specific humoral immunity [102].  
ΔF/TriAdj was prepared according to the following protocol. Briefly, according to a 
codon-optimized sequence, the open reading frame (ORF) of the F protein was synthesized (by 
Geneart), encoding a truncated version of the native protein that is devoid of the transmembrane 
domain (ΔF) but has a carboxyl terminus (Ser-Gly)10 bridge with a his10 tag. The ORF was 
cloned in an episomal vector that contained a human CMV promoter, EBNA-1 antigen ORF and 
P origin, a woodchuck hepatitis post-transcriptional regulatory element and bovine growth 
hormone poly-adenylation site. Next, this ΔF-encoding episomal vector was used to transfect 
HEK293 cells and using TALON Superflow resin (Clontech), thehis-tagged ΔF protein was 
purified from the cell culture supernatant, aliquoted and stored under frozen condition. LMW 
poly(I:C) was purchased from Invivogen (CA, USA), while IDR1002 (VQRWLIVWRIRK) was 
commercially available from Genscript (NJ, USA). Both poly(I:C) and IDR1002 were also 
aliquoted and stored under frozen condition. Poly[di(sodium carboxylatoethylphenoxy)]-
phosphazene was synthesized at Idaho National Laboratory. PCEP was dissolved in PBS (Gibco) 
and the solution was stored at room temperature. On the day of the preparation of ΔF/TriAdj 
formulation, fresh aliquots of each frozen component were used. First, poly(I:C) and IDR1002 
were mixed in PBS (Life Technologies, pH 7.4) and incubated for 30 min at room temperature. 
Then ΔF protein was added and incubated for another 15 min. Finally, PCEP was added to the 
formulation so as to make a final 1:2:1 ratio of poly(I:C), IDR1002 and PCEP. 
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CHAPTER 2 
2                         LINKER BETWEEN CHAPTER 1 AND CHAPTER 3 
 
Adjuvant(s) are important components in subunit vaccines[103], as subunit proteins often are 
insufficiently immunogenic. Incorporation of adjuvants in subunit vaccinesactivates innate 
immune responses at the site of administration. This then leads to accelerated, prolonged 
and/orimproved antigen-specific adaptive immunity[104]. Adjuvants serve as an attractive tool in 
the development of new efficacious vaccines against infectious diseases that are not preventable 
by traditional vaccines [105]. With the advent of modern next-generation adjuvants, subunit 
vaccine is now considered as an attractive vaccination strategy. Instead of empirical selection of 
adjuvants, vaccinologists have focussed their attention on probing the mechanism of action of 
adjuvants, such that tailor-made potent and effective immune responses may be elicited against 
some of the challenging pathogens, against which vaccines are still not available. The following 
review provides a detailed description of the mode of action of some of the promising adjuvants, 
and how this knowledge can be utilized to select suitable adjuvants in subunit vaccines against 
specific pathogens. 
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3.1 ABSTRACT 
 
Adjuvants form an integral component in inactivated and subunit vaccine formulations. The 
limited availability of licensed adjuvants for human use bolsters interest in elucidating the 
mechanism of action of adjuvants. Careful and proper selection of adjuvants helps in promoting 
appropriate immune responses against target pathogens at both innate and adaptive levels such 
that protective immunity can be elicited. The role of adjuvants as delivery systems and stimulants 
of the innate immune system is well appreciated. Furthermore, adjuvants play a pivotal role in 
directing the type, quality and quantity of adaptive immune responses. In this review, we have 
summarized the recent progress in our understanding of the mode of action of adjuvants that are 
licensed for use in human vaccines or in clinical or pre-clinical stages. How adjuvants act at 
multiple levels at both innate and adaptive levels has been detailed in this article. Different 
pathogens have distinct characteristics, which require the host to mount an appropriate immune 
response against them. Adjuvants can be specifically selected to elicit a tailor-made immune 
response to specific pathogens based on their unique properties. Currently, there is much 
emphasis on the identification of biomarkers of adjuvanticity for several candidate vaccines using 
omics-based technologies.  Only a concerted multi-disciplinary approach can unravel the 
mechanism of action of modern and experimental adjuvants. 
 
3.2 INTRODUCTION 
 
Development of vaccines against infectious diseases is one of the most remarkable 
accomplishments in the history of mankind [106]. Smallpox has been completely eradicated from 
the world, and other diseases like diphtheria, poliomyelitis, pertussis, measles and neonatal 
tetanus are significantly controlled by vaccination [106, 107]. Although most of these vaccines 
are live attenuated and effective, their usage is restricted only to healthy individuals. This is due 
to the fact that there is a high chance of live virus-induced disease progression in populations 
with underdeveloped or compromised immune systems [107]. For instance, FluMist, a live 
attenuated seasonal influenza vaccine is approved only for individuals between 2 and 49 years, 
rendering two major populations, the infants and elderly, to be not eligible to receive this vaccine 
[108]. In contrast, inactivated or killed virus vaccines are non-infectious and suitable for a wider 
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population. They are highly immunogenic as they contain a mixture of diverse antigens. 
However, these vaccines are unsuitable when natural infection by the pathogen itself fails to 
induce any long-term immunity [105].  
Compared to traditional vaccines based on live attenuated or whole inactivated pathogens, 
recombinant subunit vaccines are considered as one of the most attractive modern vaccine types 
in recent years due to their high safety profiles [103]. They are composed of highly purified 
pathogen-derived antigens, recombinant proteins or synthetic peptides and thus exhibit low 
reactogenicity. They are devoid of any toxin, allergen and other virulence factors associated with 
a pathogen. With the advent of reverse vaccinology and other technological advancements, 
antigens in subunit vaccines can be rationally selected, containing pathogen-specific epitopes. 
However, subunit vaccines generally lack the endogenous innate immune stimulating properties 
of an infectious agent such as pathogen associated molecular patterns (PAMPs) that are required 
to induce adaptive immune responses, so typically subunit vaccines are not inherently 
immunogenic [105, 107]. Therefore, increased safety of subunit vaccines is achieved at the 
expense of immunogenicity [103]. To overcome this limitation, adjuvants are incorporated in 
subunit vaccines to enhance immunogenicity of the vaccine antigen and thus form a fundamental 
part of subunit vaccine formulations. Adjuvants are defined as an exogenous, heterogeneous 
group of compounds capable of enhancing antigen-specific immune responses and may act as 
delivery systems and/or immunostimulants [109]. Adjuvants facilitate the development of 
vaccines targeting pathogens against which live attenuated, inactivated or killed vaccines are 
ineffective [110]. Identification and selection of new adjuvants is thus critical, but also 
challenging, for successful subunit vaccine development. 
 
3.3 MODES OF ACTION OF ADJUVANTS 
 
Adjuvants have been used in vaccine preparations against various diseases for decades and most 
of these adjuvants were selected empirically [111]. The fact that only few adjuvants have been 
licensed for human can be at least partially attributed to the dearth of precise knowledge of how 
adjuvants work [112]. As the complex interactions of pathogens with our immune system are 
more and more understood, we are beginning to appreciate the roles of adjuvants in stimulating 
both innate and adaptive immunity [113]. Structural characterization of several adjuvants and 
 34  
identification of various PRRs and co-stimulatory ligand receptors have enabled us to better 
understand the mode of action of adjuvants at a molecular level. This has led to a radical change 
in the design and development of next-generation modern adjuvants. Understanding the mode of 
action of adjuvants is critical in designing vaccines that elicit pathogen-specific effector and long-
term memory responses. Knowledge of the mechanism of action of an adjuvant also helps in 
assessing the adjuvant safety at developmental and regulatory stages. Careful selection of 
adjuvants to target a specific disease is important to achieve the level of adjuvantation needed to 
improve the efficiency of the immune responses while avoiding excessive off-target non-specific 
responses.  
 
3.3.1 Delivery system to augment innate immune responses 
The use of adjuvants as a delivery system in subunit vaccines helps to prevent rapid degradation 
of proteins and peptides in vivo, therebyenhancing the dose effectiveness, promoting increased 
uptake of the vaccine antigen by antigen presenting cells (APCs) and augmenting targeted 
stimulation of APCs. These adjuvants facilitate delivery of antigens predominantly by three 
mechanisms: endocytosis, facilitated diffusion and membrane fusion. Adjuvants such as 
liposomes, immune stimulating complexes (ISCOMs) and nanoparticles are widely used as 
vaccine antigen delivery vehicles and are considered to be effective in stimulating protective 
immunity [114].  
Liposomes mimic natural lipid bilayers of the cell. Liposome and liposome-derived 
nanovesicles (archaesomes and virosomes) belong to a class of versatile adjuvant compounds that 
offers great plasticity. This is due to the fact that the composition and preparation of liposomes 
can be tailored based on the chemical properties of the antigen. For example, the aqueous inner 
space of liposomes can be used to entrap water-soluble antigens, while lipophilic components can 
be interspersed into the lipid bilayer or attached to the surface of the liposome carrier system by 
adsorption or chemical cross-linking [115]. Co-administration of antigen with cationic liposomes 
induces stronger antigen-specific immune responses [116]. Liposomes are used in vaccine 
formulations against influenza, chlamydia, malaria, and TB [103, 117, 118].  
In contrast to liposomes, improved saponin-based tensoactive adjuvants (ISCOM, 
ISCOMATRIX and Matrix-MTM) are particulate antigen delivery systems with powerful 
immunostimulating activity [119]. ISCOMs are spherical, open cage-like structures, typically 40 
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nm in diameter, composed of cholesterol, phospholipid and saponin. Both ISCOMATRIX and 
Matrix-MTM promote strong antibody and T cell responses in pre-clinical and clinical studies. 
While ISCOMs are currently being used in the development of influenza vaccines for humans, 
ISCOMATRIX is used in hepatitis C virus (HCV), influenza and cancer candidate vaccines. The 
Matrix-MTM adjuvantis being evaluated in vaccines against influenza, herpes simplex virus 
(HSV) type 1 and malaria [120].  
Nanoparticles are polymeric colloidal carriers (10 to 1000 nm in size) and are of two 
types: nanocapsules and nanospheres [121]. Examples of polymeric nanoparticles are poly(lactic-
co-glycolic acid) (PLGA), poly(lactic acid) (PLA), poly(glycolic acid) (PGA), 
poly(hydroxybutyrate) (PHB) and chitosan. Antigens are either encapsulated within or decorated 
on the surface, which enables site-directed delivery and prolonged release of antigen. 
Importantly, such adjuvants facilitate alternative modes of vaccine administration such as 
inhalation, optical or topical delivery. Cationic (as opposed to anionic) and spherical (as opposed 
to rod-shaped) nanoparticles are more readily endocytosed via clathrin-dependent endocytosis or 
cholesterol-independent, non-clathrin and non-caveolar dependent pathways.  
In addition to liposomes, ISCOMs and nanoparticles, other types of adjuvants such as 
aluminium salts are also used as delivery systems. If alum and antigen are not co-administered or 
if delivered at separate locations, the efficacy of alum is lost, suggesting a role of alum as 
delivery system. [122]. Aluminium salts are particulate in nature, provide a scaffold for 
adsorption of vaccine antigens and facilitate internalization by APCs [123]. Crystals of alum bind 
to and alter the lipids of the DC plasma membrane lipids to trigger cell activation that facilitates 
delivery of antigen, without alum itself being internalized by the DCs [124]. However, in an in 
vitro study, it was reported that DCs do internalize antigen, whether the antigen is present in 
solution or adsorbed to aluminium hydroxide adjuvant, although the rate of antigen uptake is 
higher in the latter case [125]. Aluminium salts are used as adjuvants in human vaccines against a 
variety of viral and bacterial diseases such as diphtheria, tetanus, pertussis, rabies, anthrax and 
hepatitis A and B [80].  
The oil-in-water emulsion adjuvant, MF59 (composed of squalene stabilized by Tween 80 
and Span 85) is licensed for use in seasonal influenza vaccines and consists of uniform particles 
of ~160 nm in size. MF59 also functions as an antigen delivery system [126]. MF59 increases 
both phagocytosis and pinocytosis to promote better antigen uptake by APCs compared to alum 
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[80]. The safety of MF59 was demonstrated in various clinical investigations with antigens from 
hepatitis B virus (HBV), HCV, cytomegalovirus (CMV), HSV and human immunodeficiency 
virus (HIV) [127].  
Liposomes, ISCOMs, microparticles and other adjuvants that act as delivery system also 
enhance binding, uptake and half-life of antigens, and target vaccine antigens to the mucosal 
surfaces owing to their mucoadhesive properties. Furthermore, such adjuvants slow down 
mucociliary action and prolong contact time of the vaccine components with the mucosal tissues 
[128]. Thus, the use of adjuvant as delivery system not only ensures proper delivery of the 
antigen to the target cells, but also limits systemic distribution of the adjuvants to minimize any 
adverse side effects.  
 
3.3.2 Depot effect  
Depot effect at the site of administration is perhaps the most widely recognized mode of action of 
an adjuvant. Depot effect refers to slow and prolonged antigen release at the site of intramuscular, 
intradermal or subcutaneous injection, which results in high concentrations of antigen. This 
provides continuous stimulation of the immune system and facilitates enhanced antigen uptake by 
the APCs. These features are implicated in induction of high antibody titres later as part of the 
adaptive immune response. There are many hypotheses on the mode of action of aluminium-
containing adjuvants such as depot effect, antigen targeting and induction of inflammasome 
[129]. Depot effect is considered as one of the earliest proposed mechanism of action of 
aluminium adjuvant, but this theory has often been questioned [129]. On the other hand, oil-in-
water emulsions such as Emulsigen®, water-in-oil emulsions such as cationic adjuvant 
formulation (CAF)01 (a cationic liposome consisting of a combination of 
dimethyldioctadeclammonium/α,α’-trehalose 6,6’-dibehenate or DDA/TDB) as well as 
biodegradable micro- and nano-particles are known to exhibit adjuvant activity via depot effect. 
In general, cationic liposomes exhibit long depot effects at the site of injection and strong 
electrostatic interactions with APCs [115]. In contrast, adjuvants such as MF59 or ISCOMs do 
not require depot formation to exert their adjuvant activities; rather, antigen and adjuvant are 
cleared rapidly from the site of administration [118, 132-135].  
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3.3.3 Activation of pattern recognition receptors (PRRs) and cellular signal transduction 
pathways 
 
3.3.3.1 Toll-like receptors (TLRs) 
The success of yellow fever vaccine YF-17D, a live attenuated virus vaccine, is usually attributed 
to its ability to activate the innate immune system via TLR signaling [136]. Two-component 
RNA vaccines that consist of mRNA encoding vaccine antigen and non-codingdsRNA stimulate 
innate immunity via TLR3 and are found to be safe and efficacious, for instance as influenza 
vaccines in animal models [80]. This led to the consideration of PRR agonists as attractive 
vaccine adjuvants due to their ability to stimulate innate immunity. In fact, the devastating 
outcome of the clinical trial with a FI-RSV vaccine that resulted in hospitalization of 80% of the 
vaccine recipients and death of two children is attributed to poor TLR activation, which led to 
impaired functional antibody responses with low neutralizing and fusion-inhibiting activity and 
strong Th2-biased immune responses [68, 137]. Adjuvants can target PRRs that are either plasma 
membrane bound or localized in the endosomal compartment or in the cytosol. The cell surface 
PRR TLR2 needs to undergo heterodimerization with either TLR1 or TLR6 to initiate PRR 
signaling. The TLR2-TLR1 complexes are activated by the lipopeptide analog Pam3CSK4 (a 
mimetic for triacylated bacterial lipoproteins), while TLR2-TLR6 complexes are activated by the 
macrophage activating lipopeptide-2 (MALP-2) from mycoplasma [138]. Poly(I:C) is a synthetic 
analogue of dsRNA that acts as a ligand for endosomal TLR3 and cytosolic RNA helicases such 
as RIG-I and MDA5. Poly(I:C) and its two derivatives, polyI:C12U (Ampligen) and poly(IC:LC) 
(Hiltonol), are considered effective adjuvants, although their mechanisms of action are not 
identical. These compounds are used in clinical trials against both tumor and infectious diseases 
such as HIV [139]. TLR4, which serves as the receptor for bacterial lipopolysaccharide (LPS), is 
targeted by monophosphoryl lipid (MPL)A, a well-characterized adjuvant licensed for use in 
HBV (Fendrix) and human papilloma virus (HPV) vaccines (Cervarix) [140, 141]. TLR5 
recognizes bacterial flagellin. Flagellin and other TLR agonists (profilin and zymosan) offer the 
unique advantage of being able to synthesize recombinant fusion proteins containing both 
adjuvant and antigen. An example is the influenza vaccine (VAX125) consisting of a fusion 
between flagellin and hemagglutinin [142, 143]. TLR5 signaling in CD103+CD11b+DCs plays an 
important role in intestinal IgA production and Th17 differentiation [144] and leads to strong NF-
 38  
κB activation and Th2-biased immunity [139]. TLR7 and TLR8, which recognize ssRNA 
molecules rich in uridine residues as found in viral RNAs, are targeted by small-molecule 
immune potentiator (SMIP)-based adjuvants such as imiquimod and resiquimod used in HPV 
virus-like particle (VLP) vaccines [145]. TLR7 signaling induces B cell-mediated production of 
Ig, IL-6 and TNF-α and NK cell-mediated production of IFN-γ; while TLR8 signaling induces T 
cell proliferation, induction of IFN-γ, IL-2, IL-10 and memory T cell activation [139]. However, 
these imidazoquinolines have the drawback of poor tolerability, systemic inflammation and 
reactogenicity. To overcome these problems, less soluble first-generation SMIPs as well as 
soluble second-generation SMIPs with linked phosphonates adsorbed to aluminium hydroxide 
(Al(OH)3) have been developed with the advantage of short in vivo retention time and improved 
efficacy [146]. TLR9 recognizes unmethylated CpG motif-containing microbial DNA or 
immunostimulatory sequences (ISS). TLR9 agonists are used in HBV vaccines to promote higher 
levels of protective antibodies. Consequently, fewer immunizations and lower antigen doses are 
needed. In addition, the frequency of non-vaccine responders is reduced [147]. TLR9 signaling 
leads to Th1 type pro-inflammatory responses (IL-1, IL-6, IL-12, IL-18, TNF-α and IFN-γ), up-
regulation of MHC and co-stimulatory molecules and increased CD8+ T cell responses, while 
TLR9-mediated B cell activation is responsible for induction of humoral immunity and antibody 
class switching [139].  
 
3.3.3.2 Nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs)  
In addition to TLRs, intracellular NLRs such as NOD1 and NOD2 receptors recognize 
diaminopimelatic acid (DAP)-containing muropeptide from gram-negative bacteria, while NOD2 
detects the muramyl dipeptide (MDP) component present in all bacterial peptidoglycans [148]. 
The adjuvanticity of the mucosal adjuvant Cholera Toxin (CT) is mediated through the NOD2 
receptor [149].  
The cytosolic receptor NLR family pyrin domain containing 3 (NLRP3) is the best-
characterized member of a NLR subfamily containing pyrin domain-containing proteins that 
recognize a diverse range of adjuvants such as Quil-A and chitosan, as well as ATP, MDP, uric 
acid crystals and silica. All these compounds generate damage-associated molecular pattern 
(DAMP) signals such as reactive oxygen species (ROS) or induce potassium efflux to activate 
NLRP3. Together with its adaptor protein, apoptosis-associated speck-like protein containing C-
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terminal caspase recruitment domain (CARD) [ASC], NLRP3 forms a multiprotein complex that 
leads to the activation of caspase 1, ultimately resulting in the production of mature IL-1β and IL-
18 from their inactive precursor forms. Aluminium hydroxide induces production of endogenous 
uric acids to activate NLRP3 in APCs. Release of host DNA from the dying cells as a DAMP 
signal to activate APCs is another mechanism by which alum exerts adjuvanticity. Alum’s 
adjuvanticity is also attributed to the activation of NLRP3/NACHT, LRR, and PYD domains-
containing protein 3 (NALP3) inflammasome, release of uric acid or activation of the stimulator 
of IFN genes (STING)-IRF3 pathway due to the release of the DNA [130, 148].  
When intranasally administered, Endocine, a lipid adjuvant, induces cellular damage to 
generate DAMPs such as lactate dehydrogenase (LDH), DNA and RNA in the nasal washes. The 
mode of action of Endocine is essentially dependent on TANK binding kinase 1 (TBK1) 
signaling, suggesting nucleic acid release due to tissue-damage to be responsible for its 
adjuvanticity. Endocine adjuvanticity is independent of canonical RNA sensors such as TLR3, 
TLR7, RIG-I and NLRP3 inflammasome [150]. Chitosan induces mitochondrial stress resulting 
in the release of mitochondria-specific ROS to induce secretion of type 1 IFNs and expression of 
ISGs or can induce release of mitochondrial DNA into the cytoplasm to activate the NLRP3 
inflammasome [151]. Chitosan-induced cell death might provide the DAMP ligands [151]. Other 
DAMP adjuvants such as hydroxypropyl-β-cyclodextrin (bCD) also induce local cellular stress 
and death resulting in the release of the host cellular DNA that serves as a DAMP to induce Th2 
immune responses via TBK1 signaling [107].  
 
3.3.3.3 Other PRRs 
In addition to TLR9, cytosolic dsDNAs are sensed by several other PRRs such as absent in 
melanoma2 (AIM2), as well as by the protein cyclic guanosine monophosphate-adenosine 
monophosphate (cGAMP) synthase (cGAS)).  Upon detection of DNA by AIM2, inflammasome 
formation is initiated with ASC and pro-caspase 1, while binding of dsDNA by cGAS leads to 
the synthesis of cGAMP, which in turn signals through endoplasmic reticulum (ER)-STING to 
simultaneously activate STING-dependent TBK1-IRF3-IFN-1 pathways and RelA-TNF-α 
pathways [152]. STING can also bind cyclic dinucleotides (CDN), cyclic di-GMP (CDG) and 
cyclic di-AMP (CDA). CDG is a promising mucosal adjuvant. However, STING-mediated TNF-
α, but not IFN-1, is indispensable for adjuvant activity of CDG. CDG is a safer mucosal adjuvant 
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than cholera toxin and promotes protective immunity against H5N1 influenza, Staphylococcus, 
Streptococcus and Klebsiella infections. STING signaling by CDG is also required for 
chemokine and cytokine production in vivo, DC maturation, NF-κB activation and antibody 
responses; while STING signaling is not required for IgG responses promoted by alum [153]. 
The mucosal adjuvant chitosan triggers release of intracellular DNA that results in the 
engagement of the cGAS-STING pathway in DCs to induce type 1 IFN production and ISGs, 
thereby inducing a robust Th1 immunity. This ultimately leads to the upregulation of 
costimulatory immune markers and the subsequent activation of DCs as well as induction of 
IgG2c and CMI [151]. 
 
3.3.3.4 Role of carbohydrate-based adjuvants 
The role of carbohydrate-based immune adjuvants is well reviewed by Petrovsky et al[154]. 
Carbohydrate-based adjuvants include glucans (including α-glucans, β-glucans, lentinan, algal 
glucan, β-glucan particles), fructans, mannans, chitin/chitosan and other carbohydrate compounds 
derived from Mycobacteriumspp. (including lipoarabinomannan, MDP, trehalose-6-6-
dimycolate/TDM), as well as LPS and saponin compounds [including QS-21, a saponin in an oil-
in-water emulsion]. These adjuvants offer unique advantages. They are readily biodegradable and 
are metabolized or excreted quite easily without any chronic immune activation. The primary 
mechanism of action of carbohydrate-based adjuvants involves interaction with PRRs such as 
TLRs, NOD2 and C-type lectin receptors (CLRs, such as Dectins including Dectin-1, Dectin-2 
and Mincle) on monocytes and APCs. These receptors exhibit a non-canonical immunoreceptor 
tyrosine-based activation motif (ITAM) that recruits the signaling adaptor tyrosine kinase Syk, 
which activates Card9-Bcl10-Malt1-mediated NF-κB signal transduction pathways [155]. This 
results in inflammatory chemokine and cytokine responses (such as CCL3, TNF-α, IL-1β and IL-
6) that have a profound influence in the generation of antigen-specific humoral and CMI 
responses. Carbohydrate adjuvants also activate complement pathways to generate complement 
components acting as opsonins and chemokines. Other important mechanisms of action of 
carbohydrate-based adjuvants include chemotaxis of lymphocytes, activation of inflammasome 
(ex. zymosan and mannans) as well as pore-forming ability facilitating antigen entry into 
APCs(via interaction with cholesterol in the plasma membrane, ex. QS-21) [154]. 
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3.3.3.5 Signal transduction pathways 
As a result of PRR activation, adjuvants induce adaptor proteins, kinases, transcription factors 
and other signaling molecules that participate in intracellular signal transduction pathways to 
exert their effector functions. All TLRs, except TLR3, participate in MyD88-dependent signaling 
pathways to activate NF-κB via the transforming growth factor-β (TGF-β)-activated kinase 1 
(TAK1)/TAK1-binding protein (TAB) complex or activate activator protein 1 (AP-1) via 
MAPKs, which ultimately leads to induction of inflammatory mediators and immune cell 
activation. In addition, MyD88-dependent signaling by TLR7, TLR8 and TLR9 also leads to 
induction of type I IFNs via IRF7. TLR3 participates in MyD88-independent signaling (via 
TRIF) to induce IFN-β via IRF3. TLR4 signals via TRIF, while RIG-1 and MDA5 activate IRF3 
via IPS-1to induce transcription of type I IFN genes [156].  
Adjuvants induce a series of signal transduction pathways to exert their adjuvanticity at 
both innate and adaptive levels. For instance, intramuscular injection of MPL or ASO4 is 
responsible for NF-κB activation in the muscles and local draining lymph nodes (dLNs) [157]. 
Synthetic derivatives of MPL induce activation of TLR4 and selectively activate the p38 MAPK 
pathway, which is strongly associated with optimal induction of IP-10, TNF-α and IL-10 [158]. 
IL-21 as an adjuvant activates JAK-STAT, PI3K and MAPK pathways, thereby promoting B-cell 
and T-cell differentiation via sustained activation of STAT3 and Th17 differentiation through 
IRF4 [159]. Subtle chemical alterations to MPLA were made to develop a designer SMIP-based 
TLR4-agonist, known as SLA that induces TRIF signaling to produce Th1-biased cytokines and 
chemokines like IFN and IP-10, respectively, and less IL-1β. Furthermore, SLA in oil-in-water 
emulsion (SLA-SE) was produced capitalizing on the knowledge that a combination of IFN and 
caspase-dependent inflammasome signaling leads to powerful adjuvant action [160]. Other 
SMIP-based adjuvant ligands for TLR4 known as substituted pyrimido[5,4-b]indoles have been 
developed, which are potent inducers of NF-κB. Synthetic modified versions have also been 
developed, which can be used to differentially activate NF-κB to produce IL-6 or activate the 
type 1 IFN pathway to produce higher levels of IP-10, thus promoting Th1-based immune 
responses [161].  
Activation of the NF-κB pathway, as well as p38 and JNK MAPK pathways, program 
DCs to produce IL-12p70 to induce Th1 responses. On the other hand, the ERK-c-Fos MAPK 
pathways favour Th2-type responses while Erk-retinaldehyde dehydrogenase (RALDH) enzymes 
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or β-catenin program DCs to induce Treg responses [162]. CpG oligodeoxynucleotide (ODN) as 
adjuvant in human seasonal influenza virus vaccines for ferrets induces TLR4 and IRF4 
activation involved in antibody class-switching and plasma cell differentiation. Similarly, 
complete Freund’s adjuvant (CFA) is known to induce transcription of MHC-II and B cell 
activation markers via the Lyn-Syk-PI3K, the calcineurin-nuclear factor of activated T-cells 
(NFAT) and the Ras-MEK-ERK signaling pathways [163].  
Saponin adjuvanticity is dependent on MyD88-dependent and IL-18 receptor-signaling 
pathways [111]. Chitosan engages cGAS-STING pathways to induce IgG2c and Th1 responses 
[151]. Recently it was reported that intact MyD88 signaling in each of the three types of APCs 
(DCs, macrophages and B cells) is essential for robust activity of TLR-ligand based vaccine 
adjuvants (PorB, a TLR2 ligand and CpG, a TLR9 ligand) such as in vivo cytokine responses, 
germinal center (GC) formation and antibody production [164]. Thus, adjuvants activate 
receptors and pathways to modulate innate immune responses and therefore, serve as attractive 
compounds to enhance adaptive immune responses induced by subunit vaccines. 
 
3.3.4 Induction of cytokines, chemokines and interferons (IFNs) to facilitate recruitment of 
immune cells 
 
Based on microarray analysis, Mosca et al demonstrated that three potent human vaccine 
adjuvants, MF59, CpG ODN and alum, modulate a common set of 168 genes at the site of 
injection in the mouse muscle [165]. This cluster of genes is named ‘adjuvant core response 
genes’, which encode cytokines, chemokines, innate immune receptors, IFN-induced proteins and 
adhesion molecules. Up-regulation of pro-inflammatory genes drives cellular recruitment from 
the blood stream into the muscle. The establishment of such a local immunocompetent 
environment due to non-pathogenic inflammatory responses is associated with vaccine 
adjuvanticity. When compared to CpG ODN and alum, MF59 was found to be the stronger 
inducer of adjuvant core response genes, which was reflected in enhanced and more rapid influx 
of MHC-II+ and CD11b+ cells at the injection site and more efficient transport of antigen to the 
dLNs [80]. MF59 and CpG ODN were potent inducers of IL-5 and IL-12 in BALB/c mice 
consistent with Th2- and Th1-biased immune responses, respectively. Both alum and MF59 
induced chemokines involved in cellular influx such as CCL2, CCL3, CCL4 and CXCL-8 [166]. 
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MF59 does not directly target DCs to internalize antigen but induces recruitment and subsequent 
differentiation of DC precursors [167]. At the injection site, aluminium adjuvants also trigger 
recruitment of immune cells, with neutrophils accumulating first, followed by macrophages and 
eosinophils [168]. 
The presence of α-tocopherol in AS03 modulates gene induction of leukocyte-recruiting 
chemokines (CCL2, CCL3 and CCL5), neutrophil-mobilising cytokine (granulocyte colony-
stimulating factor 3 (CSF3)) and pro-inflammatory cytokine/chemokines (IL-6 and CXCL-1), 
which is in agreement with increased recruitment of granulocytes and antigen-loaded monocytes 
in the dLNs [169]. Alum induces strong production of uric acid from the damaged cells as a 
danger signal and produces IL-6 and IL-1β, which mediates recruitment of leukocytes to the 
inflammation site. However, in an in vitro study, aluminium-containing adjuvant did not induce 
IL-6 secretion by DCs [170]. Aluminium adjuvants facilitate recruitment and differentiation of 
inflammatory monocytes (F4/80intCD11b+LyG-Ly6C+) into inflammatory DCs, thereby 
enhancing both humoral and cellular immunity [171]. Subcutaneous administration of 
ISCOMATRIX induces a rapid and transient production of cytokines (IL-6, IL-8, IFN-γ) and 
influx of innate cells such as NK cells, NKT cells, neutrophils, migratory DCs (CD205+CD8-) 
and CD8α+DCs to the dLNs [172, 173].  
Poly(I:C) is considered as a ‘live virus vaccine equivalent’ as it activates multiple 
elements of both innate (via chemokine induction, antigen processing and activation of APCs) 
and adaptive (via induction of co-stimulatory molecules, polyfunctional CTL responses, memory 
B and T cells, antibodies and long-term memory) immunity [174]. The HDPs and their synthetic 
derivatives such as innate defense regulator (IDR) peptides have immunomodulatory activities in 
terms of chemokine and cytokine responses and recruitment of immune cells [87]. 
Polyphosphazenes are high-molecular weight, water-soluble, synthetic and biodegradable 
polymers made up of alternating phosphorus and nitrogen atoms and organic side groups attached 
to each phosphorus atom. Prototype members of this class of polymer are PCEP and 
poly[di(sodium carboxylatophenoxy)]-phosphazene (PCPP). When injected intramuscularly, 
PCEP creates a strong immunocompetent environment by inducing ‘adjuvant core response 
genes’ and recruiting neutrophils, macrophages, monocytes, DCs and lymphocytes to the 
injection site and thereby modulating antigen-specific immune responses [93, 175]. A 
combination adjuvant consisting of poly(I:C), a host defence peptide and PCEP when delivered 
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intranasally transiently induces production of monocyte-recruiting chemokines (CCL2, CCL3 
and CCL7), DC-recruiting chemokines (CCL3, CCL4 and CXCL-10) and pro-inflammatory 
cytokines (TNF-α, IL-1β and IL-6) in respiratory mucosal tissues, which promotes infiltration 
and activation of DCs, macrophages and neutrophils to generate improved mucosal and systemic 
immune responses [176].  
 
3.3.5 Induction of humoral immunity 
 
3.3.5.1 Improving the quality of antibody responses 
Anemerging body of evidence suggests that innate immune responses play a profound role in 
regulating the magnitude, quality and persistence of antibody responses. The magnitude of the 
antibody response is critical in conferring protection against diphtheria, hepatitis A, lyme disease, 
tetanus, yellow fever, polio, rabies and pneumococcal infections [177], while for certain diseases 
such as RSV and meningococcal infections, the magnitude and quality of the cell-mediated 
response are important. The antibody and T cell responses to natural RSV infection are of poor 
quality, functionality and durability, thus rendering ineffective prevention of reinfection. The 
quality of the antibody responses is correlated to their neutralizing property, affinity and effector 
functions such as phagocytosis and antibody-dependent cell-mediated cytotoxicity (ADCC). To 
induce the appropriate quality of antibody response, adjuvants can be designed to target the 
appropriate DC subsets. Adjuvant systems (AS) such as AS01 are used in malaria (RTS,S), 
herpes zoster (HZ/su), TB and HIV vaccines, while AS03 is used in several influenza vaccines 
such as trivalent inactivated H1N1 influenza, H5N1 pre-pandemic influenza and candidate H7N1 
and H7N9 pandemic influenza vaccines. On the other hand, AS04 is used in licenced HPV-16/18 
and HBV vaccines. Such ASs are known to augment antigen-specific T cell and antibody 
responses [178]. Adjuvants can also facilitate DC activation by increased surface expression of 
co-stimulatory CD80 and CD86 molecules and secretion of cytokines. In B cells, depending upon 
the antigen used, TLR ligands as adjuvants induce upregulation of surface markers involved in 
antigen uptake (MHC-I and MHC-II) and surface markers involved in cross-talk with the T cells 
(CD40, CD80 and CD86), which ultimately leads to increased antigen-specific antibody 
production [139]. Emulsigen, an oil-in-water adjuvant, similar to adjuvants used in human 
clinical trials such as MF59 and AS03, boosts the innate responses and increases the number of 
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CD4+ T cells required for robust antibody responses [180].MF59 supports induction of T 
follicular helper (Tfh) cells and GC responses to vaccination by an unknown mechanism [181]. In 
addition, adjuvant-mediated antibody responses must persist for sufficient period of time. 
Synthetic nanoparticles, for example, are known to induce high-affinity neutralizing antibodies 
lasting for decades.  
 
3.3.5.2 Ability to induce GC reactions to promote memory B cell development 
Immunological memory is a distinctive hallmark of the adaptive immune system that contributes 
to protective immunity against infectious diseases [182]. The GC reaction is central to memory 
development [183]. Induction of certain key molecules such as CD40, inducible T-cell 
costimulator (ICOS), IL-21, programmed death-ligand 1 (PD-1), CD95, IRF4 and B-cell 
lymphoma 6 protein (Bcl-6) play a critical role in regulation of GC differentiation, affinity 
maturation and long-lived memory responses [177]. TLRs expressed on GC B cells, follicular 
DCs (FDCs) and T cells have a profound effect on induction of antibody responses. 
Nanoparticles resembling virions in size and containing two TLR ligands, MPL (a TLR4 ligand) 
and R837 (a TLR7 ligand) as adjuvants in combination with H5N1 hemagglutinin antigen, 
mediate increased persistence of GCs, which significantly influence the differentiation of 
memory B cells critical for long-lived antibody responses [184]. A subset of CD4+ T cells, 
ICOS+CXCR3+CXCR5+ T cells, was identified as the cell type associated with protective 
antibody responses conferred by a trivalent split-virus influenza vaccine and efficiently induced 
memory B cells to differentiate into plasma cells [185]. Novel adjuvants may enhance B-cell 
activation in GCs and bone-marrow plasma cell survival. For example, the heat-labile enterotoxin 
(LT) of Escherichia coli, LTK63, when administered parenterally to neonatal mice, facilitates 
maturation of follicular DCs and generation of GCs [186]. 
 
3.3.6 Induction of cellular immunity: Effector Th1/Th2 and memory T cell responses: 
 
Th1 immunity is usually characterized by pro-inflammatory cytokines such as IL-12, IFN-γ, 
TNF-α, high levels of IgG2a/b, IgG2c, IgG3 and IgA in mice (or IgG1, IgG3 and IgA in 
humans), and CD4+ T cell- and CD8+ CTL-dependent CMI. On the other hand, Th2-immunity is 
usually defined by cytokines such as IL-4, IL-5, IL-6, IL-10, IL-13, as well as CD4+ T cell-
 46  
dependent B cell-mediated humoral immunity elicited by IgG1 and IgE/IgA in mice (or IgG4 and 
IgE in humans) [139]. In general, signaling via TLR3, TLR4, TLR7, TLR8 and TLR9 promotes 
Th1-biased immunity, while signaling via TLR2/TLR1, TLR2/TLR6 and TLR5 promotes Th2-
biased immunity. CD11c+CD11b-CD8α+ DCs localized in the marginal zones of LNs are capable 
of inducing both Th1 responses as well as exhibit cross-presentation functions. As a result of 
TLR3-mediated enhanced MHC-I expression and type I IFN production, poly(I:C) promotes 
antigen cross-presentation to CD8+ T cells and antigen-specific CTLs. Alum is known to cause 
Th2 responses (strong antigen-specific IgG1 and IgE production) and does not induce CD8+ T 
cell immunity, and even inhibits Th1 immune responses [139]. However, when alum is present in 
combination with MPLA, Th1 responses can be generated as is found for ASO4 [157]. In fact, 
due to the presence of MPLA, adjuvant systems such as AS01, AS02 and AS04 induce TLR4-
mediated NF-κB activation, production of cytokines, infiltration of DCs and monocytes into 
dLNs, and antigen-specific CD4+ T cell responses. Squalene-based oil emulsion is a potent 
inducer of both Th1- and Th2-mediated immunity and is well tolerated and safe [62]. Adjuvants 
such as QS-21, MF59 or CFA preferentially induce Th1-biased or a mixed Th1/Th17 and 
Th1/Th2 immune response.Experimental CAFs combined with immunostimulators such as TDB 
as adjuvants in TB vaccines stimulate both cellular and humoral immune responses, as well as 
promote efficient polyfunctional memory T cells, Th1- and Th17-biased immune responses 
[111].  
In neonates, CD4+ T cells are polarized towards Th2 responses (IL-4, IL-5 and IL-10) and 
reduced Th1 (IFN-γ, IL-2 and TNF-α) and CD8+ T cell responses [187]. However, novel 
adjuvants such as IC31 and CAF01 can induce adult-like Th1 responses in newborn mice [188]. 
CDG when used as a mucosal adjuvant induces Th1 and Th17 immune responses [189]. CAF01 
induces CD4+ T cell responses predominantly, while CAF05 (consisting of DDA, TDB and 
poly(I:C)) induces both CD8+ and CD4+ T cell responses [111]. Replacing AS02 in a 
RTS,S/AS02 candidate malaria vaccine with AS01 improved antibody and CD4+ T cell 
responses, as well as protective efficacy [190, 191].A central memory phenotype helps the T cells 
to promptly migrate to the sites of virus entry or exist at such sites before infection. Vaccine 
adjuvants must induce innate signals that can program activated T cells to migrate to mucosal 
tissues, for example, the vitamin A metabolite retinoic acid enhances α4β7 integrin and CCR9 to 
imprint gut tropism and increases IgA responses [177].  
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 PAMP adjuvant-mediated induction of PRRs (such as TLR, RIG-I, RLR, inflammasome) 
and DAMP adjuvant-mediated induction of stress-sensing pathways (such as lysosomal 
destabilization-Syk/Card9) leads to overall innate immune activation that is responsible for 
infiltration of both innate and adaptive immune cells and also plays an important role in 
determining the phenotype of antigen-specific T cells that would be generated. Activated sub-
capsular macrophages produce IL-18 that promotes generation of CD4+ T cells, while activated 
macrophages produce IL-6 or IL-12 that promote generation of Tfh cells, which in turn favours 
production of high-avidity antibodies by B cells [181].  A schematic representation of the 
mechanisms of action of adjuvant is depicted in Fig.3.1. Thus, a detailed understanding of the 
mechanism of action of adjuvants at both innate and adaptive levels will provide new strategies to 
improve existing adjuvants and/or design modern adjuvant platforms. 
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Figure 3.1 
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Fig. 3.1. Schematic representation to highlight the possible mechanism of action by which 
adjuvants exert their adjuvanticity. Adjuvants can serve as a depot that mediates recruitment of 
APCs or act as a delivery system to facilitate uptake of antigen by the APCs. Adjuvants may 
activate innate immune responses by signaling through cell surface CLRs (such as Dectin-1, 
Dectin-2, Mincle), cytosolic NLRs, cell surface TLRs, endosomal TLRs or cytosolic RIG-I and 
MDA5. Signaling via PRRs may lead to the activation of several transcription factors that result 
in the production of pro-inflammatory cytokines, chemokines and type I IFNs. Secretion of 
chemokines due to adjuvants may also result in the recruitment and infiltration of more immune 
cells. Adjuvants can activate c-GAS that participates in the STING-mediated IRF3-type I IFN 
pathway. Adjuvants can enhance the expression of MHC and co-stimulatory molecules to 
mediate efficient presentation of antigen to naïve CD4+ T cells. Depending upon the class of 
adjuvant, cellular (Th1) and/or humoral (Th2) immune response may be induced. Adjuvants also 
play important roles in GC reaction, affinity maturation and long-lived memory response as a 
part of humoral immunity. 
APC: antigen presenting cell, CLR: C-type Lectin receptors, NLR: nod-like receptors, TLR: toll-
like receptor; RIG-I: retinoic acid-inducible gene I, RLR: RIG-I-like receptor; IFN: interferon, c-
GAMP: cyclic guanosine monophosphate-adenosine monophosphate, c-GAS: c-GAMP synthase, 
STING: stimulator of IFN genes, GC: germinal centre, PRR: pattern recognition receptor, 
DAMP: damage-associated molecular pattern, ROS: reactive oxygen species, LDH: lactate 
dehydrogenase, Abs: antibodies, NLRP3: NLR family pyrin domain containing 3, AIM2: absent 
in melanoma2, MyD88: myeloid differentiation primary response 88, TRIF: TIR-domain-
containing adapter-inducing IFN-β, IRF: IFN regulatory factor, TIRAP: toll/interleukin-1 
receptor domain-containing adapter protein, AP-1: activator protein 1, NF-κB: nuclear factor-κB, 
MAL: MyD88 adaptor like, TRAM: TRIF-related adaptor molecule, MDA5: melanoma 
differentiation-associated protein 5, ER: endoplasmic reticulum, ICAM-1: intercellular adhesion 
molecule 1, NK: natural killer, CTL: cytotoxic T lymphocyte, MHC: major histocompatibility 
complex. 
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3.4 SELECTION OF ADJUVANTS BASED ON THEIR MECHANISM OF ACTION 
AGAINST DISTINCT TYPES OF PATHOGENS  
 
3.4.1 Mucosal pathogens 
 
Mucosal surfaces covering 400 m2 of the body are an attractive target for mucosal pathogens 
whose port of entry can be gastrointestinal (e.g. polio virus, Escherichia, Salmonella, Shigella, 
Vibrio and Helicobacter), respiratory (influenza virus, M. tuberculosis or Mtb, adenovirus, 
coronavirus, rhinovirus and RSV) or urogenital tract (HSV, HPV, HIV-1, Chlamydia and 
Neisseria) [192]. Mucosal adjuvants can be categorized as: toxin-based (LT and CT), 
immunostimulatory (MPL, CpG and QS21) and particulate (emulsion and ISCOMs). Two 
commonly used oral toxin-based adjuvants are a modified version of CT lacking the A subunit 
(CTB) from Vibrio cholerae and a double mutant of LT (dmLT) from Escherichia coli [193]. 
Both are potent but also toxic when used as mucosal adjuvants. Protective efficacy was attained 
when intranasal vaccines containing mutant LT adjuvants were used against HSV, Bordetella 
pertussis and Streptococcus pneumonia [194]. Pathogens such as RSV primarily infect upper and 
lower respiratory tracts and do not need to enter the blood stream to influence the disease 
outcome. Primary infection with RSV appears to permanently alter the characteristics of humoral 
and cell-mediated immunity and this might explain why natural infection with RSV induces poor 
antibody responses with impaired effector functions, and perturbs localization and persistence of 
effector and memory T cells [137]. Thus, induction of a potent, local mucosal immune response 
is required to prevent infection and a high systemic antibody response is also required to interrupt 
disease progression. In a recent study, Sastry et al tested multiple adjuvants such as Sigma 
adjuvant system (SAS, an oil-in-water adjuvant), carbapol, alum, Adjuplex, poly(I:C), 
poly(IC:LC), MPLA, AddaVax and Montanide ISA, and found that the adjuvant-mediated 
increase in neutralizing antibody and IgG responses was context-dependent (i.e. whether pre-
existing immunity was present or not) and species-specific (i.e. mice vs. calves) [195].  
The mucosal epithelial barrier limits the bioavailability of vaccine antigens for sampling 
by APCs. Adjuvants such as polyethyleneimine and chitosan are used as penetration enhancers 
and immunostimulants to augment binding to the mucosal surfaces and activate innate immunity 
[196]. Chitosan polymeric nanoparticles, for example, stimulate the NALT to produce mucosal 
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secretory IgA, IgG, TNF-α, IL-6 and IFN-γ. Pro-inflammatory cytokines and chemokines also act 
as mucosal adjuvants. IL-1, IL-6, IL-12, IL-15 and IL-18 induce mucosal CD8+ CTLs and 
antigen-specific IgA, while the chemokine CCL2 (or MCP-1) increases mucosal IgA and CTL 
responses [194]. Non microbial-derived mucosal adjuvants can act only as a delivery system, 
while others may act as DAMPs to induce breaks in the epithelial barrier so as to facilitate 
accessibility of vaccine antigen to the mucosal lamina propria-resident DCs. Neutralizing 
antibodies may protect against some acute self-limiting mucosal pathogens, but for highly 
invasive pathogens causing chronic infections (such as HIV, HCV, herpesviruses and 
mycobacteria), mucosal innate and adaptive immune responses including CD4+, Th17, and CD8+ 
CTLs, as well as secretory IgA and IgG1 neutralizing antibodies at the port of pathogen entry, are 
required for effective and optimal protection [197].  
While traditional parenteral vaccines fail to induce effective immune responses in the 
mucosal surfaces, mucosal adjuvant-containing vaccines elicit both local and systemic immune 
responses, effective at local as well as distant sites [193, 198]. There are several routes of 
administration of mucosal vaccines including sublingual, oral, intranasal, pulmonary, genital and 
rectal [199]. To control enteropathogens, orally administered vaccines must overcome several 
challenges, such as antigen degradation and immune tolerance. In this scenario, biodegradable 
micro- or nanoparticles are required that are resistant to low pH and can target antigen to M cells. 
U-Omp19, a bacterial protease inhibitor from Brucella abortus,is an oral adjuvant suitable for 
subunit vaccine formulation, which can inhibit stomach and gut proteases and delays antigen 
digestion at the lysosome to enhance antigen presentation and recruitment of immune cells to 
gastrointestinal mucosa [193]. Intranasal immunization with poly-I:C12U (Ampligen) in a H5N1 
influenza vaccine promotes increased levels of protective, mucosal IgA and systemic IgG. In 
phase II and III clinical trials of HIV vaccines, this adjuvant was found to induce maturation of 
mDCs, IL-12 secretion, increased antigen-specific Th1-type CD4+ T cells and CTL responses 
[139].  
 
3.4.2 Pathogens with complex life cycles 
 
Pathogenic fungi and protozoan parasites have complex life cycles and have a tendency to switch 
among several different forms during their life. Histoplasma capsulatum ordinarily grows as a 
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mold in the soil at low temperature, but upon inhalation into the lungs, it switches to yeast form 
and causes histoplasmosis. Interaction of infected macrophages with CD4+ and CD8+ T cells 
leads to increased production of Th1 cytokines, IL-12, IFN-γ and TNF-α that are critically 
important in generating protective immunity against H. capsulatum infection in mice. 
Leukotrienes, lipid mediators derived from arachidonic acid metabolism, are found to be potent 
adjuvants against such fungal infections [200].  
The malarial protozoan parasite Plasmodium spp. poses a threat to 3.3 billion people in 97 
countries and is estimated to cause 584,000 deaths in 2013 (WHO) [201]. Malaria vaccine 
development is impeded by the complex life cycle of Plasmodium spp., the intracellular stage in 
its life cycle, large physical size, surface antigenic diversity and enormous genetic and genomic 
plasticity [202]. Replication of the blood-stage parasite takes place extensively inside the cells, so 
it is partially protected from immune recognition allowing prolific growth and transmission of 
parasite clones. The parasite also plays a trick with the host innate immune responses by 
sequestering any innate immune ligand away from PRRs in the sporozoite and gametocyte stages 
of their life cycle. A malaria vaccine needs to establish humoral immunity to prevent merozoites 
from entering the erythrocytes and the liver or destroy the merozoites through opsonization and 
CMI. RTS,S/AS01 (Mosquirix) is a malaria candidate vaccine that has progressed through phase 
III clinical studies with an acceptable clinical safety profile and a positive benefit-risk ratio [110]. 
Targeted against the infectious sporozoite stage, RTS,S/AS01 is designed to enhance both 
antigen-specific humoral and cellular immunity. It is still debatable if a good antibody response 
to the circumsporozoite protein in the vaccine or TNF-α and IL-2 producing CD4+ T cells are the 
immunological correlates of protection. Th1 effector cells are essential to target asexual blood 
stages, while eventual control and/or clearance of the parasites requires antibody-mediated 
responses [203]. MPL and Q-S21, the two components used in AS01 have important functions. 
MPL is a TLR4 agonist [204] that induces production of IFN-γ by T cells and antibody isotype 
switching to IgG2a/c in mice [110], while QS-21 is capable of inducing neutralizing antibodies 
and cytotoxic T cell responses [205]. QS-21 is also found to activate the ASC-NLRP3 
inflammasome to release matured IL-1β and IL-18; however, NLRP3 is not activated in vivo 
when QS-21 is used with HIV-1 gp120, a clinically relevant vaccine antigen [206]. AS01 
requires synergistic activities of both MPL and QS-21 for optimal adjuvant activity [110]. AS01 
in combination with Plasmodium antigens induces rapid and transient innate immune responses 
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in the injection site and dLNs, activation of a broad population of immune cells including APCs, 
as well as generation of 20-fold higher antibody titres than those induced by natural exposure 
[203].  However, in a large phase III trial in 8922 children and 6537 young infants in seven sub-
Saharan African countries, the vaccine efficacy declined with subsequent follow-ups in the 
infants and did not provide significant protection against severe malaria, warranting an alternative 
development plan [207]. Poly(I:C) and its derivatives are of great importance for vaccines that 
need to induce a Th1/CTL immune response against various viruses and pathogens including P. 
falciparum [174]. Pam3CSK4 was used in a malaria vaccine containing P. falciparum 
circumsporozoite protein B cell epitopes and universal T cell epitopes, which resulted in the 
induction of high titres of antigen-specific IgG, IgG1, IgG3 and IgG4 [139].  
 
3.4.3 Pathogens with latent disease phase 
 
Herpesviruses are large viruses with a complex genome. The single most unique feature shared 
by all herpes viruses is latency. Primary infection with varicella zoster virus (VZV), a human 
herpesvirus that causes varicella (chickenpox) may go into latent phase in human cranial and 
dorsal root ganglia. Later in life, several factors may reactivate the virus to cause herpes zoster 
(shingles) [208]. Aging or iatrogenic immune dampening results in decline of VZV-specific CMI, 
which may induce reactivation of the virus and may cause the severity of shingles [209]. Hence, 
CMI is necessary to prevent reactivation of the latent virus. A VZV vaccine must prevent herpes 
zoster and boost pre-existing cellular immunity due to primary infection/immunization. The VZV 
candidate vaccine HZ/su (Shingrix) composed of the VZV glycoprotein E subunit (gE) antigen 
and AS01B as the adjuvant platform was approved by the Food and Drug Administration (FDA) 
on Oct 2017 for the prevention of herpes zoster in adults aged 50 years or older [210]. AS01 was 
selected as the adjuvant for VZV vaccine, because compared to other adjuvant systems (including 
AS02, AS03 and AS04), AS01 induced higher numbers of IFN-γ secreting CD4+ T cells, and 
thus improved T cell as well as antibody responses with acceptable clinical safety profiles [211, 
212].  
HPV effectively evades innate immunity by inhibiting the IFN receptor signaling 
pathways and activation of ISGs via the E6 and E7 proteins. HPV also downregulates TLR9 and 
does not induce any danger signal to alert the immune system [213]. This prolongs the duration 
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of infection and the onset of activation of adaptive immunity. Thus, an effective CMI is required 
to clear and control HPV infection. Effective vaccine immunity against HPV should consist of 
CMI to the early proteins, E2 and E6 [214] and neutralizing antibodies against the virus coat 
protein L1. Two currently approved HPV vaccines, Cervarix (a bivalent HPV 16/18 vaccine, 
GSK) and Gardasil (a quadrivalent HPV 6/11/16/18 vaccine, Merck) are highly protective against 
HPV 6, 11, 16 and 18 [215]. Both are L1 VLPs; however, Cervarix is AS04-adjuvanted [216], 
while Gardasil is AAHS (amorphous aluminium hydroxyphosphate sulfate)-adjuvanted [217, 
218]. VLPs strongly activate the stromal DCs in the injection site that migrate to the dLNs or 
may directly bind to the surface of APCs or other immune cells and migrate to the LNs where 
they prime naïve B cells. The L1 VLP vaccines when delivered intramuscularly are advantageous 
because they are morphologically and antigenically comparable to the wild-type virus, generate 
1-4 log higher levels of antibodies after the third immunization than those elicited by natural 
infection and also result in B cell memory, antibody persistence and robust recall responses 
[213]. According to a recent study in girls aged 9-14 years, two doses of Cervarix elicited 
superior HPV-16/18 antibody responses compared to two or three doses of Gardasil. The 
differences in immunogenicity between the two vaccines may be due to different types of 
adjuvants used. AS04 enhances humoral immune responses and CMI by triggering local and 
transient cytokine responses that promote enhanced activation and presentation ability of APCs. 
However, compared to aluminium salt alone, AS04-adjuvanted vaccines may increase side 
effects such as pain. On the other hand, it has previously been found that when compared to 
aluminium phosphate and aluminium hydroxide, AAHS binds HPV L1 VLPs more 
strongly[218]. This is in line with induction of significantly higher antibody titres in mice 
immunized with HPV-16 L1 VLPs adsorbed onto AAHS when compared to VLPS adsorbed onto 
aluminium hydroxide, along with an improved L1-specific IFN-γ secreting T cell response [219]. 
 
3.4.4 Intracellular pathogens 
 
TB is a leading cause of mortality worldwide with an estimated 10.4 million new cases and 1.8 
million deaths reported in 2015 [220]. Mtb is an intracellular pathogen that has the ability to 
survive within the hostile environment of the alveolar macrophages after being phagocytosed and 
to multiply unchecked [221]. Mtb infection is characterized by active symptomatic and dormant 
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(latent) asymptomatic stages. Cell populations that play critical roles in controlling Mtb 
infections are CD4+ T cells, CD8+ T cells, CTLs, Th17 cells, NK cells and activated macrophages 
[222]. Bacilli Calmette-Guérin (BCG) is the only prophylactic vaccine available and induces 
moderate antibody responses. However, BCG fails to protect adults from pulmonary TB and 
prevent transmission of Mtb in adolescents and adults [128]. Thus, there is an urgent need for 
improved vaccines against TB. One of the potential vaccine strategies against Mtb is to eliminate 
or control latent infection and prevent reactivation or progression to clinical TB in latently 
infected patients. This may be accomplished by incorporating adjuvants that are capable of 
inducing both CD4+ and CD8+ T cell responses in both immunocompetent and 
immunocompromised individuals.  
Mechanisms of antibody-mediated protection against TB include opsonization, 
complement activation and Fc receptor engagement. Current research is focused on adjuvants that 
act on innate lymphoid cells (ILCs), NK cells and non-classical T cells such as CD1, MR1, HLA-
E and γδ T cells present in large numbers in the circulation and mucosa [223]. Adjuvants that 
boost high-avidity antibody responses primed by the BCG vaccine are also warranted. Currently 
8 out of 13 TB vaccines that are in clinical development are subunit vaccines. Although the 
immune correlates of protection from TB disease are not validated yet, current clinical vaccines 
in development predominantly focus on generating CD4+ and CD8+ Th1-type immune responses 
[223]. Several adjuvants such as mineral salts, saponin, emulsion, micro- or nanoparticles, toxin 
derivatives, cationic lipids, CpG DNA, adjuvant systems and cytokines have been tested in 
subunit vaccine preparations, either alone or in combination with BCG in a prime-boost strategy 
[128, 224]. These adjuvants enhance antigen/adjuvant uptake, as well as improve antigen 
presentation by DCs and induction of CD4+ and CD8+ T cell responses. The strongest Th1-
inducing adjuvants for TB are unmethylated mycobacterial DNA and CpG ODN, which promote 
CTL activation and IFN-γ production [128]. TLR2/1 and TLR2/6 ligands are presented on the 
surface of Mtb (triacylated and diacylated forms of mycobacterial p19 lipoprotein) [225] or 
secreted by the bacterium, while NLRs such as NOD2 are responsible for intracellular 
recognition of mycobacteria [226]. Novel adjuvants, including DDA, TDB, IC31, poly(I:C), 
gelatin, CpG ODN, MPLA, GLA-SE, MF59, CAF01 and AS01B are also being clinically tested. 
DDA is responsible for generating both humoral, cell-mediated and IFN-γ responses against Mtb, 
while MPLA and MF59 induce strong Th1 immunity against Mtb. CpG ODN activates the innate 
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immune system and triggers transition from Th2- to Th1-biased immune responses. All these 
adjuvanted subunit vaccines induce protective immunity and enhance BCG-primed immunity in 
animal models [222]. Nanoparticle-based vaccines easily enter into APCs by different pathways, 
modulate the immune responses to the antigen and are critical for the induction of protective Th1-
type immune responses to intracellular pathogens [121]. The liposomal CAF01 adjuvant induced 
Th1 and long-lasting memory T cell response in human TB vaccination trials [118]. CAF01-
adjuvanted TB vaccine stimulates the CLR, Mincle, and triggers the Syk/Card9 signaling cascade 
to activate the Th17 signaling pathway [111]. 
Overall, a careful selection of adjuvants is critical in eliciting appropriate immune 
responses against different kinds of pathogens. In general, AS01 induces Th1-type immunity, and 
enhances antibody and CD8+ T cell responses to TB, VZV, HIV and malaria. On the other hand, 
AS02 induces a more balanced Th1/Th2 immune response as found for HBV, HIV, Mtb and 
Plasmodium spp. AS02 induces higher CTL responses than AS04 as tested in HBV, HPV, HSV 
and Epstein-barr virus (EBV) vaccines and elicits improved protective immunity compared to 
alum. GLA-SE induces strong Th1-type immunity and enhanced safety [139]. CpG ODNs used 
in malaria vaccines induce strong antibody responses to the malarial antigen and also generate 
long-term antibody responses against HBV. In contrast, TLR2 ligands such as MALP-2 
(TLR2/TLR6 ligand) and Pam3CSK4 (TLR2/TLR1 ligand) exert adjuvanticity primarily through 
enhancement of Th2-biased immune responses, while TLR2/TLR1 signaling is also known to 
promote protective mucosal Th17 immunity to mucosal pathogens. TLR agonists as adjuvants are 
beneficial not only due to their ability to preferentially elicit Th1, Th2, CD4+ or CD8+ T cell 
responses but also to modulate B cell activation, improve the quality and quantity of specific 
antibody production and greatly enhance mucosal immunity [139]. 
 
3.5 NEW APPROACHES TO STUDY ADJUVANTS’ MODES OF ACTION  
 
One of the biggest challenges in vaccine development is that the immunological mechanisms that 
govern vaccine safety and efficacy are still largely unknown. Animal models have their own 
limitations and human sampling from multiple tissues is at times inconvenient [227]. 
Transcriptional, signaling and metabolic pathways are altered in various immune cells in 
response to vaccination. In recent years, systems vaccinology has emerged as an interdisciplinary 
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approach that relies on high-throughput omics-based techniques to study vaccine-induced 
changes in the entire genome, set of transcripts (transcriptomics), proteins (proteomics) and 
metabolites (metabolomics) in various tissues [228, 229]. All these technologies are then 
combined with bioinformatics tools such as transcription network analysis and predictive 
modeling to determine signatures that correlate with the ensuing adaptive immune responses or 
protective immunity. Systems vaccinology is gaining tremendous importance as it also offers an 
integrated picture of the molecular network driving vaccine immunity, adjuvant mechanism of 
action, molecular mechanism underlying adjuvant safety and efficacy, and also helps in the 
rational design of vaccine adjuvants [230]. Systems vaccinology can be used to study the cell 
type responding directly to the vaccine adjuvants, mechanism of interactions between PRRs and 
PAMPs, their downstream signaling cascades and the final effects on the innate and adaptive 
immune responses. However, it is also imperative to perform traditional immunological assays 
such as enzyme-linked immunosorbent assay (ELISA), Enzyme-Linked ImmunoSpot (ELISpot), 
flow cytometry and neutralization assays in parallel, to correlate with the results generated by 
high-throughput technologies [229]. When systems vaccinology is coupled to computational and 
statistical algorithms, we can obtain valuable information on how to design and choose the 
optimal adjuvant for disease-specific vaccines so that we do not rely only on empirical adjuvants. 
A systems vaccinology approach has been used to elucidate immune responses to vaccines 
against yellow fever [231-233] influenza [234], malaria [235, 236], smallpox [237] and HIV 
[238, 239]. In  recent study, a systems vaccinology approach was used to identify molecular and 
cellular immune signatures as well as the effect of route of administration of a vaccine against 
Bordetella pertussis [240]. Through systems vaccinology, IP-10 was identified as an early innate 
immune signature that correlated with antibody responses to an Ebola vaccine (rVSV-ZEBOV) 
[241]. 
 
3.5.1 Understanding the mechanism of vaccine immunity: identifying biomarkers of vaccine 
adjuvanticity  
 
In humans, systems vaccinology facilitates understanding of vaccine-induced innate and adaptive 
immune responses at a mechanistic level [184]. Computational analysis of the transcriptomic 
profile in human PBMCsinduced by yellow fever vaccine YF-17D identified two molecular 
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signatures or biomarkers: eukaryotic translation initiation factor 2 alpha kinase 4 (EIF2AK4, also 
known as general control nonderepressible 2 or GCN2), and TNFRSF17, encoding the receptor 
for the B-cell growth factor BLyS-BAFF [231]. EIF2AK4 correlated with the magnitude of the 
CD8+ T cell responses, while TNFRSF17 correlated with the magnitude of neutralizing antibody 
responses. Moreover, EIF2AK4 is involved in the integrated stress response and the above 
observation indicates that stimulation of the integrated stress response has an important effect in 
the regulation of adaptive immune responses to YF-17D. In addition to EIF2AK4, other genes 
involved in the integrated stress response pathway, such as calreticulin, c-Jun and glucocorticoid 
receptor, were also induced by YF-17D, and this induction correlated with CD8+ T cell responses 
[231]. The above study provided the ‘proof of concept’ evidence that molecular signatures can 
indeed be identified early after vaccination with the help of a systems vaccinology approach, 
which in turn, can be used to predict the immunogenicity of a vaccine at a later stage. In a study 
in China with the YF-17D vaccine, Hou et al reported that genes involved in innate cell 
differentiation and immune response pathways, cytokine and receptor genes, as well as various 
transcription factors were differentially regulated at the transcriptomic level, which helped to 
better understand the mechanism of action of this vaccine at innate and adaptive levels [233]. In 
another study, the early TNFRSF17 level induced in response to trivalent inactivated influenza 
vaccine (TIV) correlated with hemagglutination inhibition (HAI) titres, while early expression of 
a kinase (calcium/calmodulin-dependent protein kinase type IV or CaMKIV) inversely correlated 
with later HAI titres [234]. In a comparative system vaccinology study between intranasally 
delivered live attenuated influenza vaccine (LAIV) and intramuscularly administered TIV, it was 
revealed that TIV induced higher antibody levels and plasmablasts when compared to LAIV with 
induction of distinct transcriptional signatures such as enhanced expression of type 1 IFN genes 
in LAIV recipients, but not in TIV recipients [242]. Similarly, based on a systems vaccinology 
approach, TLR5 agonists as adjuvants were found to potently enhance the immunogenicity of 
influenza vaccine, resulting in an improved antibody response. The longevity of the 
immunoglobulin response post vaccination could be predicted from the ability of the adjuvanted 
vaccine to induce proliferation of antigen-specific IL-21+ICOS1+CXCR5-CD4+ T cells in the 
peripheral blood [242].    
As discussed earlier, genome-wide microarray analysis of the muscle tissue of mice 
immunized with alum, CpG or MF59 induced ‘adjuvant core response genes’, which were linked 
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to recruitment of immune cells to the site of immunization, activation of type I IFNs and 
inflammatory responses. Two genes, Junb and Ptx3, were specifically activated by MF59. 
Identification of these two biomarkers also helped to identify skeletal muscle tissue cells (in 
addition to APCs) to be the direct target of MF59 to execute its adjuvant action [165]. Caproni et 
al investigated molecular signatures induced by different TLR-dependent (CpG ODN, 
Resiquimod and Pam3CSK4) and TLR-independent (MF59 and alum) adjuvants in influenza 
subunit vaccines to establish the innate immune correlates of adjuvanticity using DNA 
microarrays [243]. Results of this study revealed that only two adjuvants, MF59 and Pam3CSK4 
increased overall antibody and HAI titres. Furthermore, MF59 and Pam3CSK4 induced active 
infiltration of CD11b+ cells, especially neutrophils, to the injection site, suggesting early 
induction of CD11b+ cells due to emulsion-based adjuvant to be predictive of subsequent robust 
humoral immunity. This was also consistent with the transcriptomic profiling that identified an 
increase in the expression of leukocyte transendothelial migration gene cluster, including Itgam 
encoding CD11b [109, 243]. Inclusion of MF59 in influenza vaccines for infants induced a potent 
antibody response that correlated with a strong early IFN transcriptional signature similar to non-
adjuvanted influenza vaccine responses in adults, thus, such a signature can be considered as a 
correlate of protection against influenza [227].  
Systems vaccinology has also been applied to identify novel mechanisms of induction of 
Th2 responses by an adjuvant. For instance, the Th2-promoting adjuvant activity of cysteine 
protease allergen is dependent on the production of ROS by DCs. As a result of induction of 
ROS, oxidized lipids are induced that in turn promote epithelial cell-mediated production of 
thymic stromal lymphopoietin (TSLP) via TLR4-TRIF signaling and also trigger production of 
the chemokine CCL7 by the DCs. This is responsible for the recruitment of IL-4+ basophils to the 
LNs for induction of Th2-type immune responses [244]. Genes associated with memory B cell 
formation and productive antibody responses such as Bcl2, Bcl11a, Tank, Plcg2 and Cd38 are 
induced when mice are immunized with ovalbumin (OVA) adjuvanted with TLR7 and TLR4 
agonists [109]. In a study with the candidate malaria vaccine RTS,S/AS01B by Vahey et 
al,enhanced expression of genes involved in immunoproteasome formation, PSME2 
inparticular,was found to be responsible for conferring protectionfrom parasitemia. Induction of 
the immunoproteasome enhances MHC antigen presentation, which in turn, indirectly enhances 
antibody responses and directly augments CD4+ T cell development and production of IFN-γ, 
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TNF-α, IL-2 and CD40L. The above immune signatures may contribute to the protective efficacy 
of the candidate malarial vaccine [109, 235]. A comparative systems analysis of four vaccine 
adjuvants, GLA-SE, IC31, CAF01 and alum, in mice revealed distinct molecular signatures. 
GLA-SE induced massive changes in the transcriptomic profile in the whole blood and dLNs that 
correlated with increased cellular influx (such as CD11c+GR1+ mDCs) in the dLNs, in contrast to 
limited transcriptomic changes induced by other adjuvants. Co-expression analysis of 
differentially expressed genes in the whole blood revealed that CAF01 and GLA-SE (but not 
IC31) induced transcriptional signatures related to innate immune responses. The analysis also 
revealed gene modules enriched for genes associated with Tfh and GC-mediated B cell 
responses; for example, GLA-SE induced Nfatc1, Nfatc2 and IL21R; CAF01 induced Batf and 
IC31 induced Pou2af1 [245].  
 
3.5.2 Identifying factors controlling vaccine safety and efficacy 
 
Systems vaccinology approaches are beginning to elucidate the mechanism of action of vaccines 
and identify signatures of vaccine safety and efficacy. Non-specific adverse side effects 
associated with unsuccessful vaccines are often associated with over-stimulation of certain 
components of the innate immune system. Systems vaccinology can be applied to screen 
adjuvants to help design protective and safe vaccines [246]. Integration of systems vaccinology 
approaches into clinical trials will help to define the correlates of protection or efficacy. 
Correlates of protection have been established for a number of licensed vaccines as reviewed by 
Tomaras et al. However, attempts to identify correlates of protection are still ongoing for TB 
[247], while the commonly assumed immune correlates often fail to correctly predict an 
individual’s risk of developing malaria [248]. For HIV, complex immune correlates of protection 
characterized by multiple types of immune responses are found to be involved in controlling 
HIV-1 transmission [249]. For vaccines whose immune correlates of protection are unknown, 
systems vaccinology approaches can be used to identify signatures induced rapidly after 
vaccination that will help to predict the later immune outcome. A systems vaccinology approach 
can also help in screening vaccine non-responders as well as vaccine high- and low-responders 
[71, 250]. 
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Innate and adaptive immune responses are profoundly influenced by any significant 
changes in metabolic activity. Inflammation triggered by vaccine adjuvants involves infiltration 
and high proliferation rates of inflammatory cells including neutrophils and monocytes. This 
results in a shift in energy supply leading to metabolic acidosis and impaired oxygen supply, 
which in turn results in phenotypic shifts. These phenotypic shifts heavily affect the metabolic 
state of an individual [251]. Lipid metabolism plays an important role in inflammation. 
Analytical chemistry techniques such as LC-MS are employed to identify and quantify cell- or 
tissue-specific metabolites [71]. Metabolite immune-correlates such as nucleotides, amino acids, 
lipids, fatty acids and anti-oxidants may represent inflammatory mediators and/or biomarkers that 
profoundly influence several inflammatory processes such as cellular infiltration, activation of 
signaling pathways and oxidative stress [252]. Thus, a comprehensive understanding of the 
molecular signatures induced by adjuvants early after vaccination will help to predict the later 
adaptive immune responses in humans. Furthermore, such knowledge will also improve or help 
in re-designing next-generation adjuvants and drive development of next-generation vaccines 
with the concerted effort of vaccinologists, clinicians, immunologists, systems biologists, 
statisticians, computational specialists, industrial and regulatory authorities.  
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Table 3.1: A comprehensive list of vaccine adjuvants and their mode of actions 
 
 
Adjuvant class Examples Mechanism of action References 
 
Liposome- 
based adjuvants 
 
Virosome*$ 
Archaeosome$ 
CAF01 
Antigen delivery system; mucoadhesive; depot effect; 
immunostimulatory; strong antigen specific antibody 
and Th1/Th2 cell responses 
 
[114-116, 
128, 192] 
 
Tensoactive 
 
 
Saponin-based (ISCOMs#$, ISCOMATRIX#, 
Matrix-MTM and QS-21$) 
 
Antigen delivery system; immunostimulatory; 
induction of cytokines and cellular influx; induction 
of Th1- or mixed Th1/Th17-, Th1/Th2-type as well as 
strong antibody immune responses 
 
[111, 114, 
119, 120] 
 
 
 
Particulates 
 
Polymeric nanoparticles: Ex. PLGA$, PLG, PLA, 
PGA and PHB 
 
Inorganic nanoparticles: Ex. Gold nanorods, gold 
nanoparticles, carbon nanoparticles, silica-based 
nanoparticles like mesoporous silica nanoparticles 
(MSN) 
 
Polyphosphazene 
 
 
Antigen delivery system; depot effect; mucoadhesive; 
strong antigen-specific Th1/Th2, CD8+ T cell and 
antibody responses; potent inducer of ‘adjuvant core 
response genes’ as well as induction of cytokines, 
chemokines and enhanced cellular influx (PCEP) 
 
 
 
[114, 121, 
130, 132] 
 
 
Mineral salts  
 
Aluminium salt$: alum* (aluminium potassium 
sulphate), alhydrogel (aluminium hydroxide), Adju-
Plus (aluminium phosphate) 
 
Calcium salt$ 
Iron salt 
Zirconium salt 
Antigen delivery systems; source of DAMP; potent 
inducer of ‘adjuvant core response genes’ (alum); 
cytokine, chemokine, antibody and Th2 responses 
[123, 124, 
139, 165, 
166, 179, 
192] 
 
 
 
 
 
Emulsions 
  
Water in oil emulsion (W/O): Ex. Complete Freund’s 
adjuvant (CFA), Montanide ISA51$, Incomplete 
Freund’s adjuvant (IFA)#$ 
 
Oil in water emulsion (O/W): Ex. MF59*$ 
(Squalene+Tween80+sorbitran trioleate), Emulsigen$ 
 
GLA-SE 
Antigen delivery system (MF59); depot effect 
(emulsigen); enhanced antigen uptake by APCs; 
potent inducer of ‘adjuvant core response genes’ as 
well as cytokine, chemokine, and antibody responses; 
Th1- or mixed Th1/Th17- and Th1/Th2-type immune 
responses (MF59 and CFA); induction of CD4+ T 
cells to promote antibody responses (Emulsigen); 
strong Th1 responses (GLA-SE) 
 
 
 
[80, 126, 
132, 139, 
165-167, 
180, 192] 
 
 
Nucleic acid/ 
Nucleotides 
dsRNA: Ex. poly(I:C)#, polyI:C12U (Ampligen), 
poly(IC:LC)# (Hiltonol), M8, defective interfering 
(DI) RNA 
 
CpG ODNs#$: Ex. IC31 (unmethylated CpG DNA) 
 
Cyclic dinucleotide: Ex. CDG 
 
PRR activation; potent inducer of ‘adjuvant core 
response genes’ (CpG); type I IFN induction; pro-
inflammatory 
cytokine/chemokine/antibody/CD4+/CD8+ T cell 
responses; mucosal adjuvant inducing Th1 and Th17 
immune responses (CDG) 
 
 
 
 
[153, 165, 
192] 
 
 
 
 
Toxins 
 
Cholera toxin (CT)$ and CTA1-DD (CT derivative) 
Heat-labile toxin (LT)$ and mutant LT toxin 
(LTK63) 
Clostridium difficile toxin 
Shiga toxin 
Staphylococcal enterotoxins 
LPS (endotoxin or lipoglycan) 
MPLA#$ 
 
Mucosal adjuvants; immunostimulatory; PRR 
activation; induction of cytokine responses and 
cellular influx (LPS and MPLA); induction of strong 
mucosal IgA, Th1, Th2, Th17 and CTL responses 
 
 
 
[149, 186, 
192] 
 
 
 
Carbohydrate/ 
Polysaccharide 
 
Glucans: α-glucans (Ex. Dextran), β-glucans (Ex. 
Zymosan), lentinan, algal glucan, β-glucan particles 
Fructans 
Mannans  
Chitin/Chitosan 
Zymosan 
Site-directed delivery of antigens; source of DAMP 
(chitosan); mucosal (chitosan); PRR activation; 
upregulation of co-stimulatory molecules; activation 
of complement pathways; chemotaxis; activation of 
inflammasome; penetration enhancer; induction of 
pro-inflammatory cytokines and secretory antibody 
responses; Th2 and mucosal IgA responses 
 
 
[151, 154, 
196] 
 
Peptides/ 
Lipopeptides/ 
Peptidoglycans 
 
Muramyl dipeptide (MDP)#$ 
Lipopeptides: Ex. MALP-2 
Lipopeptide analogs: Ex. Pam3CSK4 
Host defense peptides: Ex. IDR1001, IDR1002, LL-
37 and Defensin 
PRR activation; mucosal IgA; pro-inflammatory 
cytokine; induction of Th1 (GLA-SE), Th2 (MALP-2 
and Pam3CSK4), mucosal Th17 (Pam3CSK4) and 
antibody responses 
 
[87, 138, 
139, 148, 
192] 
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Proteins Flagellin# 
Profilin 
PRR activation; strong mucosal IgA/Th2/Th17 
responses 
[142, 143] 
 
Lipids  
  
α-GalCer (Glycosphingolipids) 
RC529 (lipid A mimetic) 
Monophosphoryl lipid A 
Endocine 
 
PRR activation; source of DAMP (Endocine); 
Th1/CTL and mucosal IgA responses 
[150, 192] 
 
 
Cytokines and 
chemokines 
 
GM-CSF$ 
Type I IFNs 
IFN-γ$ 
IL-1, IL-2$, IL-6, IL-12$, IL-15, IL-18 and IL-21 
CCL2 
Induction of Th1/Th2/CD8+ T and mucosal IgA 
responses; B and T cell differentiation (IL-21); 
activation of DCs as well as increased migration and 
antigen presentation to CD4+ T cells; cross-priming 
of CD8+ T cells; activation of B cells and NK cells; 
generation of Th1 biased CD4+ T cells (IFNs); 
mucosal IgA and CTL responses (CCL2) 
 
 
[159, 194] 
 
Small molecule 
immune 
potentiator 
(SMIPs) 
SMIPs for TLR7/8: Ex. Imiquimod#(or R837), 
Resiquimod#(or R848), Gardiquimod 
SMIPs for TLR4 (SLA, substituted pyrimido[5,4-
b]indoles) 
Second generation SMIP-based adjuvants for TLR7/8 
formulated with Al(OH)3 
 
Localized innate immune activation; short in vivo 
residence time and PRR activation (second generation 
SMIP-based adjuvants for TLR7/8); induction of 
Th1-biased cytokines and chemokines (SMIPs for 
TLR4) 
 
 
[145, 146, 
160, 161, 
192] 
 
* indicates adjuvants licensed for human vaccines [112] 
# indicates adjuvants that have been tested in human clinical trials[112, 130] 
$ indicates adjuvants used in veterinary vaccines [253, 254] 
 
PRR: pattern recognition receptor, DAMP: damage-associated molecular pattern, APC: antigen 
presenting cell, IFN: interferon, CAF: cationic adjuvant formulation, Th: Thelper, ISCOM: 
immune stimulating complexes, PLGA: poly(lactic-co-glycolic acid), PLA: poly(lactic acid), 
PGA: poly(glycolic acid), PHB: poly(hydroxybutyrate), PCEP: poly[di(sodium 
carboxylatoethylphenoxy)]-phosphazene, PCPP: poly[di(sodium carboxylatophenoxy)]-
phosphazene, GLA-SE: glycopyranosyl lipid adjuvant (GLA) in combination with squalene (SE), 
ds: double-stranded, ODN: oligodeoxynucleotide, CDG: cyclic di-GMP, LPS: 
lipopolysaccharide, MPLA: monophosphoryl lipid A, MALP-2: macrophage activating 
lipopeptide-2, IDR: innate defense regulator, GM-CSF: granulocyte-macrophage colony-
stimulating factor. 
 
 
 64 
 
CHAPTER 4 
4                                       HYPOTHESIS AND OBJECTIVE 
 
4.1 Rationale and hypotheses 
Stimulation of the innate immunity is a critical determining factor for induction of an effective 
and robust adaptive immune response to a vaccine [255, 256]. Despite decades of research, there 
is no licensed vaccine against RSV [257]. Since RSV is a respiratory pathogen, intranasal 
immunization is the most attractive immunization strategy for induction of both mucosal and 
systemic immune responses. We developed a subunit RSV vaccine candidate (ΔF/TriAdj) that 
was found to be safe and its protective efficacy was demonstrated in several animal models, 
including mice, cotton rats and lambs [102, 258, 259]. This raised the possibility that ΔF/TriAdj 
might play an important role in stimulating innate immunity. We propose that ΔF/TriAdj when 
delivered intranasally may modulate the innate immune responses in the mucosal compartments 
of both upper and lower respiratory tract of the immunized subjects, which ultimately leads to 
induction of an effective and potent adaptive immune response as demonstrated previously. 
Vaccine-induced innate signal transduction pathways determine the immunological 
mechanisms by which vaccines work [260]. In-depth understanding of the signaling requirements 
of a vaccine is highly relevant for future evaluation in clinical studies as well as necessary for 
regulatory and licensing procedures [260]. We hypothesize that ΔF/TriAdj might act on several 
innate immune receptors present on innate immune cells such as macrophages. This would 
trigger multiple signal transduction pathways to induce effector responses. Metabolites are the 
final downstream end stage products of biochemical and physiological processes within the body 
and are described as the crucial regulators of immune cell functions [261-263]. We hypothesize 
that mice develop an altered metabolic profile due to RSV infection compared to healthy 
controls, while ΔF/TriAdj helps to mitigate such alterations in the metabolic profile following 
RSV infection. Understanding the role of ΔF/TriAdj in stimulating innate immunity, triggering 
signal transduction pathways and modulating any alteration at the metabolome level due to RSV 
infection might uncover important mechanisms of action of this RSV vaccine candidate.
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4.2 Objectives 
o Determine the role of ΔF/TriAdj in stimulating innate immune responses in the 
respiratory mucosal tissues following intranasal immunization in BALB/c mice. 
o Identify the signal transduction pathways involved in ΔF/TriAdj-mediated activation of 
macrophages. 
o Investigate the metabolomic profile in response to RSV infection, and the effect of prior 
vaccination with ΔF/TriAdj in modulation of the metabolic profile. 
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5.1 ABSTRACT 
 
Respiratory syncytial virus (RSV) causes serious upper and lower respiratory tract infections in 
newborns and infants. Presently, there is no licensed vaccine against RSV. We previously 
reported the safety and efficacy of a novel vaccine candidate (ΔF/TriAdj) in rodent and lamb 
models following intranasal immunization. However, the effects of the vaccine on the innate 
immune system in the upper and lower respiratory tracts, when delivered intranasally, have not 
been characterized. In the present study, we found that ΔF/TriAdj triggered transient production 
of chemokines, cytokines and interferons in the nasal tissues and lungs of BALB/c mice. The 
types of chemokines produced were consistent with the populations of immune cells recruited, 
i.e. DCs, macrophages and neutrophils, in the nose-associated lymphoid tissue (NALT), lung and 
their draining lymph nodes of the ΔF/TriAdj-immunized group. In addition, ΔF/TriAdj 
stimulated cellular activation with generation of mucosal and systemic antibody responses, and 
conferred complete protection from viral infection in the lung upon RSV challenge.The effect of 
ΔF/TriAdj was short-lived in the nasal tissues and more prolonged in the lung. In addition, both 
innate and adaptive immune responses were lower when mice were immunized with ΔF alone. 
These results suggest that ΔF/TriAdjmodulates the innate mucosal environment in both upper and 
lower respiratory tracts, which contributes to robust adaptive immune responses and long-term 
protective efficacy of this novel vaccine formulation. 
 
5.2 INTRODUCTION 
 
Human respiratory syncytial virus (RSV) causes a major global burden of disease and is 
estimated to be responsible for 53,000-199,000 infant deaths annually [264, 265]. When 
compared to influenza virus, RSV causes over nine times more deaths in children less than one 
year of age [266]. Presently, there is no licenced RSV vaccine. The nasal cavity in the upper 
respiratory tract (URT) is the first anatomical interface between RSV and the respiratory mucosa 
before it infects the lower respiratory tract (LRT) [267, 268].  The nose-associated lymphoid 
tissue (NALT) found at the entrance of the nasopharyngeal duct are the only pair of well-
organized mucosal lymphoid tissues in the URT in rodents where induction of immune responses 
can be initiated upon intranasal immunization [269-272].   
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Recently, various adjuvants and immune modulators have been developed to specifically 
trigger early innate immune responses [273]. We generated a subunit vaccine against RSV 
(ΔF/TriAdj) consisting of a truncated version of the fusion protein (ΔF) formulated with 
poly(I:C), innate defense regulator peptide 1002 (IDR1002) and poly[di(sodium 
carboxylatoethylphenoxy)]-phosphazene (PCEP). Intranasal immunization with this vaccine 
candidate establishes humoral and cell-mediated protective immune responses in rodent and lamb 
models [102, 258, 259].  
The present study was undertaken to delineate the innate mechanism by which ΔF/TriAdj 
mediates strong adaptive immune responses and to determine whether ΔF/TriAdj induces 
immune responses in both the URT (i.e. NALT) and the LRT (i.e. lung). The results demonstrate 
that ΔF/TriAdj stimulates the innate immune system by causing secretion of chemokines, pro-
inflammatory cytokines and interferons (IFNs), which in turn, triggers a series of molecular and 
cellular events including immune cell infiltration and activation. This then leads to the induction 
of protective immune responses in both nasal tissues and lung.  
 
5.3 MATERIALS AND METHODS 
 
5.3.1 Vaccine formulation, immunization and challenge 
RSV ΔF protein and ΔF/TriAdj were prepared as described previously [88, 258]. Briefly, HEK-
293 cells were transfected with an episomal vector expressing the truncated form of the native 
RSV F protein (amino acids 1-529) without the transmembrane domain (ΔF). The ΔF protein was 
his10-tagged at the carboxyl terminus and purified using TALON Superflow resin (Clontech, CA, 
USA). LMW Poly(I:C) (Invivogen, CA, USA) and IDR1002 (VQRWLIVWRIRK, Genscript, 
NJ, USA) were mixed in PBS (Life Technologies, pH 7.4) and incubated for 30 min at room 
temperature followed by addition of the ΔF protein. After another 15 min, PCEP was added to 
make a final 1:2:1 ratio of poly(I:C), IDR1002 and PCEP. Six to 8 week-old female BALB/c 
mice (Charles River Laboratories, QC, Canada) were immunized once intranasally with 
ΔF/TriAdjwith each mouse receiving 1 μg of ΔF protein, 10 μg of poly(I:C), 20 μg of IDR1002 
and 10 μg of PCEP in a 20 μl volume. In some experiments, animals were challenged intranasally 
with RSV A2 strain (5 x 105 p.f.u., ATCC, VA, USA) in a  50 μl volume three weeks post-
immunization (p.i.) and sacrificed four days later. All animal trials were conducted according to 
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the guidelines established at the University of Saskatchewan in accordance with the Canadian 
Council on Animal Care.  
 
5.3.2 Preparation of the nasal tissue and lung homogenate  
 
Nasal tissues were isolated as described previously [270]. To isolate the nasal structure of a 
euthanized mouse, the mouth was opened from the corners separating the mandible and the skull 
on both sides and continued to the back of the head. After removing the skin from the head, the 
incisors were removed. With the NALT facing up, a second incision was made at the front tip of 
the zygomatic arch to remove any existing muscle around the back edge of the NALT. A third 
incision was made into empty eye sockets and continued along the division line of frontal and 
parietal skull sections. Finally, the nose was broken off gently. The nasal structure thus obtained 
contained the nasal turbinates and mucosal tissues including NALT. The nasal structure and the 
lungs were homogenized in a Mini-Beadbeater (BioSpec Products, OK, USA) in either culture 
medium for chemokine/cytokine ELISA or in TRIzol reagent (Life Technologies, Burlington, 
ON, Canada) for RNA isolation as described previously [274, 275]. Tissue homogenization was 
carried out in a 2 ml screw cap tube containing 2.0 mm zirconia beads (BioSpec Products Inc., 
OK, USA). 
 
5.3.3 Quantitative Real Time PCR 
 
Total RNA was isolated from the lung of each mouse with TRIzol reagent (Life Technologies) 
according to manufacturer’s instructions. RNA integrity and stability was checked with an 
Agilent 2100 Bio analyzer system (Agilent Technologies, CA, USA). cDNA was synthesized by 
using a QuantiTect Reverse Transcription kit (Qiagen, Limburg, Netherlands) following the 
manufacturer’s instructions in a GeneAmp PCR System 9700 (Applied Biosystems, Life 
Technologies). Real-Time PCR was performed using FastStart SYBR Green Master (Roche, 
Basel, Switzerland) according to manufacturer’s instructions. Some primers were designed in-
house using NCBI PrimerBLAST (http://www.ncbi.nlm.nih.gov/tools/primer-blast/). PCR 
reactions were carried out in iCycler iQ Multicolor Real-Time PCR Detection System (Bio-Rad 
Laboratories, Inc.). Amplifications were carried out according to the following parameters: 950C 
 70  
for 10 min 40 cycles of denaturation at 950C for 15 sec, 55-67.60C (primer dependent) for 30 sec 
annealing and 720C for 30 sec extension. The primers used are listed in Table 5.1. Melt curves 
were analyzed to check the specificity of the amplicon. The reference gene GAPDH was used to 
normalize the expression levels of the transcripts. Final data were represented as fold-change 
normalized over untreated mice and calculated using the 2-ΔΔCT method. Data were analyzed 
using the Bio-Rad software. 
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Table  5.1 List of primers used in qRT-PCR   
Target gene Direction Sequence Amplicon size 
Annealing 
Temp (°C) Source 
CCL2   
(MCP-1) 
Forward 5' CTTCTGGGCCTGCTGTTCA3' 
127 bp 57.5 [275] 
Reverse 5' CCAGCCTACTCATTGGGATCA 3' 
CCL3    
(MIP-1α) 
Forward 5' CTTCTCTGTACCATGACACTC 3' 
208 bp 57.5 [275] 
Reverse 5' AGGTCTCTTTGGAGTCAGCG 3' 
CCL4    
(MIP-1β) 
Forward 5' AAACCTAACCCCGAGCAACA 3' 
90 bp 56.3 Designed in house Reverse 5' GAGAACCCTGGAGCACAGAA 3' 
CCL5   
(RANTES) 
Forward 5' CTCACTGCAGCCGCCCTCTG 3' 
112 bp 57.5 [275] 
Reverse 5' CCTTGACGTGGGCACGAGGC 3' 
CCL7   
(MCP-3) 
Forward 5' CCAATGCATCCACATGCTGC 3' 
100 bp 63.9 Designed in house Reverse 5' GCTTCCCAGGGACACCGAC 3' 
CCL11    
(Eotaxin-1) 
Forward 5' AGAGGCTGAGATCCAAGCAG 3' 
263 bp 63.9 [275] 
Reverse 5' CAGATCTCTTTGCCCAACCT 3' 
CXCL1  
(KC-GRO) 
Forward 5' ATGAGCTGCGCTGTCAGTGC 3' 
247 bp 56.3 Designed in house Reverse 5' CACCAGACGGTGCCATCAGA 3' 
CXCL2  
(MIP-2) 
Forward 5' TGCGCCCAGACAGAAGTCATAGC 3' 
129 bp 63.9 [275] 
Reverse 5' GCTCTAGAGTCAGTTAGCCTTGCCTTTG 3' 
CXCL10  
(IP-10) 
Forward 5' ATGACGGGCCAGTGAGAATG 3' 249 bp 67.6 Designed in house Reverse 5' GAGGCTCTCTGCTGTCCATC 3' 
TNFα 
Forward 5' AGGCACTCCCCCAAAAGATG 3' 
84 bp 57.5 Designed in house Reverse 5' CTGCCACAAGCAGGAATGAG 3' 
IL-1β 
Forward 5' GTGTGGATCCCAAGCAATAC 3' 
173 bp 55.0 Designed in house Reverse 5' GTCCTGACCACTGTTGTTTC 3' 
IL-6 
Forward 5' GTGGCTAAGGACCAAGACCA 3' 
95 bp 59.2 Designed in house Reverse 5' TAACGCACTAGGTTTGCCGA 3' 
IL-12α (p35) 
Forward 5' GGTGAAGACGGCCAGAGAAA 3' 
144bp 61.4 Designed in house Reverse 5' GTAGCCAGGCAACTCTCGTT 3' 
IL-12β (p40) 
Forward 5' GACCCTGCCCATTGAACTGGC 3' 
415 bp 57.5 Designed in house Reverse 5' CAACGTTGCATCCTAGGATCG 3' 
IL-4 
Forward 
 
Reverse 
5' GGAGATGGATGTGCCAAACG 3' 
 
5' ACCTTGGAAGCCCTACAGAC 3' 
78 bp 61.4      [275] 
IL-5 
Forward 
 
Reverse 
5' TGTTGACAAGCAATGAGACGATGA 3' 
5'  AATAGCATTTCCACAGTACCCCCA 3' 
136 bp 61.4 [276] 
 
IL-10 
 
Forward 
 
Reverse 
5' GCTGCCTGCTCTTACTGACT 3' 
 
5' CTGGGAAGTGGGTGCAGTTA 3' 
81bp 57.5 Designed in house 
 
IFN-α 
 
Forward 
 
Reverse 
5' CCTGTGTGATGCAACAGGTC 3' 
 
5' TCACTCCTCCTTGCTCAATC 3' 
209 bp 59.2 [275] 
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IFN-β 
Forward 5' ATCATGAACAACAGGTGGATCCTCC 3' 
419 bp 63.9 [275] 
Reverse 5' TTCAAGTGGAGAGCAGTTGAG 3' 
IFN-γ 
Forward 5' TCAAGTGGCATAGATGTGGAAGAA 3' 
92 bp 57.5 [275] 
Reverse 5' TGGCTCTGCAGGATTTTCATG 3' 
GAPDH 
Forward 5’ AACTTTGGCATTGTGGAAGG 3’  
223 bp 57.5 [275] 
Reverse 5’ ACACATTGGGGGTAGGAACA 3’  
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5.3.4 Preparation of single-cell suspensions of NALT, lung and lymph nodes (LNs) and 
flowcytometry 
 
Single-cell suspensions of NALT, cervical LNs (CLNs) and thoracic LNs (TLNs) were prepared 
as described previously [274, 275]. First, the upper palates of euthanized mice were collected in 
Hank’s balanced salt solution (Gibco, Life Technologies) containing 5% fetal bovine serum 
(FBS; Life Technologies). The NALT was gently teased off the palate with a sterile forceps and 
needle (Becton Dickinson, East Rutherford, NJ, USA). The cells were passed through 70 μm 
nylon mesh to obtain a single cell suspension of NALT. 
Perfused lungs were collected in gentleMACS C tubes (Miltenyi Biotec Inc., CA, USA) 
containing Hank’s balanced salt solution supplemented with 5% FBS (Life Technologies), 
collagenase from Clostridium histolyticum, Type IA (0.5 mg/ml, Sigma-Aldrich) and 
deoxyribonuclease I from bovine pancreas, Type IV (20 μg/ml, Sigma-Aldrich). After incubation 
at 370C for 20 min, the lungs were mechanically digested in a gentleMACS Dissociator (Miltenyi 
Biotec Inc.) according to the manufacturer’s instructions and then passed through 40 μm nylon 
mesh to generate single cell suspensions. 
Deep cervical and superficial cervical LNs were isolated from the URT of euthanized 
mice and pooled together (referred to as CLN). Similarly, tracheobronchial and mediastinal LNs 
were isolated from the LRT and pooled together (referred to as TLN). The LNs were mashed 
with a plunger and passed through 40 μm nylon mesh to obtain single cell suspensions. 
        Single-cell suspensions of NALT, lung and LNs were incubated with TrueStain fcX
TM
anti-
mouse CD16/32 antibody (Biolegend, catalogue no. 101320) in staining buffer (PBS containing 
0.2% gelatin and 0.03% sodium azide) for 5 min prior to immunostaining with various 
fluorochrome-conjugated monoclonal antibodies. After a brief incubation for 20 min in the dark 
at 40C, the cells were washed with the staining buffer before being fixed with 2% formaldehyde 
in PBS. Flow cytometry was performed with a BD FACSCalibur (BD Biosciences, NJ, USA). 
The fluorochrome-conjugated monoclonal antibodies used are listed in Table 5.2. Data were 
analyzed using Kaluza Software (v1.2).  
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Table 5.2 List of antibodies used in flow cytometry 
Type of cell Cell surface marker Isotype Clone Fluorochrome 
Catalogue    
no. 
(BioLegend) 
Dendritic cells anti-mouse CD11c  IgG 
N418 PE 117307 
anti-mouse I-A/I-E IgG2b, κ M5/114.15.2 FITC  107606 
Activated  
dendritic cells 
anti-mouse CD86  IgG2b, κ 
 
PO3 APC  
 
105114 
anti-mouse CD106 
(VCAM-1) IgG2a, κ 
 
429         
(MVCAM.A) APC  
 
 
105718 
  
Macrophages anti-mouse CD11b IgG2b, κ 
M1/70 FITC 101206 
anti-mouse F4/80 IgG2a, κ BM8 APC 123116 
Activated  
macrophages 
anti-mouse I-A/I-E IgG2b, κ 
 
M5/114.15.2 PE 
 
107608 
anti-mouse CD106 
(VCAM-1) IgG2a, κ 
 
429 
(MVCAM.A) PE 
 
 
105714 
  
Neutrophils 
anti-mouse CD11b IgG2b, κ M1/70 FITC 101206 
 
anti-mouse Ly-6G/Ly-
6C (Gr-1) IgG2b, κ 
 
 
RB6-8C5 PE 
 
 
108408 
Activated  
neutrophils 
 
anti-mouse CD69 
 
IgG 
 
H1.2F3 
 
APC 
 
104514 
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5.3.5 Chemokine and cytokine multiplex/singleplex assays  
 
The nasal and lung homogenates were centrifuged at 2000 x g for 3 min. CCL-2 was detected 
using a MSD Multi-Array Mouse Cytokine Assay (Ultra-Sensitive Kit, Meso Scale Discovery, 
MD, USA), whereas CXCL-1, TNF-α, IL-1β, IL-6, IL-12, IFN-γ and IL-10 were detected using a 
MSD Multi-Spot V-PLEX Assay System (Pro-inflammatory Panel 1 mouse kit). Samples were 
read in a SECTOR Imager 2400 instrument (MSD) according to the manufacturer’s instructions. 
Calibrator curves were generated to convert relative electrochemiluminescent units into protein 
concentrations using MSD Discovery Workbench Software. 
 
5.3.6 Lung fragment cultures, ELISA and virus titration 
 
Lung fragment cultures (LFCs) and ELISA were performed as described previously [277]. LFCs 
were prepared to detect RSV ΔF-specific IgA. The multi-lobed lung was cut into four equal 
pieces and cultured in a 48-well plate containing RPMI 1640 medium (Gibco, Life 
Technologies), supplemented with 10% FBS, 10 mM HEPES 0.1 mM non-essential amino acids, 
1 mM sodium pyruvate, 2 mM L-glutamine, 50 μg/ml gentamicin and 1X antibiotic/antimycotic 
for 5 days at 370C. The supernatant was clarified and stored at -800C. 
ELISA was performed with cell-free supernatants of nasal wash, bronchioalveolar lavage 
fluids (BALF) and LFC for detection of RSV ΔF-specific IgA and with sera for detection of RSV 
ΔF-specific IgG1 and IgG2a. Immulon 2 HB 96-well microtitre plates (Fisher Scientific) were 
coated overnight at 40C with 0.1 μg/ml of RSV ΔF protein. Four-fold serially diluted lung 
fragment culture supernatants (1:10 starting dilution for LFC and 1:5 starting dilution for nasal 
wash and BALF) were added to the ΔF-coated plated and incubated overnight at 40C. Bound ΔF-
specific IgA was detected by adding diluted (1:2000) biotin-conjugated goat anti-mouse IgA 
(Life Technologies, catalogue no. M31115) followed by the addition of diluted (1:10,000) 
alkaline phosphatase-streptavidin (catalogue no. 016-050-084, Cedarlane, ON, Canada). Finally, 
the reaction was developed by adding p-nitrophenyl phosphate substrate (Sigma Aldrich) and 
read in a SPECTRAmax 340 PC Microplate Reader (Molecular Devices, CA, USA). The plates 
were washed three times between all steps.  For detection of RSV ΔF-specific IgG1 and IgG2a in 
the sera, four-fold serially diluted serum samples (1:100 starting dilution) were added to the ΔF-
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coated plated and incubated overnight at 40C. ΔF-specific IgG1 or IgG2a was detected by the 
addition of biotin-conjugated goat anti-mouse IgG1 (catalogue no. 1070-08, Southern Biotech, 
AL, USA) or IgG2a (catalogue no. 1080-08) (Southern Biotech).  
Virus titration was performed with lung and nasal washes for detection of RSV. Briefly, 
lungs of euthanized mice were homogenized in a Mini-Beadbeater. The clarified supernatants 
from the lung as well as nasal washes were serially diluted to add to subconfluent Hep-2 cells. 
After incubation for 2 h at 370C, the supernatants were removed and overlaid with 1.6% low-
melting agarose in MEM. The overlay medium was removed after 5 days and 0.5% crystal violet 
was used to stain the cells to visualize the plaques. Results were expressed as PFU/g of lung 
tissue and PFU/ml of nasal washes [277]. 
 
5.3.7 Statistical analysis 
 
All data were analyzed using GraphPad Prism version 6. Statistical differences among the groups 
were calculated using one-way ANOVA, followed by Newman-Keuls post-test to compare 
differences among multiple groups. Differences were considered significant if p<0.05.  
 
5.4 RESULTS 
 
5.4.1 ΔF/TriAdj stimulates differential gene expression profiles in the nasal tissues and lung.  
 
To characterize the early innate immune responses in the nasal tissues and lungs, mRNA 
expression of a panel of chemokines, cytokines and IFNs was tested by qRT-PCR and 
summarized by heat maps in Fig. 5.1a (nasal tissues) and Fig. 5.1b (lung). Overall, the gene 
expression in the nasal tissues in all three treatment groups was very transient, as by 3 h the level 
of induction of most of the genes decreased. In comparison to the nasal tissues, the gene 
induction in the lung was of greater extent and sustained for a longer period of time.  ΔF/TriAdj 
induced production of monocyte-recruiting chemokines, CCL2, CCL3 and CCL7 [278, 279], and 
DC-recruiting chemokines, CCL3, CCL4 and CXCL-10 [169, 280], in both tissues. However, the 
extent of induction was much higher in the lung and lasted for at least 48 h. Treatment with 
ΔF/PBS or PBS induced the above molecules to a much lower extent and for a shorter time in 
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both tissues. Furthermore, there was little (>10 fold) to no up-regulation of eosinophil-recruiting 
chemokines, CCL5 and CCL11 [281] in the treatment groups at any time point in both tissues. 
PBS was probably an irritant to the nasal tissues and hence, there was early up-regulation of 
neutrophil chemoattractants, CXCL-1 and CXCL-2 [282], as well as the pro-inflammatory 
cytokine IL-6. IL-6 induction was more augmented by the ΔF/PBS (~1389 fold) and ΔF/TriAdj 
(~1667 fold) treatments in the nasal tissues at 45 min. In addition to CXCL-1 and CXCL-2, 
higher transcripts of TNF-α and IL-1β were detected in the ΔF/PBS and ΔF/TriAdj groups in 
both tissues. However, CXCL-1, CXCL-2 and TNF-α induction in the ΔF/TriAdj group was 
higher in the nasal tissues than in the lungs. IL-12 mRNAs were detected in ΔF/PBS- and 
ΔF/TriAdj-treated groups in the nasal tissues only. Interestingly, in ΔF/TriAdj group IL-10 
transcripts were detected at a higher level in the nasal tissues than in the lung, whereas IFN-β and 
IFN-γ transcripts were detected at a higher level in the lung than in the nasal tissues. No Th2 
cytokine (IL-4 and IL-5) was detected in the nasal tissues (data not shown) and lungs in any 
group. Thus, ΔF/TriAdj stimulated the innate immune system in the nasal tissues and lung 
differentially, with the effect being more transient in the nasal tissues than in the lung. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
a. Nasal Tissues 
b. Lungs 
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Figure 5.1 
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Figure 5.1 Heat map showing gene expression profiles in the nasal tissues (Fig. 5.1a) and lungs 
(Fig. 5.1b) of 6-8 week-old female BALB/c mice.Mice (n=5 per group) were immunized once 
intranasally with ΔF/TriAdj, ΔF/PBS or PBS in a 20 µl volume as shown in the bottom panel of 
the heat maps. The different time points of sample collection are shown in the top panel while the 
genes tested are listed in the left panel of the map. The reference gene GAPDH was selected to 
normalize the expression levels of the chemokine and cytokine transcripts. Final data were 
represented as fold-change normalized over untreated mice. Each box represents the average 
value of fold-change of 5 mice within each group. 
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5.4.2 ΔF/TriAdj induces local production of chemokines and cytokines in a spatio-temporal 
fashion. 
 
Selected chemokines and cytokines induced by ΔF/TriAdj were measured in the nasal tissue at 3 
h and in the lung at 3, 6, 24 and 48 h p.i. In comparison to the PBS and ΔF/PBS groups, 
significantly higher levels of monocyte-recruiting CCL2 (Fig. 5.2a and b), neutrophil-recruiting 
CXCL-1 (Fig. 5.2c and d) and pro-inflammatory cytokines TNF-α (Fig. 5.2e and f), IL-1β (Fig. 
5.2g and h) and IL-6 (Fig. 5.2i and j) were detected in the ΔF/TriAdj group in both nasal tissues 
and lungs. Similar results were obtained for the Th1-promoting cytokine IL-12 (Fig. 5.2k and l), 
IFN-γ (Fig. 5.2m and n) and the anti-inflammatory cytokine IL-10 (Fig. 5.2o and p) in the nasal 
tissues and lungs. Although ΔF/PBS induced expression of transcripts of a few of the genes 
tested, induction of the same molecules at the protein level in the ΔF-immunized group was 
either below the detection limit or not significantly higher than that in the PBS group in both 
tissues. It is important to note that ΔF/TriAdj influenced the kinetics of induction of the above 
molecules in a tissue- and time-dependent manner. The amount of protein detected in the lungs of 
the ΔF/TriAdj-immunized group was much higher than that in the nasal tissues consistent with 
enhanced and longer gene expression in the lung compared to the nasal tissue. Additionally, 
induction of the effector molecules and pro-inflammatory mediators in the lungs at the protein 
level followed a very similar kinetics to that at the mRNA level. 
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Figure 5.2 Chemokine and cytokine production in the nasal tissues and lungs. Mice were 
immunized as described in the legend for Fig 1. Induction of CCL2 (Fig. 5.2a and b), CXCL-1 
(Fig. 5.2c and d), TNF-α (Fig. 5.2e and f), IL-1β (Fig. 5.2g and h), IL-6 (Fig. 5.2i and j), IL-
12p70 (Fig. 5.2k and l), IFN-γ (Fig. 5.2m and n) and IL-10 (Fig. 5.2o and p) in the nasal tissues 
and lung, respectively, is shown as protein concentration in pg ml-1. Data are presented as median 
values with interquartile range and considered significant at p<0.05. For the nasal tissues the 
differences between groups are shown as * p<0.05, ** p<0.01. For the lung tissues the difference 
between ΔF/PBS and PBS groups at p<0.05 is denoted as “a”; difference between ΔF/TriAdj and 
PBS groups at p<0.05 is denoted as “b”, whereas difference between ΔF/TriAdj and ΔF/PBS 
groups at p<0.05 is denoted as “c”. 
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5.4.3. ΔF/TriAdj promotes infiltration of immune cells consistent with the type of chemokines 
induced. 
 
Subsequently, we investigated whether the type of chemokines produced locally corresponds to 
the profile of immune cells recruited into the nasal tissues, lungs and their dLNs. There was 
significant influx of dendritic cells (DCs) in the NALT at 5 h p.i. in the ΔF/TriAdj group, 
followed by a decrease towards later time points (Fig. 5.3a). In contrast, the influx of DCs into 
the lungs of the ΔF/TriAdj group peaked at 24 h (Fig. 5.3b). This is consistent with the 
observation that in the nasal tissues, the mRNA induction of DC-recruiting chemokines CCL3, 
CCL4 and CXCL-10 peaked at 45 min or 3 h, whereas in the lung the mRNA induction of the 
same molecules peaked at 3 or 6 h and continued till 48 h. The influx of DCs in both CLNs (Fig. 
5.3c) and TLNs (Fig. 5.3d) appeared to gradually increase towards later time points and peaked at 
72 h in the ΔF/TriAdj group. Interestingly, ΔF/PBS caused recruitment of DCs at statistically the 
same level as ΔF/TriAdj into the CLNs at 72 h. This is in accordance to the similar level of 
mRNA induction (<10 fold) of CCL3 and CCL4 in the nasal tissues by the ΔF/PBS and 
ΔF/TriAdj treatments.  
Monocytes can differentiate into tissue-specific DCs as well as macrophages [283]. 
Significant influx of macrophages was observed as early as 5 h in the ΔF/TriAdj group in both 
nasal tissues (Fig. 5.3e) and lungs (Fig. 5.3f) when compared to the ΔF/PBS and PBS groups, 
with a gradual decline towards later time points. This is again in agreement with early mRNA 
induction of monocyte-recruiting CCL2, CCL3 and CCL7 in the nasal tissues and lungs. While 
CCL3 and CCL7 mRNA peaked at 45 min in the nasal tissues, CCL2 and CCL7 mRNA peaked 
at 3 h in the lungs. 
Like macrophages, neutrophils also infiltrated as early as 5 h in the ΔF/TriAdj group in 
both nasal tissues (Fig. 5.3g) and lungs (Fig. 5.3h) at a significantly higher level when compared 
to the other groups, with a gradual decline towards later time points. This is concordant to early 
induction of neutrophil-recruiting CXCL-1 and CXCL-2 mRNA in both nasal tissues and lungs. 
Both CXCL-1 and CXCL-2 mRNA induction peaked at 45 min in the nasal tissues whereas in the 
lung CXCL-1 and CXCL-2 mRNA induction peaked at 6 and 3 h, respectively. 
 
 
 85  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To
ta
l c
el
l c
ou
nt
 o
ut
 o
f 1
06
 c
el
ls
 
Figure 5.3 
ΔF/TriAdj
PBS
ΔF/PBS
a. b. 
c. d. 
e. f. 
g. h. 
Nasal Tissues Lungs 
 86  
Figure 5.3 Recruitment of DCs, macrophages and neutrophils in the NALT, lungs and their 
dLNs. Mice were immunized as described in the legend for Fig 5.1. Influx of DCs in the NALT 
(Fig. 5.3a), lung (Fig. 5.3b), CLN (Fig. 5.3c) and TLN (Fig. 5.3d) was measured by flow 
cytometry. Influx of macrophages was also measured in the NALT (Fig. 5.3e) and lung (Fig. 
5.3f). Similarly, infiltration of neutrophils was measured in the NALT (Fig. 5.3g) and lung (Fig. 
5.3h). Cells were gated for live cells and singlets and then analyzed. Results are expressed as cell 
count per million cells. Data are presented as mean values with SD. Statistical differences among 
the groups are indicated as described in the legend for Fig 5.2.  
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5.4.4 Formulation of ΔF with TriAdj is necessary for optimal activation of immune cells in the 
respiratory mucosal tissues.  
 
Optimal activation of immune cells, especially APCs, is crucial to elicit a robust adaptive 
immune response [273]. Therefore, we examined the activation status of the recruited DCs, 
macrophages and neutrophils in nasal tissues, lungs and their dLNs. Although in the NALT, 
activated CD86+ DCs (Fig. 5.4a) and VCAM-1+ DCs (Fig. 5.4c) were not detected at any time 
point, in the CLN stronger influx of activated CD86+ DCs (Fig. 5.4e) and VCAM-1+ DCs (Fig 
5.4g) was detected at 72 h in the ΔF/TriAdj group than in the PBS group. In contrast, 
significantly higher numbers of activated CD86+ DCs and VCAM-1+ DCs were observed in the 
lungs (Fig. 5.4b and d, respectively) as well as in the TLNs (Fig. 5.4f and h, respectively) in the 
ΔF/TriAdj group than in the other groups at 24 and 72 h. This is in agreement with increased 
production of IL-1β, a maturation factor for DCs [284] in the lungs, which ultimately leads to 
higher T cell proliferation. ΔF/TriAdj also caused activation of macrophages as evidenced by 
higher influx of MHCII+ macrophages and VCAM-1+ macrophages in both NALT (Fig. 5.4i and 
k, respectively) and lung (Fig. 5.4j and l, respectively) when compared to the ΔF/PBS and PBS 
groups at indicated time points (Fig. 5.4e-g, l-n). Influx of activated CD69+ neutrophils in 
response to ΔF/TriAdj treatment peaked at 5 h in the NALT (Fig. 5.4m) and at 24 h in the lung 
(Fig. 5.4n). The activation of macrophages and neutrophils agrees with the range of pro-
inflammatory cytokines detected in both nasal tissues and lung.  
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Figure 5.4 Activation status of DCs, macrophages and neutrophils in the NALT, lung and their 
dLNs.To detect activated DCs, cells were gated on CD11c+MHCII+ cells and expression of CD86 
or VCAM-1 was determined. CD86+ or VCAM-1+ activated DCs were identified in the NALT 
(Fig. 5.4a and 5.c respectively), lung (Fig. 5.4b and d respectively), CLN (Fig. 5.4e and g 
respectively) and TLN (Fig. 5.4f and h respectively). To detect activated macrophages, cells were 
gated on CD11b+F4/80+ cells and expression of MHCII or VCAM-1 was determined. MHCII+ or 
VCAM-1+ activated macrophages were identified in the NALT (Fig. 5.4i and k respectively) and 
lung (Fig. 5.4j and l respectively). To detect activated neutrophils, cells were gated on 
CD11b+Gr-1+ cells and the expression of CD69 was determined. CD69+ activated neutrophils 
were identified in the NALT and lung (Fig. 5.4m and n respectively). Results are expressed as 
cell count per million cells. Data are presented as mean values with SD. Statistical differences 
among the groups are indicated as described in the legend for Fig 5.2. 
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5.4.5 ΔF/TriAdj generates mucosal and systemic immune responses and induces protective 
immunity 
 
We further confirmed the adjuvant activity of ΔF/TriAdj at the adaptive level. Significantly 
higher ΔF-specific IgA titres were found in the nasal washes (Fig. 5.5a), BAL (Fig. 5.5b) and 
LFC supernatants (Fig. 5.5c) in mice immunized with ΔF/TriAdj when compared to mice 
immunized with either ΔF/PBS or PBS. We also found significantly higher IgG1 and IgG2a titres 
in the serum of the ΔF/TriAdj group when compared to the other groups (Fig. 5.5d). To check the 
protective efficacy of ΔF/TriAdj, we immunized mice with ΔF/TriAdj, ΔF/PBS or PBS and 
challenged them with RSV three weeks later. Immunization with ΔF/TriAdj resulted in partial 
clearance of the virus in the nasal washes (Fig. 5.5e) and complete clearance in the lungs (Fig. 
5.5f) of all ΔF/TriAdj-immunized mice. These results are in agreement with the fact that the nasal 
innate immune response to ΔF/TriAdj was not as robust as that in the lung in terms of 
chemokine/cytokine induction, cellular influx and immune cell activation. IgA titres were also 
much higher in the lung mucosal samples when compared to the nasal washes. Nevertheless, 
ΔF/TriAdj induced sufficient immunity in the URT to cause significant decrease in the virus titre 
when compared to the other groups and to confer complete protection from RSV in the lung 
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Figure 5.5 Intranasal immunization with ΔF/TriAdj induces protective immune responses. Mice 
were immunized as described in the legend for Fig 5.1, challenged with RSV A2 on day 21 p.i. 
and sacrificed four days after challenge (i.e. day 25 p.i.). Figure 5.5a shows ΔF-specific IgA in 
the nasal wash collected at the time of sacrifice. ΔF-specific IgA was also measured in the BALF 
(Fig.  5.5b) and LFC supernatants (Fig. 5.5c) on day 21 p.i. RSV ΔF-specific IgG1 and IgG2a 
(Fig. 5.5d) was measured in the serum on day 21 p.i. ELISA titres are expressed as the reciprocal 
of the highest dilution that results in a value of two standard deviations above the negative 
control samples. Fig. 5.5e and 5.5f show the virus titre in the nasal washes (expressed as PFU per 
ml of the nasal washes) and lung (expressed as PFU per gram of the lung tissue). Data are 
presented as median with interquartile range. The significance of the differences between groups 
are shown as * p<0.05, ** p<0.01, *** p< 0.001. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 5.6 A schematic representation to illustrate the adjuvant action of the ΔF/TriAdj in the 
URT and LRT of BALB/c mice upon intranasal immunization.
chemokine molecules while the coloured 
cytokines. ‘+’ refers to induction of the above molecules. The asterisk symbols indicate 
activation of the DCs, macrophages and neutrophils. The curved thick block arrows mean 
production of chemokine and cytok
The thick block arrows pointing either down or to the right indicate trafficking of APCs from the 
antigen uptake site to the draining LNs. The increasing number of thin arrows pointing up be
the indicated time points denote increase in the level of cellular infiltration. The broken thin 
arrows indicate hypothetical pathways of cellular influx from one tissue to the other. 
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 The coloured spherical dots denote 
diamond-shaped symbols denote pro
ines, cellular influx and activation in a positive feedback loop. 
 
-inflammatory 
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5.5 DISCUSSION 
 
Understanding the mechanism of action of adjuvants at an innate level especially in vivo is 
essential in designing effective and safe vaccines [129]. In the present study we examined the 
immune reactions initiated in the NALT and CLN, as well as lung and TLN, after administration 
of a single intranasal dose of ΔF/TriAdj. In addition, the key features of the activity of ΔF/TriAdj 
were determined to explain the robustness and protective efficacy of this vaccine candidate. 
The nasal route of vaccine delivery has been described for several bacterial and viral 
respiratory pathogens [285]. NALT is an inductive site for immune reactions as it has a distinct B 
and T cell area, high endothelial venules (HEV) and preferential presence of goblet cells, M cells, 
IgM+B220+ and IgA+B220+ cells [285, 286]. A single intranasal immunization with inactivated 
influenza vaccine induced increased IgA responses only in presence of cholera toxin but not by 
antigen alone [287]. Unlike human NALT, rodent NALT requires infection or some kind of 
danger signal like cholera toxin adjuvant to drive IgA- or IgG-specific germinal center formation 
and production of high affinity memory B cells [288-290]. Induction of effective immune 
responses in the nose is incumbent upon specific adjuvants ranging from interleukins to toxins 
[285]. 
Poly(I:C) is a TLR3 agonist, whereas IDR1002 selectively induces the production of 
monocyte-recruiting CCL2 and CCL7, and PCEP up-regulates NLRP3 inflammasome to promote 
pro-inflammatory cytokine production [93, 291, 292]. In our study we used a combination 
adjuvant to stimulate nasal as well as lung immunity. Although ΔF/TriAdj stimulated innate 
immune responses transiently in both nasal tissues and lung, the extent of activation was higher 
and longer-lived in the lung, possibly suggesting more depot in the LRT than in the URT. This 
might explain the overall higher induction of gene expression and greater production of 
chemokines and cytokines in the lung than in the nasal tissues. Consequently, upon RSV 
challenge partial viral clearance was achieved in the nasal tissues, and complete clearance in the 
lung. A combination of intranasal priming and boosting might be effective in complete clearance 
of RSV in the nose as was reported previously with influenza vaccine using cholera toxin [287]. 
Immunization with ΔF/PBS resulted in transient expression of only some chemokines and 
cytokines, lower than that induced by ΔF/TriAdj, demonstrating that the observed innate immune 
responses are due to the administration of the TriAdj.     
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 DCs expressing VCAM-1 and MHCII play an important role in recruitment and/or 
retention of α4β7/α4β1 expressing lymphocytes in the B cell area of LNs, promote superior antigen 
presentation and generate central memory T cells [293].  Hence, enhanced expression of 
activation markers on the DCs in the CLNs and TLNs and high frequencies of central memory 
CD8+CD127+CD62L+ T cells in the ΔF/TriAdj immunized group reported earlier may 
contribute to the improved antibody responses [102]. Furthermore, macrophages and neutrophils, 
once activated, produce several chemokines like CCL3, CCL4 and CXCL-1 that in turn leads to 
infiltration of more monocytes, macrophages, and immature DCs [294]. Thus, activation of 
innate immunity represents an interdependent positive feedback loop that leads to the co-
localization and cross-talk between immune cells to augment the adaptive immunity. Indeed, 
immune cell cross talk is implicated as one of the mechanism by which innate immunity 
regulates adaptive immunity as reported in the case of human neutrophils and DCs, NK cells, B 
or T cells. [295] In summary, the adjuvant action of the intranasally administered ΔF/TriAdj in 
stimulating the innate immunity in the URT and LRT might involve three mechanisms: a) ability 
to induce local production of chemokines and pro-inflammatory cytokines, b) ability to enhance 
trafficking of DCs, macrophages and neutrophils, c) ability to activate those immune cells by 
inducing expression of co-stimulatory and activation molecules that leads to enhanced adaptive 
immune responses (Figure 5.6). Indeed, immune cell recruitment is increasingly appreciated to 
play a major role in mediating the adjuvanticity and improving the quality of adaptive immune 
outcome in response to adjuvant [171, 296-299]. In fact, an emerging body of evidence suggests 
that innate immune activation programs adaptive immunity by stimulating long-lived antigen-
specific antibody-producing plasma cells, enhancing clonal expansion of T cells as well as 
triggering migration of T and B cells to mucosal sites [300].  
In conclusion, the present work advances our understanding of the effect of ΔF/TriAdj on the 
innate immune system in both URT and LRT when administered intranasally. However, it still 
needs to be determined, which signalling pathways are activated in the innate immune cells, 
especially DCs and macrophages, in response to ΔF/TriAdj, which may help us to identify 
potential biomarkers of adjuvanticity of ΔF/TriAdj.   
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CHAPTER 6 
6                           INKER BETWEEN CHAPTER 5 AND CHAPTER 7 
 
In chapter 5, we observed that ΔF/TriAdj elicits transient and localized innate immune responses 
that lead to strong adaptive immunity. We also determined the mechanisms by which ΔF/TriAdj 
stimulates innate immune responses in the upper and lower respiratory tract. These mechanisms 
include local production of chemokines, cytokines, and IFNs, and influx of immune cells 
including DCs, macrophages and neutrophils into the respiratory tissues. The role of ΔF/TriAdj 
in activation of immune cells was also revealed. Furthermore,stimulation of the innate immune 
responses by ΔF/TriAdj was indeed reflected in eliciting induction of mucosal and systemic 
adaptive immune responses. Finally, single intranasal immunization with ΔF/TriAdj of BALB/c 
mice was found to confer complete protection in the lung against RSV.  
 In chapter 7, we elucidated the signal transduction pathways involved in ΔF/TriAdj-
mediated effector responses in macrophages. Macrophages are important in the context of both 
innate and adaptive immune responses against RSV.Our in vivo results demonstrated that the 
macrophage is one of the cell types that respond directly to ΔF/TriAdj. Therefore, we chose this 
cell type to characterize the signaling requirements of ΔF/TriAdj in vitroand ex vivo. Both 
endosomal and cytosolic innate immune receptors were simulated by ΔF/TriAdj to induce 
multiple signal transduction pathways, thereby leading to secretory effector responses in the 
macrophages. 
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7.1 ABSTRACT 
 
Respiratory syncytial virus (RSV) causes acute respiratory tract infections in infants, the elderly 
and immunocompromised individuals. No licensed vaccine is available against RSV. We 
previously reported that intranasal immunization of rodents and lambs with a RSV vaccine 
candidate (ΔF/TriAdj) induces protective immunity with a good safety profile. ΔF/TriAdj 
promoted innate immune responses in respiratory mucosal tissues in vivo, by local chemokine 
and cytokine production, as well as infiltration and activation of immune cells including 
macrophages. The macrophage is an important cell type in context of both innate and adaptive 
immune responses against RSV. Therefore, we characterized the effects of ΔF/TriAdj on a 
murine macrophage cell line, RAW264.7, and bone marrow-derived macrophages (BMMs). A 
gene expression study of pattern recognition receptors (PRRs) revealed induction of endosomal 
and cytosolic receptors in RAW264.7 cells and BMMs by ΔF/TriAdj, but no up-regulation by ΔF 
in PBS. As a secondary response to the PRR gene expression, induction of several chemokines 
and pro-inflammatory cytokines, as well as up-regulation of MHC-II and co-stimulatory immune 
markers, was observed. To further investigate the mechanisms involved in ΔF/TriAdj-mediated 
secondary responses, we used relevant signal transduction pathway inhibitors. Based on 
inhibition studies at both transcript and protein levels, JNK, ERK1/2, CaMKII, PI3K and JAK 
pathways were clearly responsible for ΔF/TriAdj-mediated chemokine and pro-inflammatory 
cytokine responses, while the p38 and NF-κB pathways appeared to be not or minimally 
involved. ΔF/TriAdj induced IFN-β, which may participate in the JAK-STAT pathway to further 
amplify CXCL-10 production, which was strongly up-regulated. Blocking this pathway by a JAK 
inhibitor almost completely abrogated CXCL-10 production and caused a significant reduction in 
the cell surface expression of MHC-II and co-stimulatory immune markers. These data 
demonstrate that ΔF/TriAdj induces multiple signaling pathways in macrophages.  
 
7.2 INTRODUCTION 
 
Human respiratory syncytial virus (RSV) is the single most important pathogen causing acute 
lower respiratory tract infections in infants [301]. A safe and effective RSV vaccine is still not 
available. Recently, we developed a subunit vaccine candidate against RSV (ΔF/TriAdj) 
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consisting of a truncated RSV fusion protein (ΔF) formulated with poly(I:C), innate defense 
regulator peptide (IDR) and poly[di(sodium carboxylatoethylphenoxy)]-phosphazene (PCEP) 
[88]. Intranasal immunization with ΔF/TriAdj induced protective immunity in rodent and lamb 
models [102, 258, 259].  In vivo mechanistic studies revealed transient and local production of 
chemokines, pro-inflammatory cytokines and interferons (IFNs) in the nasal tissues and lung, 
shortly after immunization. This was followed by active infiltration and activation of various 
immune cells, especially macrophages, into the nasal associated lymphoid tissues and lung [176].  
Macrophages are considered as the primary sentinel phagocytic cells of the lung innate 
immune system and are crucial for the innate immune defense against RSV [302]. To understand 
the impact of ΔF/TriAdj on macrophages, we investigated which signaling pathways are induced 
by ΔF/TriAdj in that particular cell type. We used RAW264.7, an established mouse macrophage 
cell line that is extensively used to study macrophage functions [303, 304] and bone-marrow 
derived macrophages (BMMs). The results indicated that ΔF/TriAdj stimulates and activates 
macrophages to release various chemokines and pro-inflammatory cytokines and that multiple 
signal transduction pathways are involved in ΔF/TriAdj-mediated innate responses. 
 
7.3 MATERIALS AND METHODS 
 
7.3.1 Preparation of ΔF/TriAdj 
 
RSV ΔF protein was produced and purified as described previously [88]. LMW Poly(I:C) 
(Invivogen, CA, USA) and IDR peptide 1002 (VQRWLIVWRIRK; GenScript, NJ, USA) were 
mixed in PBS and incubated for 30 min at room temperature, followed by addition of the ΔF 
protein. After another 15 min, PCEP (Idaho National Laboratory, ID, USA) was added to make a 
final 1:2:1 ratio of poly(I:C), IDR1002 andPCEP as described previously [176]. 
 
7.3.2  Cells and treatment 
 
RAW264.7 (ATCC, VA, USA) cells were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) (Sigma-Aldrich, MO, USA) supplemented with 10% FBS, 1 mM sodium pyruvate and 
50 µg/ml gentamicin [305, 306]. Bone marrow cells were isolated from murine femurs and tibia 
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and cultured in RPMI 1640 medium (Life Technologies, CA, USA) supplemented with 10% 
heat-inactivated FBS, 10 mm HEPES, 1X non-essential amino acids, 1 mM sodium pyruvate, 50 
µg/ml gentamicin and 50 mM 2-mercaptoethanol in presence of 20 ng/ml of recombinant mouse 
M-CSF (BioLegend, CA, USA) for 7 days to differentiate them into macrophages [307]. Freshly 
prepared vaccine formulation (ΔF/TriAdj), ΔF in PBS (ΔF/PBS) or PBS was added to the culture 
medium. The concentrations of ΔF protein, poly(I:C), IDR1002 and PCEP were optimized to be 
0.1, 1, 2 and 1 μg/ml, respectively.  
 
7.3.3  Confocal microscopy 
 
RAW264.7 cells were treated with ΔF/PBS or ΔF/TriAdj for 4 h. Cells were then incubated with 
rabbit anti-RSV ΔF antibody (in-house; VIDO-InterVac) followed by Alexa Fluor 488-
conjugated goat anti-rabbit IgG (Life Technologies, CA, USA). The slides were mounted with 
ProLong Gold Antifade Reagent with DAPI (Molecular Probes, Life Technologies). Images were 
taken with a Leica SP5 confocal microscope and processed with Leica ApplicationSuite (Leica 
Microsystems Inc., ON, Canada). 
 
7.3.4 RNA Isolation, cDNA synthesis and Real-Time PCR 
 
Total RNA was isolated with TRIzol reagent (Life Technologies) or Quick-RNATM Mini-prep 
kit (Zymo Research, CA, USA) and converted to cDNA using a QuantiTect Reverse 
Transcription kit (Qiagen, Limburg, Netherlands). Real-Time PCR was performed using 
FastStart SYBR Green Master (Roche, Basel, Switzerland) [176]. Primer sequences are listed in 
Table 7.1. Data were analyzed with the Bio-Rad software. 
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Table 7.1: List of primers used in qRT-PCR   
Target 
gene Direction Sequence 
Amplicon 
size 
Annealing 
Temp (°C) Source 
TLR3 
Forward 5' GTGAGATACAACGTAGCT 3' 
162 bp 55 Designed in house Reverse 5' TCCTGCATCCAAGATAGCA 3' 
TLR4 
Forward 5' CCTGATGACATTCCTTCT 3' 
255 bp 57.5 Designed in house Reverse 5' AGCCACCAGATTCTCTAA 3' 
RIG-I 
Forward 5' ATTCAGGAAGAGCCAGAGTGTC 3' 
384 bp 57.5 Designed in house Reverse 5' GTCTTCAATGATGTGCTGCAC 3' 
MDA5 
Forward 5' CGATCCGAATGATTGATGCA 3' 
127 bp 57.5 Designed in house Reverse 5' AGTTGGTCATTGCAACTGCT 3' 
LGP2 
Forward 5' TTTGCGGCGCTACAATGATG 3' 
99 bp 61.4 Designed in house Reverse 5' GTGGTGCGTTCTCTGTCGTA 3' 
NLRP3 
Forward 5' TGCTCTTCACTGCTATCAAGCCCT 3' 
85 bp 59.2 Designed in house Reverse 5' ACAAGCCTTTGCTCCAGACCCTAT 3' 
CCL2   
(MCP-1) 
Forward 5' CTTCTGGGCCTGCTGTTCA3' 
127 bp 57.5 [275] 
Reverse 5' CCAGCCTACTCATTGGGATCA 3' 
CCL3    
(MIP-1α) 
Forward 5' CTTCTCTGTACCATGACACTC 3' 
208 bp 57.5 [275] 
Reverse 5' AGGTCTCTTTGGAGTCAGCG 3' 
CCL4    
(MIP-1β) 
Forward 5' AAACCTAACCCCGAGCAACA 3' 
90 bp 56.3 Designed in house Reverse 5' GAGAACCCTGGAGCACAGAA 3' 
CXCL10  
(IP-10) 
Forward 5' ATGACGGGCCAGTGAGAATG 3' 249 bp 67.6 Designed in house Reverse 5' GAGGCTCTCTGCTGTCCATC 3' 
TNF-α 
Forward 5' AGGCACTCCCCCAAAAGATG 3' 
84 bp 57.5 Designed in house Reverse 5' CTGCCACAAGCAGGAATGAG 3' 
IL-6 
Forward 5' GTGGCTAAGGACCAAGACCA 3' 
95 bp 59.2 Designed in house Reverse 5' TAACGCACTAGGTTTGCCGA 3' 
 
IRF7 
 
  Forward 
Reverse 
5' TCGGACGCTGGATTAACACC 3' 
5' GCCAAGGTGGCTGTAGATGT 3' 78 bp 57.5 
Designed in 
house 
 
IFN-β 
 
Forward 
 
Reverse 
5' ATCATGAACAACAGGTGGATCCTCC 3' 
 
5' TTCAAGTGGAGAGCAGTTGAG 3' 
419 bp 63.9 [275] 
 
 
 
 
 
 
 
 104  
7.3.5 Flow cytometry 
 
For surface staining, cells were incubated with fluorochrome-conjugated anti-MHC-II, anti-
CD40, anti-CD80 or anti-CD86 antibodies (BioLegend, Table 7.2) and analyzed in a flow 
cytometer (BD FACSCalibur, NJ, USA) [176]. Cells were first gated on singlet cells based on 
side scatter height vs. side scatter area profile. Singlet cells were further gated on live cells 
based on near-IR staining. For intracellular staining of RSV ΔF, cells were fixed and 
permeabilized with a Fixation/Permeabilization solution kit (BD Biosciences) and incubated 
with rabbit anti-ΔF antibodyfollowed by Alexa Fluor 488-conjugated goat anti-rabbit IgG. Data 
were analyzed with Kaluza Software (v1.2).  
 
Table 7.2: List of antibodies used 
Antibodies Catalogue no. (BioLegend) 
PE anti-MHC-II 
APC-anti MHC-II 
107608 
107614 
Pacific blue anti-CD40 
PE-anti-CD40 
124626 
124610 
FITC-anti-CD80 104706 
APC-anti-CD86 105114 
 
 
7.3.6  Signal transduction pathway inhibitors. 
 
The inhibitors (Calbiochem, ON, CA) used were as follows: Staurosporine [308], SB203580 
[309], PD98059 [87], SP600125 [310], KN-93 [311], BAY 11-7082 [312], LY294002 [313] and 
JAK inhibitor I [314]. All inhibitors were checked for cytotoxicity using Live/Dead Fixable near-
IR dead cell stain (ThermoFisher Scientific). Optimal concentrations well below the cytotoxic 
dose were selected (Table 7.3). 
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Table 7.3: List of inhibitors used 
Inhibitor  Catalogue no.  (Calbiochem) 
Concentrations tested 
(µM) 
Concentration selected 
(µM) 
Staurosporine 569396 0.001- 1 0.01 
SB203580 559389 0.1-40 10 
PD98059 513000 0.1-100 40 
SP600125 420128 0.1-50 5 
KN-93 422708 0.1-20 10 
BAY 11-7082 196871 0.1-100 0.2 
LY294002 440202 0.1-100 40 
JAK Inhibitor I 420099 0.1-50 5 
 
 
 
7.3.7 Chemokine and cytokine multiplex ELISA 
 
Chemokines and cytokines were detected with U-PLEX Biomarker or Multi-Spot V-PLEX 
Assays (Meso Scale Discovery, MD, USA). Samples were read in a SECTOR Imager 2400 
instrument (MSD) as described previously [176]. Calibrator curves were generated and MSD 
discovery workbench software was used to convert relative electrochemiluminescent units into 
protein concentrations.  
 
7.3.8     Statistical analysis 
 
Data were analyzed with GraphPad Prism version 7. Statistical differences among the treatment 
groups were calculated by one-way ANOVA, followed by Dunnett’s multiple comparisons test. 
Differences were considered significant at p<0.05. 
 
7.4 RESULTS 
 
7.4.1 ΔF/TriAdj induces gene expression of several pattern recognition receptors in 
macrophages in a spatio-temporal fashion 
 
Pattern recognition receptor (PRR) signaling events in macrophages are crucial regulators of innate 
immunity [315]. Stimulation of RAW264.7 cells with ΔF/TriAdj resulted in 12-fold induction of toll-like 
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receptor (TLR)3 gene expression (Fig. 7.1a) at 4 h, which increased to 25-fold at 24 h. No significant up-
regulation of transcripts of other cell surface TLRs was found at any time point (data not shown). 
Expression of the cytoplasmic receptor RIG-I (Fig. 7.1b) was induced as early as 2 h post-stimulation and 
increased to ~13 fold at 6 h. Gene expression of the RIG-I like receptors (RLRs) MDA5 (Fig. 7.1c) and 
LGP2 (Fig. 7.1d) was also up-regulated at 2 h, with maximum induction at 6 h post-treatment (~26- and 9-
fold for MDA5 and LGP2, respectively). NLRP3, a cytosolic inflammasome receptor was also induced 
(11-fold) at the mRNA level at 2 h post-stimulation, but this decreased toward later time points (Fig. 7.1e). 
Murine BMMs were used to further confirm gene expression of PRRs. While TLR3 (Fig. 7.1f) transcripts 
were expressed at 4 h post-treatment with ΔF/TriAdj, gene expression of RIG-I (Fig. 7.1g), MDA5 (Fig. 
7.1h) and LGP2 (Fig. 7.1i) started at 2 h post-treatment and increased till at least 4 h. Similar to 
RAW264.7 cells, NLRP3 (Fig. 7.1j) gene expression was higher at 2 h with a slight decrease at 4 h post-
treatment with ΔF/TriAdj.No up-regulation of any PRR transcript was induced by ΔF/PBS in RAW264.7 
cells or BMMs. 
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Figure 7.1 Gene expression of pattern recognition receptors in RAW264.7 cells and mouse bone 
marrow-derived macrophages (BMMs). Cells were cultured in 6-well tissue culture plates and 
either left untreated or stimulated with ΔF/TriAdj, ΔF/PBS or PBS for 2, 4, 6 and 24 h 
(RAW264.7 cells) or for 2 and 4 h (BMMs). Total RNA was isolated from the cells by TRIzol 
reagent or Quick-RNATM Mini-prep kit. Real-Time PCR was performed to examine the gene 
expression of TLR3 (Fig. 7.1a and 7.1f), RIG-I (Fig. 7.1b and 7.1g), MDA5 (Fig. 7.1c and 7.1h), 
LGP2 (Fig. 7.1d and 7.1i) and NLRP3 inflammasome (Fig. 7.1e and 7.1j) in RAW264.7 cells and 
BMMs respectively. The reference gene GAPDH was used to normalize the expression levels of 
the transcripts.  Final data were represented as fold-change normalized over untreated cells. A 
dotted line is drawn at the Y-axis to indicate fold-change above 2.0 as up-regulation. Data are 
presented as mean values with SD.  Statistical differences were considered significant at p<0.05. 
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7.4.2 ΔF/TriAdj induces secondary effector expression in macrophages  
 
Chemokines are the building blocks of intercellular signaling systems while pro-inflammatory 
cytokines are critical in executing cellular functions [316]. IDR peptide 1002 induces high 
chemokine production in a human monocytic cell line and human peripheral blood mononuclear 
cells ex vivo [87]. ΔF/TriAdj is a potent inducer of monocyte-recruiting chemokines (CCL2 and 
CCL3), DC-recruiting chemokines (CCL3, CCL4 and CXCL-10) and pro-inflammatory 
cytokines (TNF-α and IL-6) in vivo [176]. Therefore, we selected these effectors to check if 
macrophages respond to ΔF/TriAdj treatment ex vivo, and to assess whether this results in 
chemokine and pro-inflammatory cytokine production. Gene expression of the CC-chemokines 
CCL2 (Fig. 7.2a), CCL3 (Fig. 7.2b) and CCL4 (Fig. 7.2c) was induced as early as 2 h post-
treatment with ΔF/TriAdj, and the expression levels increased by 24 h, with exception of CCL4. 
Interestingly, the gene expression of the C-X-C-chemokine, CXCL-10 (Fig. 7.2d), peaked at 6 h 
(833-fold) and declined at 24 h. Similarly, ΔF/TriAdj treatment resulted in gene expression of 
pro-inflammatory cytokines, TNF-α (Fig. 7.2e) and IL-6 (Fig. 7.2f), at 2 h post-treatment. While 
expression of TNF-α mRNA peaked at 2 h, the IL-6 mRNA level was highest at 6 h. The 
induction of these cytokines by ΔF/TriAdj started to decrease at 24 h. Again, ΔF/PBS had no 
effect on chemokine or pro-inflammatory cytokine gene expression. 
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Figure 7.2 
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Figure 7.2 Gene expression of chemokines and pro-inflammatory cytokines in RAW264.7 cells 
following stimulation with ΔF/TriAdj, ΔF/PBS or PBS. RAW264.7 cells were treated as described 
in the legend for Fig. 7.1. Real-Time PCR was performed to examine the gene expression of 
CCL2 (Fig. 7.2a), CCL3 (Fig. 7.2b), CCL4 (Fig. 7.2c), CXCL-10 (Fig. 7.2d), TNF-α (Fig. 7.2e) 
and IL-6 (Fig. 7.2f). The final data and statistical analyses were presented as described in the 
legend for Fig. 7.1.  
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7.4.3 ΔF/TriAdj induces gene expression of IRF7 and IFN-β leading to cell surface expression 
of MHC-II and co-stimulatory markers on macrophages 
 
IRF7 may be induced due to PRR signaling and co-operate extensively leading to IFN-β 
production [303]. A steady increase in IRF7 mRNA expression (Fig. 7.3a) was observed from 4 h 
(5-fold) till 24 h (16-fold), which plateaued by 48 h, while 56-fold enhanced expression of IFN-β 
(Fig. 7.3b) was observed as early as 2 h, which increased to 322-fold at 4 h and maintained at 
least till 24 h. IFN-β profoundly enhances antigen-presenting functions of macrophages by 
inducing co-stimulatory markers [317]. Flow cytometry analysis revealed significant increases in 
the cell surface expression of MHC-II (Fig. 7.3c) and CD40 (Fig. 7.3d), CD80 (Fig. 7.3e) and 
CD86 (Fig. 7.3f) with maximal activation of macrophages at 24 h post-stimulation with 
ΔF/TriAdj. Uptake of ΔF formulated with either PBS or TriAdj by the macrophages was 
demonstrated by confocal microscopy (Fig. 7.3g); however, significantly enhanced uptake of ΔF 
antigen was observed by flow cytometry when ΔF protein was formulated with TriAdj compared 
to PBS (Fig. 7.3h).  
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Figure 7.3 Gene expression of IRF7 and IFN-β after stimulation with ΔF/TriAdj, ΔF/PBS or 
PBS, and cell surface expression of immune markers and uptake of RSV ΔF protein by RAW264.7 
cells. (a-b) Cells were treated as described in the legend for Fig. 1. Real-Time PCR was 
performed to study the gene expression of IRF7 (Fig 7.3a) and IFN-β (Fig 7.3b). The final data 
and statistical analyses were presented as described in the legend for Fig. 7.1. (c-f) Flow 
cytometry to detect cell surface expression of activation marker MHC-II and co-stimulatory 
molecules CD40, CD80 and CD86 in RAW 264.7. Cells were treated with ΔF/TriAdj or ΔF/PBS 
or left untreated for 6, 12, 24 and 48 h. Cells were stained with fluorochrome-conjugated anti-
MHC-II antibody, anti-CD40, anti-CD80 antibody or anti-CD86 antibodies. Cells were also 
stained with Live/Dead Fixable Near-IR Dead Cell Stain to check viability. Cells were gated for 
live cells and singlets and then analyzed. Results are expressed as percentage of cells positive for 
MHC-II (Fig. 7.3c), CD40 (Fig. 7.3d), CD80 (Fig. 7.3e) and CD86 (Fig. 7.3f). Statistical 
differences were considered significant at p<0.05. (g-h) Uptake of ΔF protein by macrophages. 
RAW264.7 cells were cultured in chamber slides and treated with ΔF/PBS or ΔF/TriAdj for 4 h. 
The nuclei were identified with DAPI (blue). Cells were incubated with rabbit anti-RSV ΔF 
antibody (diluted 1:1000) followed by Alexa Fluor 488-conjugated goat anti-rabbit IgG (diluted 
1:500, green) and the uptake of ΔF protein was visualized by confocal microscopy (Fig. 7.3g). 
The amount of intracellular uptake of RSV ΔF antigen at 1 and 4 h post-treatment was further 
quantified by flow cytometry analysis (Fig. 7.3h). Cells were fixed and permeabilized and 
incubated with rabbit anti-RSV ΔF antibody followed by Alexa Fluor 488-conjugated goat anti-
rabbit IgG. 
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7.4.4  Signal transduction pathways involved in ΔF/TriAdj-mediated chemokine and pro-inflammatory 
cytokine induction: MAPK pathways 
 
To elucidate signaling pathways involved in the innate responses, RAW264.7 cells were treated 
with specific chemical inhibitors for 1 h and then stimulated with ΔF/TriAdj for another 24 h. 
Staurosporine, a broad-spectrum protein kinase inhibitor abolished induction of all effectors at 
both mRNA (Fig. 7.4a) and protein levels (Fig. 7.4b), implicating strong involvement of protein 
kinases in ΔF/TriAdj-mediated chemokine and pro-inflammatory cytokine induction. This led us 
to study the role of specific kinases using selective inhibitors.  
Mitogen activated protein kinases (MAPKs) are a group of signaling molecules involved 
in all aspects of immune responses [318]. There are three major MAPK pathways in mammals: 
p38, extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK). The p38 
MAPK inhibitor, SB203580, did not prevent induction of CC-chemokine at the mRNA (Fig. 
7.4c) or protein levels (Fig. 7.4d). However, the CXCL-10 mRNA level appeared to decrease 
with the use of p38 inhibitor, and at the protein level complete inhibition of CXCL-10 production 
was observed. While the level of mRNA expression and protein production of pro-inflammatory 
cytokines, TNF-α and IL-6, was reduced by the p38 MAPK inhibitor, the inhibition was not 
strong. In contrast, significant reduction in the expression of all effectors was observed by the 
MEK (upstream of ERK1/2) inhibitor, PD98059, at both mRNA (Fig. 7.4e) and protein levels 
(Fig. 7.4f); the inhibition of CCL2, TNF-α and IL-6 protein production was very strong. 
Similarly, the JNK inhibitor, SP600125, significantly reduced expression of all effectors at the 
mRNA level (Fig. 7.4g), and even more strongly at the protein level (Fig. 7.4h). 
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Figure 7.4 Comparative study of the signal transduction pathways involved in ΔF/TriAdj-
induced effector expression at mRNA and protein levels. RAW264.7 cells were pre-treated for 1 
h with inhibitors, Staurosporine (broad spectrum protein kinase inhibitor, 0.01 μM), SB203580 
(p38 MAPK inhibitor, 10 μM), PD98059 (inhibitor of MEK, upstream of ERK1/2, 40 μM) or 
SP600125 (JNK MAPK inhibitor, 5 μM) before stimulation with ΔF/TriAdj for 24 h. All 
experiments included untreated cells as negative control and DMSO treated cells as vehicle 
control. DMSO vehicles were included at levels identical to those used as solvents for inhibitor 
treatments (0.1% v/v). Working concentrations of the inhibitors were kept well below cytotoxic 
levels. Cells were lysed with TRIzol to isolate total RNA for analysis of chemokine and 
cytokine gene expression by qRT-PCR. The cell culture supernatants were harvested for 
assessment of chemokine and cytokine production by ELISA. The left panel represents 
normalized mRNA fold-change and the right panel represents the normalized protein 
concentration of chemokines and pro-inflammatory cytokines over untreated cells. The 
normalized mRNA fold-change and the normalized protein concentrations in pg/ml are shown 
for the inhibitors Staurosporine (Fig. 7.4a and b), SB203580 (Fig. 7.4c and d), PD98059 (Fig. 
7.4e and f) and SP600125 (Fig. 7.4g and h), respectively. Data are presented as mean with SD. 
Statistical differences were considered significant at p<0.05* (indicating inhibition); highly 
significant at p<0.01** (indicating strong inhibition) and very highly significant at p<0.001*** 
or p<0.0001**** (indicating very strong inhibition). 
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7.4.5 Signal transduction pathways involved in ΔF/TriAdj-mediated chemokine and pro-
inflammatory cytokine induction: Other kinase-related pathways 
 
In addition to the MAPKs, other kinase-driven pathways were studied. Calmodulin-dependent 
protein kinase II (CaMKII) pathways were strongly involved in ΔF/TriAdj signaling as treatment 
with a specific inhibitor, KN-93, significantly reduced mRNA (Fig. 7.5a) and protein production 
of the effectors (Fig. 7.5b). Importantly, with the use of CaMKII inhibitor, very strong inhibition 
was observed for CCL2, CXCL-10, TNF-α and IL-6 at the protein level. Interestingly, inhibition 
of NF-κB with BAY 11-7082 did not reduce the induction of CC- and C-X-C-chemokines at 
either transcript (Fig. 7.5c) or protein levels (Fig. 7.5d), with the exception of CCL4 mRNA. 
Although BAY 11-7082 reduced induction of TNF-α and IL-6 at both mRNA and protein levels, 
the inhibition was not very strong for either cytokine. In contrast, inhibition of phosphoinositide 
3-kinase (PI3K) with LY294002 caused highly significant reduction in the induction of all 
effectors at both mRNA (Fig. 7.5e) and protein levels (Fig. 7.5f). Importantly, at the protein level 
complete inhibition by the PI3K inhibitor was observed for all but one of the effectors. Similarly, 
when the JAK pathway was blocked by JAK Inhibitor I, significantly reduced induction of all 
effectors at the mRNA (Fig. 7.5g) and in particular the protein (Fig. 7.5h) levels was observed.  
The JAK inhibitor completely inhibited protein production of all but two of the effectors. 
Furthermore, inhibition of the JAK pathway led to significant reduction in cell surface expression 
of MHC-II (Fig. 7.6a) and co-stimulatory immune markers, CD40 (Fig. 7.6b), CD80 (Fig. 7.6c) 
and CD86 (Fig. 7.6d).  
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Figure 7.5 Comparative study of the signal transduction pathways involved in ΔF/TriAdj-
induced effector expression at mRNA and protein levels. RAW264.7 cells were pre-treated for 1 h 
with inhibitors KN-93 (CaMKII inhibitor, 10 μM), BAY 11-7082 (NF-κB inhibitor, 0.2 μM), 
LY294002 (PI3K inhibitor, 40 μM) or JAK Inhibitor I (inhibitor of JAK1, JAK2, JAK3 and 
Tyk2, 5 μM) before stimulation with ΔF/TriAdj for 24 h as described in the legend for Fig. 7.4. 
The normalized mRNA fold-change and the normalized protein concentrations in pg/ml are 
shown for the inhibitors KN-93 (Fig. 7.5a and b), BAY 11-7082 (Fig. 7.5c and d), LY294002 
(Fig. 7.5e and f) and JAK Inhibitor I (Fig. 7.5g and h), respectively. The final data and statistical 
analyses were presented as described in the legend for Fig. 7.4.  
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Figure 7.6 Cell surface expression of immune markers in presence of JAK Inhibitor I and 
schematic representation of the potential signal transduction pathways involved in ΔF/TriAdj-
mediated signaling in RAW264.7 cells. (a-d) RAW264.7 cells were pre-treated for 1 h with JAK 
Inhibitor I before stimulation with ΔF/TriAdj for 24 h as described in the legend for Fig. 4. Cells 
were stained with fluorochrome-conjugated anti-MHC-II, anti-CD40, anti-CD80 or anti-CD86 
antibodies. Results are expressed as percentage of cells stained positive for MHC-II (Fig. 7.6a), 
CD40 (Fig. 7.6b), CD80 (Fig. 7.6c) and CD86 (Fig. 7.6d). Statistical differences were considered 
significant at p<0.05. (e) Following internalization, ΔF/TriAdj induced gene expression of 
endosomal TLR3, the cytosolic RNA helicases or NLRP3 inflammasome. Engagement of TLR3 
or RNA helicases by ΔF/TriAdj may induce transforming growth factor beta-activated kinase 
(TAK1) to produce chemokines and pro-inflammatory cytokines (via MAPKs and NF-κB) or 
may induce tank-binding kinase-1 (TBK1) to trigger expression of IFN-β (via IRF7) [156, 303]. 
TLR3 signaling or ΔF/TriAdj itself may induce Ca2+ release from internal stores in the 
macrophages that may promote induction of CaMKII to induce production of chemokines and 
pro-inflammatory cytokines either directly or indirectly through TAK1 [303, 319, 320]. The p38 
and JNK MAPK pathways may be further amplified by TNF-α/TNFR signaling [321]. IFN-β 
produced as a result of TLR3, RNA helicases and CaMKII signaling may activate JAK or RTKs 
to induce three pathways: (a) JAK/STAT to induce up-regulation of CXCL-10 and immune 
markers, (b) c-Raf-ERK1/2 MAPK and (c) PI3K pathways [317, 322-324]. The PI3K pathway 
can be induced by TLR3/CCRs/RTKs[325]. The inhibition symbols indicate pathways that were 
blocked in inhibition studies. The red inhibition symbols indicate pathways that inhibited most 
effectors, while the rose inhibition symbols indicate pathways that were little or not inhibited. 
The color-coded arrows (on the DNA) pointing to the right, represent individual pathway-specific 
roles in the induction of indicated chemokines and pro-inflammatory cytokines. The effector 
molecules that we observed to be strongly (p<0.01**) or very strongly inhibited (p<0.001*** and 
p<0.0001****) with the use of respective pathway-specific inhibitors at the protein level are 
indicated in bold.  
 
7.5 DISCUSSION 
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Elucidation of vaccine-induced innate signal transduction pathways is paramount in studying the 
safety/immunogenicity profiles of both licensed and experimental vaccines and to understand the 
immunological mechanisms by which vaccines work [260, 300]. As RAW264.7 cells closely 
mimic murine primary macrophagesboth in terms of phenotype and functions [326], this cell line 
was used to elucidate the mechanisms behind the innate immune responses to ΔF/TriAdj. 
Poly(I:C) is a ligand for TLR3, RNA helicases  [327] and cell surface TLRs [328, 329]. 
The RSV F protein binds to TLR4/CD14 on human monocytes [321]. While the receptor for 
IDR1002 is unknown [330], NLRP3 is activated by PCEP [93]. ΔF/TriAdj induced expression of 
TLR3, RIG-I, MDA5, LGP2 and NLRP3 in RAW264.7 cells and BMMs in a spatio-temporal 
fashion, suggesting important roles of both cytosolic and endosomal receptors in ΔF/TriAdj-
induced PRR signaling. Interestingly, maximal NLRP3 mRNA induction occurred shortly after 
treatment, while the MDA5 transcript was induced the most among the cytosolic receptors in 
both RAW264.7 cells and BMMs.  
PRR downstream signaling induces chemokines and pro-inflammatory cytokines that initiate 
intracellular signal transduction events leading to various cellular responses [278]. PRR signaling 
induced by ΔF/TriAdj was indeed reflected in the generation of chemokines and pro-
inflammatory cytokines. Interestingly, TNF-α mRNA peaked very early at 2 h; CXCL-10 and IL-
6 transcripts peaked at 6 h, while those of other chemokines were highest at 24 h post-
stimulation. This multi-phasic mode of gene induction is consistent with the fact that PRR-
induced genes are classified into three categories: early primary, late primary and secondary 
response genes based on their transcriptional requirements [331]. Adjuvants that drive PRR 
activation and favour transient production of pro-inflammatory cytokines (and increased Th1 
responses), as we observed for TriAdj, are considered as better and desired in vaccine candidates 
[315]. Furthermore, TriAdj enhanced antigen uptake, demonstrating another mechanism by 
which TriAdj may exert adjuvanticity in vivo.  
IFN-β is crucial in mediating up-regulation of co-stimulatory molecules on APCs [317]. 
IRF-7, a master regulator of IFN-β induction, governs the induction of CD8+ T cell responses 
[332]. ΔF/TriAdj induced IRF7 mRNA expression, which correlated to high induction of IFN-β 
and cell surface expression of immune markers. The potent adjuvant activity of aluminium 
adjuvants widely used in human vaccines was similarly explained by increased expression of 
MHC-II, CD40 and CD86 [333].  
 124  
PRR stimulation induces a common set of gene products through the shared use of core 
signaling pathways involving kinases and transcription factors [320, 331]. Use of a broad-
spectrum inhibitor Staurosporine revealed that protein kinases indeed play a critical role in 
ΔF/TriAdj-mediated signaling events. Furthermore, p38 MAPK did not play a role in ΔF/TriAdj-
mediated secretion of CC-chemokines, but was involved in the production of CXCL-10 and 
possibly TNF-α. Monophosphoryl lipid A (MPL) also induced potent activation of the p38 
MAPK pathway and high induction of CXCL-10 and TNF-α resulting in Th1-type immune 
responses [158]. ERK1/2 signaling appeared to be strongly involved in ΔF/TriAdj-mediated 
production of chemokines, specifically CCL2, and pro-inflammatory cytokines. The JNK 
pathway also mediated highly significant induction of both chemokine and pro-inflammatory 
cytokine production by ΔF/TriAdj, implicating very strong involvement of JNK in ΔF/TriAdj-
signaling.  
Calcium and its major downstream effector CaMKII are necessary for immune cell 
functions such as T cell activation, maturation and antigen presentation [320]. CaMKII played a 
major role in the induction of chemokine and pro-inflammatory cytokine secretion in response to 
ΔF/TriAdj. However, the NF-κB pathway was not involved in ΔF/TriAdj-mediated chemokine 
production, while TNF-α and IL-6 production was minimally reduced by the NF-κB inhibitor. 
TLR3 ligands may induce intracellular calcium fluxes and activate CaMKII to trigger MAPK and 
IRF3/7 pathways [320]. PI3K, a lipid kinase, is associated with upstream activating receptors and 
plays a critical role in inflammatory responses, recruitment and activation of innate immune cells, 
and B and T cell functions [313, 325, 334, 335]. The PI3K pathway was very strongly involved 
in ΔF/TriAdj-mediated chemokine and pro-inflammatory cytokine production.  
IRF-7-induced IFN-β can trigger JAK/STAT, Raf-MEK/ERK and PI3K pathways [322]. 
Inhibition of the JAK pathway, involved in transducing signals from IFN-β to upregulate immune 
markers, resulted in complete abrogation of CCL2, CCL4, CXCL-10 and IL-6 production and 
significant reduction in the surface expression of immune markers. Other adjuvants such as IL-21 
also exert their effects via signal transduction through JAK-STAT, PI3K and MAPK pathways 
[159], while Complete Freund’s adjuvanted influenza virus vaccine induced PI3K and Ras-MEK-
ERK pathways that led to B-cell activation [163].A schematic representation of the complex 
interplay of signaling cascades induced by ΔF/TriAdj in RAW264.7 cells is depicted in Fig. 7.6e.  
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In conclusion, macrophages were found to respond directly to ΔF/TriAdj, supporting our 
previous in vivo cell influx results [176]. We demonstrated that ΔF/TriAdj activates macrophages 
by inducing gene expression of multiple PRRs including TLR3, RIG-I, MDA5, LGP2 and 
NLRP3 to stimulate a broad chemokine and pro-inflammatory cytokine response. The JNK, 
ERK1/2, CaMKII, PI3K and JAK pathways played an important role, while p38 and NF-κB 
pathways appeared to be minimally involved. An in-depth knowledge of the signaling pathways 
induced by our RSV vaccine candidate as well as the TriAdj will be highly relevant for future 
evaluation in clinical studies. Since ΔF/PBS did not induce PRR gene expression or chemokine 
and cytokine production, this study also advances our understanding of the molecular action of 
TriAdj, and confirms the importance of formulation of subunit vaccines with combination 
adjuvants to promote polyvalent and synergistic immune responses. Several other vaccines and 
adjuvants utilize multiple pathways to exert their functions, some of which are similar, while 
others differ from those activated by TriAdj. Examples include Alum [333], MPL [158], IL-21 
[159], Complete Freund’s-adjuvanted influenza virus[163] and the successful Yellow Fever 
vaccine (YF-17D) [136]. Induction of multiple PRRs as we observed with our vaccine candidate 
often correlates to the magnitude and quality of immune responses in vivo [136].Overall, our data 
provide further support for the contention that effective vaccines and adjuvants signal through 
many unique and/or overlapping pathways.  
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CHAPTER 8 
8                LINKER BETWEEN CHAPTER 7 AND CHAPTER 9 
 
Having established the role of ΔF/TriAdj in stimulating innate immunity in the respiratory tissues 
(Chapter 5) and identified the key signal transduction pathways involved in ΔF/TriAdj-mediated 
effector responses (Chapter 7), we continued to elucidate the mechanism of action of ΔF/TriAdj 
at the final downstream metabolome level in the next chapter. Metabolomics is one of the 
‘omics’-based technologies that are currently being employed to explore disease- or vaccine-
specific metabolomic changes [336]. Metabolites are low-molecular weight compounds that 
function as signaling molecules, energy sources and in defining the phenotype and biological 
functions in a living system [337]. RSV infection led to sustained and heightened inflammatory 
responses in the lungs of unvaccinated mice, while such inflammatory responses were found to 
be lower in the vaccinated group. Moreover, RSV infection altered the concentration of the 
metabolites of specific metabolic pathways and ΔF/TriAdj was found to modulate alterations in 
the levels of those metabolites. The results highlight important aspects of the mechanism of 
action of ΔF/TriAdj. 
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9.1 ABSTRACT 
 
Respiratory syncytial virus (RSV) is a significant cause of mortality and morbidity in infants, 
elderly, immunocompromised individuals and patients with congenital heart diseases. Despite 
extensive efforts over the past several decades, a vaccine against RSV is still not available. We 
have developed a subunit vaccine against RSV (ΔF/TriAdj) that consists of a truncated version of 
the fusion protein (ΔF) formulated with a polymer-based combination adjuvant (TriAdj). The 
protective efficacy and safety of this vaccine candidate has been demonstrated in several animal 
models including mouse, cotton rat and lamb. The vaccine when delivered intranasally was found 
to promote innate immune responses that conditioned for an excellent adaptive outcome even 
with a single immunization. In the present study, we compared inflammatory responses in 
ΔF/TriAdj-vaccinated and unvaccinated mice following intranasal challenge with RSV. Rapid 
and early inflammatory responses were observed in both groups, as demonstrated by elevated 
levels of inflammatory cytokines, chemokines and immune cells. The inflammatory responses 
were lower in the vaccinated group by seven days post viral challenge, but were sustained in the 
lungs of the unvaccinated group. This led us to study the underlying mechanism of action of 
ΔF/TriAdj at the downstream metabolome level. A comprehensive liquid chromatography and 
mass spectrometry-based metabolomic profiling of the lung tissues using 12C or 13C-Dansyl 
labeling for amine/phenol submetabolome was conducted. RSV infection was predominantly 
found to alter the tryptophan metabolism including the kynurenine pathway as revealed by 
significantly altered concentrations of tryptophan metabolites such as indole, L-kynurenine, 
xanthurenic acid, serotonin, 5-hydroxyindoleacetic acid and 6-hydroxymelatonin. Importantly, 
ΔF/TriAdj modulated the concentrations of almost all of these altered metabolites. Metabolites 
involved in amino acid biosynthesis including arginine biosynthesis, urea cycle and tyrosine 
metabolismwere also significantly altered in the RSV-challengedgroup. Again, prior vaccination 
with ΔF/TriAdj modulated alterations in the concentrations of these metabolites. The results from 
the present study provide further mechanistic insights into the mode of action of this RSV 
vaccine candidate and have important implications in the design of metabolic therapeutic 
interventions. 
 
9.2 INTRODUCTION 
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Respiratory syncytial virus (RSV) is an enveloped, negative-sense, single-stranded RNA virus of 
the family Pneumoviridae [3]. RSV causes a major global burden of acute lower respiratory tract 
infections and is the major causative agent of bronchiolitis and pneumonia in young children 
[338]. It is common for the majority of children to get infected by RSV by the age of two years 
[339]. Reinfection with RSV can take place anytime during the life of an individual [340]. 
Accounting for an annual ~33 million cases of infection globally in children less than 5 years of 
age, RSV is responsible for hospitalization of 10% of infected children with an in-hospital 
mortality rate of 1-3% [341]. The rate of hospitalization is highest in three month-old infants 
[342]. Palivizumab is the only drug licensed for use in high-risk patients [343]. Since no vaccine 
against RSV is yet available, designing new vaccine strategies and formulations of subunit or 
inactivated vaccines with novel, modern adjuvant is an area of active research interest.  
There is considerable interest in studying and characterizing the mechanism of action of 
vaccines and/or adjuvants. Previously, we have demonstrated the protective efficacy and safety of 
a subunit RSV vaccine candidate consisting of a truncated version of the fusion protein 
formulated with a combination adjuvant (TriAdj) containing poly(I:C), an innate defense 
regulatory (IDR) peptide, and a water-soluble polymer,poly[di(sodium 
carboxylatoethylphenoxy)]-phosphazene (PCEP), in several animal models including mice, 
cotton rats and lambs [88, 102, 258, 259]. When delivered intranasally, ΔF/TriAdj activates 
innate immune responses in both upper and lower respiratory tracts via induction of cytokines, 
chemokines and IFNs, and infiltration of immune cells into the nasal tissues and lung [176]. 
ΔF/TriAdj activated the immune cells and induced local and systemic production of ΔF/TriAdj-
specific antibody responses. Further in vitro characterization of ΔF/TriAdj in macrophages was 
carried out to understand the signaling pathways triggered by the vaccine. Multiple pathways 
including JNK and ERK1/2 MAPKs, CaMKII, PI3K and JAK pathways were involved in 
ΔF/TriAdj-mediated responses in macrophages [344].  
In the present study, we further characterized the mechanism of action of ΔF/TriAdj at the 
metabolome level. The metabolome represents an extensive repertoire of endogenous and 
exogenous metabolites that can be affected by various factors such as external stimuli, drugs, 
diseases, and vaccines; therefore, the study of metabolomics can unravel disease- or vaccine-
specific metabolomic changes and help to identify new therapeutic or prophylactic interventions 
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[336]. Furthermore, metabolomic alterations can be linked to immunological changes in response 
to vaccination to unravel correlates of immunogenicity and/or correlates of protection [345]. This 
approach represents an emerging technological advancement that combines analytical techniques 
such as mass spectrometry and bioinformatics tools to study changes in the metabolic profile 
[336]. Metabolic profiling was therefore carried out to gain a more in-depth understanding of the 
role of this RSV vaccine candidate in eliciting protective immunity [261].  
We hypothesized that ΔF/TriAdj-vaccinated and unvaccinated mice infected with RSV 
would develop differential inflammatory responses in the lung and that the unvaccinated mice 
would develop a heightened and more sustained inflammatory response when compared to 
vaccinated and healthy animals, even at later stages of infection. We also hypothesized that 
unvaccinated mice would develop a strongly altered metabolic profile due to RSV infection when 
compared to healthy controls, while ΔF/TriAdj would mitigate alterations in the metabolomic 
profile following RSV infection. This would provide a reason why the inflammatory immune 
responses in the lung of the unvaccinated mice were higher and more persistent than those of 
vaccinated mice post-RSV challenge at later stages of RSV infection. While the lung is the site of 
a multitude of metabolic reactions, we used differential CIL-LC-MS techniques to specifically 
focus on the amine/phenol submetabolome. 
 
9.3 MATERIALS AND METHODS 
 
9.3.1 Vaccine formulation, immunization and challenge 
 
The vaccine was prepared according to the protocol described previously [176]. An episomal 
vector expressing a truncated version of the native RSV F protein (amino acids 1-529) lacking 
the transmembrane domain (ΔF) was used to transfect HEK-293 cells. The truncated F protein 
was his10-tagged at the carboxyl terminus so that it can be purified by affinity chromatography 
using TALON Superflow resin (Clontech, CA, USA). The ΔF protein thus purified was used as 
the protective antigen in our RSV subunit vaccine formulation. Three adjuvants, LMW poly(I:C) 
(Invivogen, CA, USA), IDR1002 (VQRWLIVWRIRK, Genscript, NJ, USA), and PCEP (Idaho 
National Laboratory, ID, USA) were used to formulate theΔF protein as follows. First, poly(I:C) 
and IDR1002 were mixed in PBS (pH 7.4, Life Technologies, ON, Canada). Following a brief 
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incubation at room temperature for 30 min, ΔF protein was added. After another incubation for 
15 min, PCEP was added such that the final ratio of poly(I:C), IDR1002 and PCEP in the 
formulation was 1:2:1.  
 For all experiments, 6 to 8 week-old female BALB/c mice (Charles River Laboratories, 
QC, Canada) were used. Each animal was immunized intranasally with 1 μg of ΔF protein, 10 μg 
of poly(I:C), 20 μg of IDR1002 and 10 μg of PCEP in a 20 μl volume [176]. Three weeks post 
immunization, animals were challenged intranasally with the RSV A2 strain (5 x 105 p.f.u., 
ATCC, VA, USA) in a 50 μl volume and were sacrificed either at 1 and 7 days, or at 2, 4, 6, 8 
and 10 days, post challenge.  
 
9.3.2 Sample collection and processing 
 
Sera were collected both before and after viral challenge. Prior to removal, bothlungs were 
washed with 700 μl of ice-cold PBS pH 7.4 and the lavage was collected. The lungs were 
homogenized in a mini-beadbeater (BioSpec Products, Inc., OK, USA) either in TRIzol reagent 
(Life Technologies) or in culture medium. Lungs were homogenized in a 2 ml screw cap tube 
containing 2.0 mm zirconia beads (BioSpec Products, Inc.) [176].  
For flow cytometry, single cell suspensions of the lungs were prepared. First, the lungs were 
collected in gentleMACS C tubes (Miltenyi Biotec Inc., CA, USA) containing Hank’s balanced 
salt solution supplemented with 5% FBS (Life Technologies), collagenase from Clostridium 
histolyticum, Type IA (0.5 mg/ml, Sigma-Aldrich, MO, USA) and deoxyribonuclease I from 
bovine pancreas, Type IV (20 μg/ml, Sigma-Aldrich) and incubated at 370C for 20 min. 
Following incubation, the lungs were mechanically digested in a gentleMACS Dissociator 
(Miltenyi Biotec Inc.) according to the manufacturer’s instructions and then passed through 40 
μm nylon mesh [176].  
For the metabolomics experiment, the lungs werecollected from each mouse and washed in 
ice-cold physiological saline (0.85% NaCl) to eliminate any blood. Subsequently, the lungs were 
transferred onto sterile gauze or a sterile pad to blot them dry. The lungs were immediately snap-
frozen in liquid nitrogen. The samples were processed further for isolation of metabolites. 
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The thoracic lymph nodes (TLNs) consisting of tracheobronchial and mediastinal LNs were 
isolated from the lower respiratory tract and pooled together. The LNs were then mashed with a 
plunger and filtered through 40 µm nylon mesh to obtain single cell suspensions [176]. 
 
9.3.3 Quantitative real time PCR 
 
TRIzol reagent (Life Technologies) was used to isolate total RNA from the lungs of each mouse 
according to the manufacturer’s instructions [176]. RNA integrity and stability was checked with 
an Agilent 2100 Bio analyzer system (Agilent Technologies, CA, USA). cDNA was synthesized 
by using a QuantiTect Reverse Transcription kit (Qiagen, Limburg, Netherlands) following the 
manufacturer’s instructions in a GeneAmp PCR System 9700 (Applied Biosystems, Life 
Technologies). Following cDNA synthesis, real-time PCR was performed by using FastStart 
SYBR Green Master (Roche, Basel, Switzerland) according to the manufacturer’s instructions. 
PCR reactions were carried out in an iCycler iQ Multicolor Real-Time PCR Detection System 
(Bio-Rad Laboratories Ltd., ON, Canada). Primers used were described previously [176]. 
Indoleamine 2,3 dioxygenase (IDO-1) was added to this list. The sequence and other details of 
IDO-1 are as follows. Forward: 5' ATGTGGGCTTTGCTCTACCA 3' and Reverse: 5' 
CCCCTCGGTTCCACACATAC 3'. The amplicon size is 228 bp, the annealing temperature is 
57.50C and the primer was designed in-house (NCBI). Amplifications were carried out according 
to the following parameters: 950C for 10 min, 40 cycles of denaturation at 950C for 15 sec, 55-
67.60C (primer dependent) for 30 sec annealing and 720C for 30 sec extension. To check the 
specificity of the amplicons, melt curves were analyzed. The reference gene GAPDH was used to 
normalize the expression levels of the transcripts. Final data were represented as fold-change 
normalized over untreated mice and calculated using the 2-ΔΔCT method. Data were analyzed by 
using Bio-Rad analysis software. 
 
9.3.4 Chemokine and Cytokine Multiplex ELISA 
 
The lung homogenates were further clarified by centrifugation at 2000 x g for 3 min. Chemokines 
and cytokines (CCL2, CCL3, CXCL-1, CXCL-10, TNF-α, IL-6, IL-10, IL-12p70, IFN-γ and IL-
4) were detected by using a Meso Scale Discovery (MSD, MD, USA) U-PLEX Custom 
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Biomarker (Mouse) Multiplex Assay. Samples were read in a SECTOR Imager 2400 instrument 
(MSD) according to the manufacturer’s instructions [176].Calibrator curves were generated and 
MSD discovery workbench software was used to convert relative electrochemiluminescent units 
into protein concentrations. 
 
9.3.5 Flow cytometry 
 
To block the Fc receptors, single-cell suspensions of lungand TLNs were incubated with 
TrueStain fcXanti-mouse CD16/32 antibody (catalogue no. 101320, BioLegend, CA, USA) in 
staining buffer (PBS containing 0.2% gelatin and 0.03% sodium azide) for 5 min. Then the cells 
were stained with various fluorochrome-conjugated monoclonal antibodies (Table 9.1). 
Following a brief incubation for 20 min in the dark at 40C, the cells were washed. Viability of 
the cells was checked by staining with Live/Dead Fixable Near-IR Dead Cell Stain and then fixed 
with 2% formaldehyde (Sigma-Aldrich) in PBS. Cells were gated for live cells and singlets and 
then analyzed. Flow cytometry was performed with a BD FACSCalibur (BD Biosciences, NJ, 
USA). Data were analyzed by using Kaluza Software v1.2 (Beckman Coulter, ON, Canada). The 
immune cell types examined in the lung were DCs (CD11chighMHC-IIhigh), interstitial 
macrophages (CD11b+Siglec-F-), neutrophils (CD11b+Gr-1high) and NK cells (CD3-NKp46+). 
The immune cell types examined in the TLNs were DCs (CD11chighMHC-IIhigh) and CD4+ T cells 
(CD3+CD4+). Cells were first gated on live cells based on Live/Dead Fixable Near-IR Dead Cell 
staining, and then cells stained positive for two surface markers were examined. 
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Table 9.1: List of antibodies used in flow cytometry 
Antibodies Source Catalogue no. 
CD11c-FITC 
 
MHC-II-APC 
 
CD11b-FITC 
 
Siglec-F-eFluor660 
 
Gr-1-APC 
 
CD3-FITC 
 
NKp46-APC 
 
CD4-APC 
BioLegend 
 
BioLegend 
 
BioLegend 
 
e-Biosciences 
 
BioLegend 
 
BioLegend 
 
BioLegend 
 
BioLegend 
117306 
 
107614 
 
101206 
 
50-1702-82 
 
108412 
 
100203 
 
137607 
 
100516 
 
9.3.6 ELISA and virus titration 
 
RSV ΔF-specific IgA was detected in the cell-free supernatants of BALF and RSV ΔF-specific 
IgG1 and IgG2a were detected in sera by ELISA[176]. Briefly, Immulon 2 HB 96-well microtitre 
plates (Life Technologies) were coated overnight at 40C with 0.1 μg/ml of RSV ΔF protein. The 
BALF supernatants at 1:5 starting dilution were four-fold serially diluted and added to the ΔF-
coated plates for an overnight incubation at 40C. Bound ΔF-specific IgA was detected by adding 
diluted (1:2000) biotin-conjugated goat anti-mouse IgA (catalogue no. M31115, Life 
Technologies). Four-fold serially diluted serum samples at 1:100 starting dilution were used to 
detect RSV ΔF-specific IgG1 and IgG2a. ΔF-specific IgG1 or IgG2a was detected by the addition 
of biotin-conjugated goat anti-mouse IgG1 (catalogue no. 1070-08, Southern Biotech, AL, USA) 
or IgG2a (catalogue no. 1080-08, Southern Biotech). This was followed by the addition of diluted 
(1:10,000) alkaline phosphatase-streptavidin (catalogue no. 016-050-084, Cedarlane, ON, 
Canada). Finally, p-nitrophenyl phosphate substrate (Sigma-Aldrich) was added to develop the 
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reaction and read in a SPECTRAmax 340 PC Microplate Reader (Molecular Devices, CA, USA). 
A three-time washing step followed all steps.   
For RSV titration, the lungs of euthanized mice were homogenized with a Mini 
Beadbeater (BioSpec Products, Inc.)[176]. The lung homogenates were centrifuged and the 
clarified supernatants were serially diluted and added to sub-confluent Hep-2 cells. Following a 
brief incubation for 2 h at 370C, the supernatants were removed and overlaid with 1.6% low-
melting agarose in MEM. After 5 days, the overlay medium was removed. The plaques were 
visualized by staining the cells with 0.5% crystal violet. Finally, the results were presented as 
PFU/g of lung tissue. 
 
9.3.7 Lung sample preparation for metabolomics 
 
For analysis of the amine/phenol containing-submetabolome, each lung lobe was homogenized in 
methanol (4:1 volume/mass of tissue) and water (0.85:1 volume/mass of tissue) with a tissue 
homogenizer (Bio-Gen PRO200 Homogenizer, PRO Scientific Inc., Oxford, CT, USA) in an ice 
bath. The homogenate was extracted with dichloromethane and water (4:1 and 2:1 volume/mass 
of tissue, respectively), followed by centrifugation (10,000 rpm for 10 min at 4°C). The top 
aqueous layer was employed for the analysis of amines and phenols through 12C- or 13C-dansyl 
chloride labeling, while the bottom organic layer was stored for future lipidomics analysis (not 
presented herein).  
 
9.3.8 Dansyl chloride labeling and LC-MS 
 
For dansyl chloride labeling of amines and phenols, the aqueous layer obtained from each 
individual lung extract was evaporated to dryness on a SpeedVac, followed by resuspension in 
1/3 of the original volume of water. Each individual sample was labeled with 12C-dansyl chloride, 
while a pool of all lung extracts, consisting of 25% of the final volume of each sample, was 
labeled with 13C-dansyl chloride (Supplementary Figure 9.1a,b) [346]. Briefly, 50.0 µL of each 
sample or the pooled mixture was vortexed with 25.0 µL of acetonitrile, 25.0 µL of 250 mM 
NaHCO2 / Na2CO3 buffer (pH 9.4) and 50.0 µL of 18 mg/mL 12C- or 13C-dansyl chloride in 
acetonitrile. The mixture was incubated at 40°C for 60 min, followed by quenching with 12.0 µL 
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of 250 mM NaOH solution (40°C for 10 min). Last, the pH was adjusted with 50.0 µL of 425 
mM formic acid in 50% acetonitrile. 
The total metabolite concentrations of individual 12C-dansyl labeled samples and the 13C-
dansyl labeled pool were determined by UHPLC-UV, as previously described [346]. Each 
individual 12C-dansyl labeled sample was combined with the 13C-dansyl labeled pool in a 1:1 
ratio of total metabolite concentration. Intensity ratios between the 12C-dansyl labeled metabolites 
from the individual sample and the 13C-dansyl labeled metabolites from the pool were determined 
by UHPLC-QToF-MS (Dionex UltiMate 3000 UHPLC, Thermo Scientific, Waltham, MA, USA, 
coupled to the Maxis II ESI-QqTOF, Bruker Corporation, Billerica, MA, USA) with injection 
triplicates [346]. An aliquot of 10 µL of each sample was injected into an Acquity UPLC BEH 
C18 column (2.1 X 100 mm, 1.7 µm). The mobile phases were composed by MPA: 0.1% formic 
acid 5% acetonitrile in water; and MPB: 0.1% formic acid 5% water in acetonitrile. Analytes 
were separated by a 34.0 min gradient, namely: 20% MPB at 0 min; 35% MPB at 3.5 min; 65% 
MPB at 18 min; 99% MPB at 24 min; 99% MPB at 34 min (30°C, 0.180 µL/min). Each injection 
was followed by a 10 min equilibrium run (99% MPB at 0 m min, 99% MPB at 2 min, 20% MPB 
at 3 min, and 20% MPB at 10 min; no sample injection; 30°C; 0.180 µL/min). A 60 s calibration 
segment of sodium formate was included in the beginning of each analytical run for internal mass 
recalibration. Samples were randomized for preparation and injection.  
By spiking the 13C-labeled pool into each individual 12C-labeled sample, the differentially 
labeled metabolites were detected as peak pairs and relative quantification of individual 
metabolites was performed based on peak intensity ratio. Due to the fact that all the 12C-labeled 
individual samples use the same 13C-labeled pool as a reference, the peak intensity ratio of any 
particular metabolite is indicative of the concentration change in different treatment groups. This 
approach provides normalization as the intensity of each detected metabolite was corrected for 
ion suppression and any other small differences that might arise during sample preparation and 
injection; therefore, the observed differences between samples or groups did not result from 
experimental errors or adverse effects, but only by the evaluated conditions [347].  
For quality control (QC), aliquots of each final sample were collected and pooled together. The 
QC pooled sample was injected six consecutive times before the sample sequence, as well as 
once after every 10 sample injections. 
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Supplementary Fig. 9.1 Dansyl chloride labeling of amines and phenols, experimental workflow 
of Dansyl chloride labeling and principal component of analysis (PCA) score plot showing 
clustering of quality control (QC) samples. (a) Chemical reaction of labeling of amine and phenol 
groups with Dansyl chloride. (b) Experimental workflow of differential chemical isotope labeling 
(CIL) of amines and phenols using 12C or 13C-Dansyl chloride. (c) PCA score plot showing 
clustering of QC samples for Dansyl chloride-labeled amines and phenols 
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9.3.9 Data analysis for Dansyl chloride-labeled amine/phenol-containing metabolites  
 
An integrated approach was employed for data processing and analysis.  A peak pair picking 
algorithm tool, IsoMS Shiny 0.3.1, was used to process the raw data generated from LC-MS runs. 
Peak picking, filtering, alignment and missing value imputation were performed as previously 
described [349]. Peak pairs that were detected in less than 50% of all injections were eliminated 
before missing value imputation to reduce noise and detection of random peaks. The remaining 
missing values were imputed based on our in-house developed Zero-Fill algorithm, i.e. for each 
missing value, the algorithm searches for the 13C-labeled feature from the pooled mixture in the 
raw data file, based on a threshold match score that considers retention time, m/z and intensities. 
Then, the missing intensity ratio is calculated from the original 12C-labeled feature, but with less 
stringent parameters [350].  
 
9.3.10 Metabolite identification of Dansyl chloride-labeled metabolites 
 
After a final peak pair list was obtained, the in-house developed MyCompoundID mass 
spectrometry library (www.mycompoundid.org) was used for the putative (accurate mass match 
within a 0.005 Da tolerance) and definitive (accurate mass and retention time match to selected 
standards) identification of the detected peak pairs [352].  
Statistical analysis was performed on the web-based platform MetaboAnalyst 
(www.metaboanalyst.ca), namely: non-parametric ANOVA (Kruskal-Wallis test) for the 
univariate selection of statistically significant peak pairs, i.e. p-value adjusted for false discovery 
rate (FDR) smaller than 0.05; Principal Component Analysis (PCA) for the assessment of the 
reproducibility and consistency of results through the clustering of quality control (QC) sample 
injections; and Partial Least Squares - Discriminant Analysis (PLS-DA) for evaluation of the 
separation between different conditions and selection of significant peak pairs through the use of 
Variable Importance in the Projection (VIP). The data set was pre-processed by filtering out peak 
pairs with relative standard deviation higher than 30% for QC injections and auto-scaling. 
 
9.3.11 Statistical analysis of immunological experiments 
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Data were plotted using GraphPad Prism version 6. In the immunological studies, statistical 
differences between any two groups were calculated using Mann-Whitney test. Differences were 
considered significant if p < 0.05.  
 
9.4 RESULTS 
 
9.4.1 Optimal time point for sample collection for immunological studies and metabolomics 
 
  Prior to metabolomic profiling, it was important to establish the time course of RSV infection in 
the mouse model to be able to determine the optimal time point for sample collection for both 
immunological and metabolomic studies. BALB/c mice were infected with RSV and total RNA 
was extracted at day 2, 4, 6, 8 and 10 post challenge (p.c.) to study the transcriptomic changes of 
a panel of chemokines, pro-inflammatory cytokines and IFNs in the lungs. The results are 
represented in a heat map (Fig. 9.1a). RSV induced gene expression of CCL2 (~81-fold), CCL3 
(~10-fold), CCL4 (~19-fold), CCL5 (~2-fold), CXCL-1 (~22-fold) and CXCL-2 (~9-fold) on day 
2 p.c., with induction of CCL2 and CCL4 maintained until day 8 and day 6 p.c. at a high level 
(~16-fold and ~15-fold) respectively. Induction of CCL2, CCL4 and CCL5 lasted as long as 10 
days p.c. No induction of CCL11 was observed at any time point. However, CXCL-10 was 
increased by ~121-fold at day 2 p.c., peaked at day 4 p.c. (~215-fold) and was maintained at 15-
fold as late as 10 days p.c.  
The pro-inflammatory cytokines, TNF-α and IL-1β were induced at day 2 p.c.; however, 
the induction level was only modest (2-<10-fold) and maintained at the same level till day 8 and 
4 p.c. for TNF-α and IL-1β, respectively. However, other pro-inflammatory cytokines, IL-6 and 
IL-12β, were induced ~32- and ~15-fold, respectively, at day 2 p.c. While the IL-6 expression 
level was still at ~14 fold at day 6 p.c., the induction level of IL-12β increased further to ~17 fold 
as late as 10 day p.c. No induction of IL-5 was observed at any time point tested. The Th2 
cytokine IL-4, was expressed at day 2 p.c. by ~2-fold and increased to ~5-fold at day 4 p.c. and 
then declined at later time points. The anti-inflammatory cytokine IL-10 was also induced by ~4 
fold at day 2 p.c. and increased to ~16 fold at day 6 p.c. and then declined at later time points. 
Interestingly, high induction of IFN-β (~108-fold) was observed as early as day 2 p.c., but this 
declined rapidly at day 4 p.c. (~19-fold). A high level of induction of IFN-γ (~68-fold) was 
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observed at day 4 p.c., which was maintained at 9-fold as late as 10 days p.c.  
The RSV titres in the lungs rose quickly, peaked at day 4 p.c., then declined at day 6 p.c. 
and totally disappeared by day 8 p.c. (Fig. 9.1b). In the transcriptomic and viral titration 
experiments, day 2 p.c. was the earliest time point tested. We also observed that the overall 
induction of inflammatory mediators was high between days 2 and day 6 p.c. To check both early 
and late effects of RSV infection in inducing inflammatory responses in the lung tissue, we 
performed immunological studies at days 1 and7 p.c., respectively. Wealso wanted toexamine if 
prior vaccination with ΔF/TriAdj plays any role in modulation of such RSV-induced 
inflammatory responses. Since alteration of the metabolite profile is a late event;we decided to 
focus only on day 7 p.c. for the metabolomic study.  
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Fig. 9.1 Heat map showing the gene expression profile of chemokines, cytokines and interferons 
(IFNs) in the lung of mice at different time points after RSV challenge and kinetics of RSV 
replication. Six to eight week-old female BALB/c mice (n = 5 per group) were challenged with 
RSV strain A2 (5x105 p.f.u.) in a 50 μl volume intranasally. At days 2, 4, 6, 8 and 10 p.c., lungs 
were removed and homogenized. (a) Following isolation of total RNA, cDNA synthesis and real 
time-PCR were performed. The different time points of sample collection are shown in the top 
panel, while the genes tested are listed in the left panel of the map. The reference gene GAPDH 
was selected to normalize the levels of the chemokine, cytokine and IFN transcripts. Final data 
are represented as fold-change normalized over untreated mice. Each box represents the average 
fold-change values of 5 mice in each group. The fold-change values in the different treatment 
groups after normalization with the untreated group are indicated in the box. The color codes of 
the fold-change values in the heat map are also indicated. (b) Virus titres in the lungs were 
determined and expressed as PFU/gm of lung tissue. Data are presented as median with 
interquartile range.  Statistical differences between two time points are calculated by Mann-
Whitney test (*p<0.05). 
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9.4.2 Local innate immune changes in the gene expression profiles of chemokines, cytokines and 
interferons in vaccinated and unvaccinated mice after RSV challenge 
 
To investigate induction of inflammatory responses due to RSV infection and also to examine if 
prior vaccination with ΔF/TriAdj played a role in modulation of inflammatory responses, gene 
expression of chemokines, cytokines and IFNs was checked. BALB/c mice were vaccinated 
either with ΔF/TriAdj or PBS and three weeks post vaccination, mice were challenged with RSV 
(ΔF/TriAdj/RSV and PBS/RSV groups, respectively). A negative control group consisted of 
untreated mice, which were neither vaccinated nor challenged. The mice were euthanized for 
sampling at day 1 or 7 p.c. Transcriptomic profiling was carried out to determine the effect of 
ΔF/TriAdj and is shown in the form of a heat map (Fig. 9.2). Chemokines are critical players in 
controlling the migration and positioning of the innate immune effector cells to the sites of 
infection or inflammation. In conjunction with cytokines and IFNs, chemokines also coordinate 
interactions among innate and adaptive immune cells that plays a major role in imprinting the 
adaptive immune system [353]. Importantly, the level of induction at day 1 p.c. was significantly 
higher in the unvaccinated group (PBS/RSV) than in the vaccinated group (ΔF/TriAdj/RSV) for 
CCL2 (~176 vs. 297 fold), CXCL-1 (~40-fold vs. 54-fold), CXCL-10 (~466 vs. 709 fold) and IL-
6 (~73 vs. 126 fold), respectively. The differences between the two groups were more evident at 
day 7 p.c. both in terms of fold-change values and types of inflammatory mediators. For example, 
while the expression of several inflammatory mediators at day 7 p.c. decreased in the vaccinated 
group, the expression levels of the same effector molecules were still much higher in the 
unvaccinated group, especially for CCL2 (~8 vs. 29 fold), CCL3 (~3 vs. 12 fold), CCL4 (~5 vs. 
12 fold), CXCL-10 (21 vs. 58 fold), IL-6 (~2 vs. 9 fold), IL-10 (~9 vs. 20 fold), IFN-β (~2 vs. 7 
fold) and IFN-γ (9 vs. 24 fold) respectively. This indicates increased and sustained inflammation 
in the lungs of the PBS/RSV group and controlled inflammation in the ΔF/TriAdj/RSV group.  
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Fig. 9.2Heat map showing the gene expression profiles of chemokines, cytokines and 
interferons(IFNs) in the lung of vaccinated and unvaccinated RSV-infected mice. Six to eight 
week-old female BALB/c mice (n=5) were immunized once intranasally with ΔF/TriAdj or PBS 
in a 20 μl volume or left untreated. Three weeks post-immunization, mice were challenged with 
RSV strain A2 (5x105 p.f.u.) in a 50 μl volume intranasally. At day 1 or day 7 after 
RSVchallenge, lungs were collected from the vaccinated and unvaccinated RSV-challenged mice 
to study gene expression by qRT-PCR as described in the legend for Fig. 9.1a. The asterisks in 
the indicated boxes in the heat map indicate statistically significant differences between the 
unvaccinated (PBS/RSV) and vaccinated (ΔF/TriAdj/RSV) RSV-challenged groups at respective 
time points after RSV challenge. Statistical difference between two groups were calculated by 
Mann-Whitney test and considered significant at *p<0.05 and **p<0.01. 
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9.4.3 Local production of cytokines, chemokines and interferons in the lungs of vaccinated and 
unvaccinated mice after RSV challenge 
 
To validate the gene expression results at the protein level, we performed a multiplex ELISA. As 
expected, both vaccinated and unvaccinated groups produced chemokines, cytokines and IFNs in 
the lung at significantly higher levels than the untreated group at both days 1 and 7 p.c. 
Furthermore, similar to the gene expression, production of CCL2 and IL-6 (as well as IL-12p70) 
was significantly higher in the unvaccinated group when compared to the vaccinated group at day 
1 p.c. (Fig. 9.3). Most importantly, at day 7 p.c., the local production of the other inflammatory 
mediators tested (except CXCL-1) was also significantly higher in the unvaccinated group than 
the vaccinated group. These results are consistent to those obtained at the gene expression level. 
However, TNF-α was produced in significantly higher amounts in the unvaccinated group 
compared to the vaccinated group at day 7 p.c. only at the protein level, while IL-12p70 was 
produced in significantly higher amounts in the unvaccinated group compared to the vaccinated 
group at both days 1 and 7 after RSV challenge. This may be explained by the fact that TNF-α 
mRNAs are more labile than the protein, and that IL-12 is encoded by two separate genes, IL-
12A (p35) and IL-12B (p40). These two subunits combine at the protein level to form an active 
heterodimer (IL-12p70) that can only be detected by ELISA. 
  
 
 
 
 
 
 
 
 
 
 
 
  148 
 Figure 9.3 
 149  
Fig. 9.3 Local production of chemokines, cytokines andinterferons (IFNs) in the lung.Mice were 
immunized and challenged as described in the legend for Fig. 9.2. At day 1 or 7 after RSV 
challenge, induction of CCL2 (Fig. 9.3a), CCL3 (Fig. 9.3b), CXCL-1 (Fig. 9.3c), CXCL-10 (Fig. 
9.3d), TNF-α (Fig. 9.3e), IL-6 (Fig. 9.3f), IL-10 (Fig. 9.3g), IL-12p70 (Fig. 9.3h), IFN-γ (Fig. 
9.3i) and IL-4 (Fig. 9.3j) in the lung of untreated control, ΔF/TriAdj/RSV and PBS/RSV groups 
is shown as protein concentration in pg/ml.  Data are presented as median with interquartile 
range. Statistical difference between two groups are indicated as described in the legend for 
Figure 9.2. ns, non-significant. 
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9.4.4 Differential immune cell influx in the lungsand lung-draining thoracic lymph nodes (TLNs) 
in vaccinated and unvaccinated mice after RSV challenge 
To investigate the effect of the production of inflammatory mediators in response to ΔF/TriAdj 
on the recruitment of inflammatory cells and to ascertain if the chemokines induced are 
consistent with the type of immune cells recruited, we analyzed the lung tissue by flow 
cytometry.CCL2 and CCL3 recruit monocytes that later might differentiate into DCs and/or 
macrophages, while CCL3, CCL4 and CXCL-10 attract DCs. CXCL-1 and CXCL-2 trigger 
recruitment of neutrophils, while CCL3, CCL4 and CCL5 attract NK cells[176]. Overall, there 
indeed was significantly more infiltration of DCs (Fig. 9.4a), interstitial macrophages (Fig. 9.4b), 
neutrophils (Fig. 9.4c) and NK cells (Fig. 9.4d) in the lungs of both vaccinated and unvaccinated 
groups when compared to the untreated group at day 7 p.c. The influx of DCs, interstitial 
macrophages, neutrophils and NK cells was significantly higher in the vaccinated group when 
compared to that in unvaccinated group at day 1 p.c. Interestingly at day 7 p.c., the numbers of 
inflammatory cells were higher in the unvaccinated group than in the vaccinated group, 
corroborating the increased production of DC/macrophage chemoattractants (CCL2, CCL3 and 
CXCL-10) and NK chemoattractant (CCL3) by the lung. This result is important as it suggests 
that even at day 7 p.c., the cell numbers are still higher in the lungs of the unvaccinated group 
implicating potential lung damage and pulmonary immunopathology due to sustained 
inflammation. In contrast, in the vaccinated group, the cell numbers were decreased, restoring 
pulmonary homeostasis and indicating a role of ΔF/TriAdj in amelioration of inflammatory 
responses. Pearson correlation analysis was used to identify any statistical association among 
lung inflammatory chemokines/cytokines and inflammatory cells (Fig. 9.4g). Significant positive 
correlations were observed between lung DCs and CCL3/IFN-γ, macrophages and CCL3/CXCL-
10/IL-10/IL-4, neutrophils and CCL2/CCL3/CXCL-1/CXCL-10/TNF-α/IL-10/IL-12p70/IL-4, as 
well between lung NK cells and IFN-γ, and are indicated as red squares in the heat map. Any 
negative correlation among chemokines, cytokines and inflammatory cells were found to be non-
significant and indicated as gray squares in the heat map.  
Furthermore, cellular influx into the lung-draining TLNs was evaluated. Interestingly, 
DCs (Fig. 9.4e) and CD4+ T cells (Fig. 9.4f) were recruited into the TLNs at a significantly 
higher level in the vaccinated group than in the unvaccinated group at day 7 p.c., suggesting the 
role of ΔF/TriAdjin promoting better adaptive immune responses.  
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Fig. 9.4 Recruitment of immune cells in the lung and lung-draining thoracic lymph nodes (TLNs) 
and heat map showing Pearson correlation between inflammatory chemokines/cytokines and 
inflammatory cells.(a-f) Mice were immunized and challenged as described in the legend for Fig. 
9.2. At day 1 or 7 after RSV challenge, influx of DCs (Fig.9.4a), interstitial macrophages 
(Fig.9.4b), neutrophils (Fig.9.4c) and NK cells (Fig.9.4d) in the lung was measured by flow 
cytometry. Similarly, influx of DCs (Fig.9.4e) and CD4+ T cells (Fig.9.4f) in the lung-draining 
TLNs was measured by flow cytometry. Cells were gated on live cells and then analyzed. Results 
are expressed as percentage of cells stained positive for dual cell surface markers conjugated 
directly to two different fluorochromes. Data are presented as mean values with SEM. Statistical 
difference between two groups are indicated as described in the legend for Fig. 9.2. The asterisks 
on the top of the bars representing the ΔF/TriAdj/RSV or PBS/RSV group indicate statistically 
significant differences with respect to the untreated group. Any statistically significant difference 
between ΔF/TriAdj/RSV and PBS/RSV groups are represented by brackets and asterisks; ns, 
non-significant. (g) Pearson correlation analysis revealed statistical associations between lung 
inflammatory chemokines/cytokines and inflammatory cells. A correlation heat map is used to 
represent statistical correlation values (r) among lung inflammatory chemokines/cytokines and 
inflammatory cells in the lungs of RSV-infected vaccinated and unvaccinated mice at days 1 and 
7 p.c. as well as time-matched healthy control mice. Gray squares indicate non-significant 
correlations (p>0.05), white squares indicate non-applicable correlations and red squares indicate 
significant positive correlations (p<0.05).  
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9.4.5 Differential induction of local and systemic antibody responses in vaccinated and 
unvaccinated mice after RSV challenge 
 
Next we investigated if immunization with ΔF/TriAdj primed for improved local and systemic 
humoral immunity. Analysis of the BALF samples by ELISA revealed that RSV ΔF-specific IgA 
(Fig. 9.5a) was produced at a significantly higher level at day 1 p.c. in the vaccinated group when 
compared to the unvaccinated or control groups. A further increase in the IgA level was observed 
by day 7 p.c. in the vaccinated group.  Similarly, RSV ΔF-specific IgG1 (Fig. 9.5b) and IgG2a 
(Fig. 9.5c) were produced at a significantly higher level in the sera in the vaccinated group when 
compared to the untreated or unvaccinated group, both before RSV challenge and at days 1 and 7 
p.c. In the unvaccinated group, only RSV ΔF-specific IgG2a was found to be induced at day 7 
p.c.  
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Figure 9.5 
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Fig. 9.5 Measurement of antibody levels in the bronchioalveolar lavage fluid and sera. Mice 
were immunized and challenged as described in the legend for Fig. 9.2. At day 1 or 7 after RSV 
challenge, ΔF-specific IgA was measured in the BALF (Fig.9.5a), while RSV ΔF-specific IgG1 
(Fig.9.5b) and IgG2a (Fig.9.5c) were measured in the sera. ELISA titres were expressed as the 
reciprocal of the highest dilution that results in a value of two standard deviations above the 
negative control samples. Data are presented as median with interquartile range. Statistical 
differences among the groups are indicated as described in the legend for Fig. 9.2.  
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9.4.6 Distinct metabolic modulation of the amine/phenol group-containing submetabolome in 
unvaccinated and vaccinated RSV-infected mice 
 
A differential chemical isotope labeling (CIL) technique was employed to detect and quantify the 
relative levels of the metabolites in the lung tissues in unvaccinated and vaccinated RSV-
challenged mice. In the differential CIL labeling technique, an individual sample is labeled with 
12C-labeling reagent while 13C-labeling reagent is used to label a pooled sample generated by 
mixing aliquots of all individual samples in equal amounts [354]. Dansyl labeling was performed 
for improved detection of metabolites containing a common functional group i.e. amine/phenol 
[348]. By this method, amines and phenols can be labeled by 13C or 12C-Dansyl chloride under 
basic medium and the Dansyl tag imparts higher sensitivity to this technique of detection of this 
particular type of metabolite. This technique of 13C-/12C-isotope dansylation labeling markedly 
increases the electrospray ionization (ESI) signal response and also enhances reversed-phase (RP) 
LC separation, thereby accomplishing wider and more comprehensive metabolome coverage. 
This method also allows relative quantification of metabolites in different treatment samples 
[355].   
To ensure robustness of the analytical methods and obtain reliable results of the metabolic 
profile in the lung, the stability and reproducibility of the LC-MS method was evaluated by 
performing PCA on all the samples including QC samples. As shown in the Supplementary 
Figure 9.1c, the QC samples are clustered in the PCA score plots of the lung with a distribution 
much narrower than for the samples. Following data extraction and quality filtering, a total of 
2599 metabolic features were detected in the lung. To test for metabolic features that were 
significantly altered in the lungs from the three treatment groups, the 2599 metabolic features 
were further analyzed by Kruskal Wallis test. This test revealed 663 metabolic features to be 
significantly altered in the three treatment groups with the p-FDR adjusted as <0.05 (Fig. 9.6a). 
The FDR algorithm was used to adjust for multiple comparisons [351]. The PLS-DA analysis 
further revealed distinct separation between the vaccinated and unvaccinated RSV-infected 
groups and the control untreated group, indicating significant alteration in the lung metabolic 
pattern among the three groups due to vaccination and/or challenge[356](Fig. 9.6b). The clear 
separation between RSV-infected (including vaccinated and unvaccinated groups) and uninfected 
control mice as revealed by the PLS-DA plots provided an important positive control [345]. 
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IDO is encoded by either of the two homologous genes IDO-1 and IDO-2 [357]. RSV 
infection induced IDO-1 expression in both unvaccinated (12.4 fold) and vaccinated (12.2 fold) 
mice at day 1 p.c. (Fig. 9.7a). However, at day 7 p.c. when compared to uninfected healthy 
controls, IDO expression increased rapidly to 49.5-fold in the unvaccinated mice, while in the 
vaccinated mice, IDO expression was reduced to 7.5-fold. Expression of IDO-1 was significantly 
higher in the lung of the unvaccinated RSV-infected group than in the lung of the vaccinated 
RSV-infected group at day 7 p.c. This indicates that ΔF/TriAdj prevented RSV-induced increased 
IDO expression and helped to bring the expression level closer to the normal basal level.  
IDO is the first rate and rate-limiting enzyme responsible for catalyzing the initial step in 
the tryptophan degradation pathway [358]. Differential CIL LC-MS analysis of the lung tissues 
isolated from vaccinated and unvaccinated mice at day 7 after RSV infection revealed several 
metabolic features that were significantly altered due to RSV infection and are listed in Table 9.2. 
The pathways that these metabolites are functionally involved are shown in Table 9.3.Metabolites 
were identified by comparing their m/z masses against an accurate mass database by using 
MyCompoundID library [359]. A few selected significantly altered metabolic features from the 
list were also presented in the box diagrams (Fig. 9.7b-g). The metabolic features included m/z 
ions with mass that matched with tryptophan (tryptophan, a indole derivative) metabolites 
including indole (Fig. 9.7b), L-kynurenine (Fig. 9.7c), xanthurenic acid (Fig. 9.7d), serotonin 
(Fig. 9.7e), 5-hydroxyindoleacetic acid (Fig. 9.7f) and 6-hydroxymelatonin (Fig. 9.7g) indicating 
that tryptophan represents a major metabolite class detected in the lung (Table 9.2 and 9.3) [345]. 
Furthermore, these box plots revealed that the concentrations of these tryptophan metabolites 
were significantly altered in the unvaccinated RSV-infected group when compared to the healthy 
controls. Interestingly, the alterations in the concentrations of tryptophan metabolites (except 
xanthurenic acid) induced by RSV infection were modulated in the vaccinated RSV-infected 
group. The tryptophan metabolic pathways are represented schematically in Fig. 9.8.  
In addition to tryptophan metabolism, the metabolic features identified by CIL LC-MS 
included m/z ions with mass that matched with metabolites involved in biosynthesis of amino 
acids, including arginine biosynthesis, urea cycle and tyrosine metabolism (Tables9.2 and 9.3). A 
few selected metabolites from the list were also presented in the box diagrams (Fig. 9.9a-j). RSV 
infection significantly altered metabolites involved in biosynthesis of amino acids (including 
arginine biosynthesis) and urea cycle such as L-histidine (Fig. 9.9a), glycine (Fig. 9.9b), L-
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threonine (Fig. 9.9c), citrulline (Fig. 9.9d), arginine (Fig. 9.9e), ornithine (Fig. 9.9f), 1,4-
diaminobutane (putrescine) (Fig. 9.9g) and aminoadipic acid (Fig. 9.9h). RSV infection also 
significantly altered tyrosine metabolism as revealed by increased concentrations of tyrosine 
metabolites, such as hydroxyphenlyllactic acid (Fig. 9.9i) and desaminotyrosine (Fig. 9.9j) in the 
unvaccinated RSV-infected mice as compared to healthy control mice. Interestingly, such 
alterations in the concentrations of the above metabolites induced by RSV infection were 
modulated in the vaccinated RSV-infected group, or almost restored to the basal level as found in 
healthy control mice. The pathways involved in biosynthesis of amino acids, including arginine 
biosynthesis, urea cycle and tyrosine metabolism are represented schematically in Fig. 9.10. 
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Metabolite IDs mz_light rt (s) p value FDR Metabolite identification Definitive/Putative 
379.1112/20.34 379.1112 1220.1 1.77E-08 3.60E-05 Indole Putative 
442.1433/12.57 442.1433 754.3 4.31E-08 3.60E-05 L-kynurenine Definitive 
743.2607/19.14 743.2607 1148.3 6.62E-08 3.60E-05 6-hydroxymelatonin Putative 
436.2012/8.82 436.2012 529 7.45E-08 7.45E-08 Arginine Putative 
410.1385/6.24 410.1385 374.4 2.63E-07 4.20E-05 Ornithine Putative 
456.1589/12.49 456.1589 749.6 3.88E-07 4.39E-05 Glycyl-Phenylalanine Definitive 
416.1164/14.73 416.1164 884 2.47E-06 0.00013685 Hydroxyphenyllactici acid Definitive 
395.1272/5.86 395.1272 351.7 2.72E-06 0.00014412 Aminoadipic acid Definitive 
425.1167/15.98 425.1167 959.1 4.79E-06 0.0002089 5-hydroxyindoleacetic acid Definitive 
367.0959/4.99 367.0959 299.6 4.05E-05 0.00077515 L-aspartic Acid Definitive 
375.0771/2.16 375.0771 129.8 5.16E-05 0.00090831 O-phosphoethanolamine Definitive 
408.159/9.71 408.159 582.5 0.00010752 0.0015617 Glycyl-Valine Definitive 
409.154/4.19 409.154 251.4 0.00012411 0.0016969 Citrulline Definitive 
460.1652/18.58 460.1652 1114.9 0.00013864 0.0018205 Alanyl-Histidine Definitive 
439.0994/10.32 439.0994 619.3 0.00071844 0.0060483 Xanthurenic acid Definitive 
531.1481/8.29 531.1481 497.2 0.00089713 0.0070683 5'-Methylthioadenosine Definitive 
400.1213/18.07 400.1213 1084.2 0.00095561 0.0074612 Desaminotyrosine Definitive 
353.1065/21.07 353.1065 1264.1 0.0010634 0.0080608 Tyrosyl-Glycine Definitive 
399.1372/12.91 399.1372 774.6 0.0010821 0.0081553 L-phenylalanine Definitive 
278.1087/21.42 278.1087 1285.4 0.0012886 0.0092805 1,4-diaminobutane Definitive 
285.1169/22.08 285.1169 1324.7 0.0016129 0.010644 Cadaverine Definitive 
422.1748/11.98 422.1748 719 0.0026602 0.015846 Glycyl-L-Leucine Definitive 
370.0969/9.41 370.0969 564.3 0.0028367 0.016574 Hypoxanthine-multi-tags Definitive 
370.097/10.68 370.097 640.6 0.0034761 0.01952 Hypoxanthine-Isomer Definitive 
322.1062/24.13 322.1062 1447.6 0.0035167 0.019621 Serotonin Definitive 
389.1279/19.54 389.1279 1172.3 0.0056034 0.028071 L-histidine Definitive 
581.1215/6.71 581.1215 402.4 0.0058585 0.029069 2'-Deoxyguanosine 5'-monophosphate Definitive 
388.1072/3.27 388.1072 196.2 0.0059854 0.029418 Hypoxanthine+H2O Definitive 
309.091/7.05 309.091 422.7 0.0060917 0.029771 Glycine Definitive 
353.1165/4.94 353.1165 296.5 0.0061853 0.030172 L-threonine Definitive 
459.1333/6.57 459.1333 394 0.0072451 0.033819 Cytidine-H2O Definitive 
 
 
 
 
Table 9.2 Listof significantly altered metabolites due to RSV infectionas identified by CIL LC-
MS 
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Metabolites Pathways  
L-kynurenine 
 Tryptophan metabolism 
5-hydroxyindoleacetic acid 
Xanthurenic acid 
Serotonin 
Indole* 
6-hydroxymelatonin* 
L-histidine  
 Biosynthesis of amino acids  
Tyrosine 
Glycine 
Threonine 
Citrulline 
Arginine* 
Aminoadipic acid 
Citrulline 
 Arginine biosynthesis and Urea cycle Arginine* Ornithine* 
1,4-diaminobutane (Putrescine) 
Hydroxyphenyllactic acid  Tyrosine metabolism Desaminotyrosine 
 
Asterisks indicate metabolic features that were putatively identified. 
 
 
 
 
 
 
 
 
 
 
 
Table 9.3 Metabolites and their functional relationship with their respective metabolic pathways 
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 Figure 9.6 
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Fig. 9.6 Scatter plot indicatingsignificantly altered amine/phenol group-containing metabolic 
features detected in the lung by Kruskal Wallis test and partial least squares discriminant 
analysis (PLS-DA) plots to reveal group separation. (a) Scatter plot indicating significantly 
altered amine/phenol group-containing metabolic features in the three groups of mice as 
determined by Kruskal Wallis test. The significantly altered features in the three groups of mice 
are indicated by red symbols and the features that were not significantly altered are indicated by 
green symbols. (b) The PLS-DA score scatter plot of samples classified according to untreated 
controls (Gr-A, red), ΔF/TriAdj/RSV (Gr-B, green) or PBS/RSV (Gr-C, blue). The scatter plots 
are prepared with R2 value of 0.99923 and Q2 value of 0.98883 (R2 measures the internal 
predictivity of a model, i.e. the ability to predict the activities of the compounds from which the 
model was constructed, while Q2 measures how well the model predicts the activities of 
compounds not used to construct the model, i.e. an estimate of the predictive ability of the 
model). Metabolomic profiles were significantly different among the three groups (permutation 
test, p: 0.02 for p<0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
163 
 
Figure 9.7 
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Fig. 9.7 Induction of indoleamine 2,3 dioxygenase (IDO-1) and box plots showing the alteration 
of amine/phenol group-containing metabolic features involved in the tryptophan metabolic 
pathway(a) Induction of IDO-1 in the lung of the vaccinated and unvaccinated RSV-infected 
mice at days 1 and 7 after RSV challenge was measured by qRT-PCR as described in the legend 
for Fig. 9.1a. Results are expressed as normalized fold-change over untreated mice. (b-g) Box 
plots of tryptophan metabolites, indole (9.7b), L-kynurenine (9.7c), xanthurenic acid (9.7d), 
serotonin (9.7e), 5-hydroxyindoleacetic acid (9.7f) and 6-hydroxymelatonin (9.7g)showing 
relative intensities of the above individual metabolites. Asterisks beside the name of metabolites 
in Fig.9.7b and 9.7g indicate that these two metabolites were putatively identified, while the rest 
were all definitively identified. 
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Fig. 9.8 Pathways for tryptophan metabolism: Schematic representation of tryptophan metabolic 
pathways as obtained from KEGG (www.genome.jp/kegg/). The name of the enzyme with the 
accession ID 1.13.1111 is indicated as IDO in blue. Tryptophan metabolites that were altered in 
response to RSV infection are indicated with bold arrows. Red-colored bold arrows indicate 
positively identified metabolites and yellow-colored bold arrows indicate putatively identified 
metabolites. 
 
 
 
Figure 9.8 
IDO 
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Figure 9.9 
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Fig. 9.9 Box plots showing the alteration of amine/phenol group-containing metabolic features 
involved in pathways for biosynthesis of amino acids, including arginine biosynthesis, urea cycle 
and tyrosine metabolism (a-j) Box plots of metabolites involved in biosynthesis of amino acids, 
including arginine biosynthesis and urea cycle such as L-histidine (9.9a), glycine (9.9b), L-
threonine (9.9c), citrulline (9.9d), arginine (9.9e), ornithine (9.9f), 1,4-diaminobutane 
(putrescine) (9.9g), aminoadipic acid (9.9h),as well as metabolites involved in tyrosine 
metabolism such as hydroxyphenlyllactic acid (9.9i) and desaminotyrosine (9.9j), showing 
relative intensities of the above individual metabolites. Asterisks beside the name of metabolites 
in Fig.9.9e and 9.9f indicate that these two metabolites were putatively identified, while the rest 
were all definitively identified. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Fig. 9.10 Pathways for biosynthesis of amino acids, including arginine biosynthesis and urea 
cycle: Schematic representation of 
and urea cycle as obtained from KEGG
response to RSV infection are indicated
positively identified metabolites and yellow
metabolites. 
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 (www.genome.jp/kegg/). Metabolites that were altered in 
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 arrows indicate 
Figure 9.10 
 169  
Metabolomics is defined as the study of the metabolic pathways and unique biochemical 
entities in a living being [360]. Metabolites are the end stage products and considered as the 
mediators of biological processes that can present us with a holistic picture of underlying 
physiological and biochemical processes [263]. In the present study, we aimed to understand the 
underlying cause of ΔF/TriAdj-induced vaccine immunity in response to RSV infection, which 
might allow us to identify potential biomarker(s) of the adjuvanticity of ΔF/TriAdj. Multiplex 
chemokine/cytokine profile analysis and integrated LC-MS-based metabolomics techniques were 
used to investigate the chemokine/cytokine changes and metabolic alterations, respectively, in the 
lung. This study provides for the first time a comprehensive understanding of the inflammatory 
response-associated alterations in the lung metabolome profile of RSV-infected mice and 
modulation of the altered lung metabolites due to vaccination with ΔF/TriAdj. 
Based on the transcriptomeof the lungs of RSV-infected mice, overall induction of 
inflammatory mediators was found to be higher from days 2 till 6 p.c. The kinetics of RSV 
replication revealed that the viral replication in the lung peaks on day 4, declines on day 6, and is 
completely cleared by day 8 p.c. Next we compared the gene expression profiles of inflammatory 
cytokines, chemokines and IFNs in the lung between unvaccinated and vaccinated RSV-infected 
mice. Induction of most of the inflammatory mediators was comparable between the 
unvaccinated and vaccinated groups at day 1 p.c.; however, at day 7 p.c., the levels of 
inflammatory mediators were higher in the unvaccinated RSV-infected group than in the 
vaccinated RSV-challenged group. This was further confirmed at the protein level by multiplex 
chemokine/cytokine ELISA in the lung homogenate. At the cellular level, RSV was also found to 
trigger significantly higher numbers of inflammatory cells, including DCs, macrophages, 
neutrophils and NK cells, in the unvaccinated group than in the vaccinated group at day 7 p.c.  
Pearson correlation analysis identified positive correlations between lung DCs and CCL3/ 
IFN-γ, macrophages and CCL3/CXCL-10/IL-10/IL-4, neutrophils and CCL2/CCL3/CXCL-
1/CXCL-10/TNF-α/IL-10/IL-12p70/IL-4, as well between lung NK cells and IFN-γ. CCL3 is 
involved in the recruitment and trafficking of monocyte-lineage cells (such as DCs and 
macrophages), while IFN-γ mediates autocrine maturation of DCs [361-363]. Macrophages are 
also known to induce differentiation of plasma cells through CXCL-10[364], while IL-10 is 
known to inhibit macrophage activation [365]. IL-4 is implicated in increased proliferation of 
resident macrophages during inflammation induced due to Th2-biased infection [366]. On the 
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other hand, CXCL-1, CCL2 and CCL3 mediate neutrophil influx via induction of lipid mediators. 
CXCL-10 (via the CXCL10-CXCR3 signaling axis) is directly responsible for pathogenesis of 
neutrophil-mediated, exaggerated lung inflammation. TNF-αis also involved in infiltration of 
neutrophils during airway inflammation [367]. Neutrophils abundantly produce IL-10 at the site 
of infection during sepsis [368]. IL-4 is considered as a neutrophil activator [369], while IL-12 is 
crucial in neutrophil migration and activation[370]. NK cellsare known to play a crucial role in 
controlling viral infection via secretion of IFN-γ and are also involved in acute lung injury 
induced by RSV infection [371, 372]. Thus, the positive correlations observed between 
inflammatory chemokines/cytokines and inflammatory cells in the present study clearly 
supported their functional relationship as discussed above. 
In our study, significantly heightened inflammatory responses were observed in the 
unvaccinated group one day (day 7 p.c.) before the viruswas completely cleared (day 8 p.c.). This 
indicates that host factors and/or host responses were contributing to the prolonged inflammatory 
response in the unvaccinated RSV-challenged group. In contrast, in the vaccinated RSV-
challenged group, the level of inflammatory mediators was significantly diminished at day 7 p.c., 
presumably as a result of inhibition of RSV replication due to immunization with ΔF/TriAdj as 
demonstrated previously[373]. Unchecked inflammatory responses due to sustained induction of 
chemokines, cytokines and inflammatory cells is responsible for destruction of lung alveoli 
followed by edema and disruption of alveolar functions [374]. Long-term recruitment of 
macrophages into the virus-infected lung can cause alveolar epithelial cell apoptosis, damage and 
lung injury. Sustained and uncontrolled influx of neutrophils is known to disrupt lung 
homeostasis, and may generate reactive oxygen species and release harmful granule proteins to 
induce further damage to the lung [374]. NK cells are involved in acute lung injury (ALI) 
induced by RSV infection [371, 372].   
At day 7 p.c., influx of DCs into the TLNs was significantly higher in the vaccinated 
RSV-infected group than in the unvaccinated group, implicating stronger and improved antigen 
presentation to the TLN-resident CD4+ T cells due to ΔF/TriAdj. This is further supported by 
induction of significantly elevated levels of RSV ΔF-specific IgA in the BALF and RSV ΔF-
specific IgG1 and IgG2a in the sera at day 7 p.c. in the vaccinated group when compared to the 
unvaccinated group, which might be explained by memory or recall responses. 
Metabolic activities in resting tissues are distinctively different from that under 
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inflammatory conditions characterized by continuous infiltration, proliferation and differentiation 
of immune cells [375]. Metabolites represent the final downstream products of gene expression 
and therefore, are directly linked to the phenotypes and cellular functional activities [374]. 
Banoei et al noted that although the respiratory system is the primary organ involved in any 
respiratory viral infection, these viruses also may target the liver and kidney, and therefore, have 
a profound effect on overall local and systemic metabolism [376]. It has been reported previously 
that RSV infection involves a large spectrum of pathways including carbohydrate metabolism, 
lipid metabolism,energy metabolism and amino acid metabolism [351]. Dysregulated amino acid 
metabolism is also reported in HIV-infected patients as demonstrated by elevated blood levels of 
phenylalanine and kynurenine (a tryptophan breakdown product) [377]. Amino acid catabolism is 
considered as an ancestral survival strategy that plays an important role in controlling immune 
responses [378]. Tryptophan is an essential amino acid and a critical molecule in the pathway 
linked to inflammatory diseases. Alteration of tryptophan metabolism is considered as a marker 
of inflammation [345]. Tryptophan is also involved in glycolysis and Krebs cycle processes 
[359]. Excess of tryptophan in blood is linked to mental retardation while its deficiency is linked 
to nervous system disease [359]. It has been previously demonstrated that critical metabolites of 
tryptophan regulation including hydroxy-tryptophan, tryptophan, formylkynurenine, kynurenine, 
indole, hydroxyindole acetic acid and indole acetaldehyde are altered significantly and produced 
in increased abundance in influenza-infected lungs [345]. This was in accordance with the fact 
that influenza infection is responsible for altered tryptophan metabolism. Cui et al also reported 
that the tryptophan metabolism is altered due to influenza A virus infection in a murine model of 
influenza pneumonia [374]. Tryptophan metabolic pathways are diverse. Indole is one of the 
main degradation products of tryptophan metabolism. Similarly, the L-Kynurenine pathway is 
another primary route for tryptophan catabolism. Tryptophan is metabolized along the 
kynurenine and serotonin pathways that lead to the formation of kynurenine metabolites, 
serotonin and melatonin [379]. Both these pathways are critically important in maintaining 
healthy homeostasis. However, each of these pathways exhibit an extremely unequal ability in 
causing degradation of tryptophan and, information on how balance is maintained between these 
two pathways islimited.  
IDO mediates catalytic conversion of tryptophan into N-formylkynurenine, which in turn 
is converted into ‘immunocytotoxic’ L-Kynurenine by the enzyme formidase [321]. IDO is not 
 172  
constitutively bioactive in immune/inflammatory cells and its expression and/or activation takes 
place only under inflammatory conditions such as atherosclerosis, depression or infections. RSV 
is implicated in activation of IDO in human monocyte-derived DCs [321]. Tissue inflammation 
leads to increased transcriptional activity of IFN-β and IFN-γ, resulting in increased activity of 
IDO. Moreover, IL-12 and IFN-γ produced by innate immune cells such as macrophages, NK 
cells, NKT cells and lymphocytes are also known to induce IDO [357, 378]. The anti-
inflammatory cytokine IL-10 may induce IDO expression by DCs [380]. IDO expression is 
known to suppress natural or vaccine-induced innate and adaptive immunity and considered as a 
potential host predisposition factor for secondary opportunistic pulmonary infections [357]. The 
enzyme also suppresses helper/effector functions of T cells and instead, converts naïve CD4+ T 
cells into Foxp3+ T regulatory cells responsible for attenuated effector T cell responses [357]. 
IDO is reportedly known to induce selective apoptosis of Th1 cells and in turn promotes 
induction of allergic-type Th2-biased immune responses in the lung [321, 381].  
In the present study, a significantly higher level of IDO-1 expression was observed at day 
7 p.c. in the unvaccinated RSV-infected group than in the vaccinated RSV-infected group, 
possibly due to significantly higher expression of IDO-inducers such as IFN-β (Fig. 9.2), IFN-γ 
(Fig. 9.2, 9.3i), IL-12 (Fig. 9.3h) and IL-10 (Fig. 9.2, 9.3g) in the lung of unvaccinated RSV-
infected mice than that of the vaccinated RSV-infected mice at day 7 p.c. The presence of IDO at 
the later stages of viral infection may be due to continued production of IFNs during the recovery 
phase. Enhanced expression of IDO-1was consistent with increased concentrations of L-
Kynurenine in the lung of the unvaccinated RSV-infected group. Similarly the ability of 
ΔF/TriAdj in suppressing IDO-1 expression was reflected in reduced concentrations of L-
Kynurenine in the lung of vaccinated RSV-infected group. Alteration of tryptophan metabolism 
by RSV is also reflected in significantly increased production of indole in the lung of the 
unvaccinated RSV-infected mice when compared to healthy control mice. In contrast, production 
of indole was significantly lower in the lung of the vaccinated RSV-infected mice compared to 
the unvaccinated RSV-infected mice. Therefore, ΔF/TriAdj was found to play a critical role in 
modulating the alteration of the tryptophan pathway involving the tryptophan metabolites, indole 
and L-Kynurenine. Tryptophan metabolites such as kynurenine and indole are also reportedly 
produced at an elevated level in the lung during H1N1 influenza virus infection [345] 
 Tryptophan is the precursor of serotonin, while 6-hydroxy melatonin and 5-
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hydroxyindoleacetic acid are serotonin metabolites generated in two different pathways (Fig. 9.8) 
[355, 359]. Secretion of serotonin in the central nervous system and spinal cords has also been 
linked to inflammation as well as irritable bowel syndrome, diarrhea and depression [345]. 5-
hydroxyindoleacetic acid is a major neurotransmitter in the brain, and a reduced level of 5-
hydroxyindoleacetic acid in human cerebrospinal fluid samples is linked to Alzheimer’s disease 
[355]. Therefore, all these metabolites are involved in inflammatory responses and disease 
conditions. In the present study, induction of serotoninand 5-hydroxyindoleacetic acid was 
significantly reduced, while that of 6-hydroxmelatonin was significantly increased in the lungs of 
the unvaccinated RSV-infected group compared to healthy control mice. As mentioned earlier, 
little information is known on the mechanism that regulates the balance between these different 
pathways of tryptophan (and serotonin) metabolism. However, this is clear that RSV infection 
has predominantly led to an overall alteration of tryptophan metabolism, while ΔF/TriAdj played 
an important role in modulating alterations of tryptophan metabolic pathways induced due to 
RSV infection.  
 It has previously been reported that disruption of amino acid metabolism pathways may 
serve as a critical factor in the differences between survivor and nonsurvivor responses to 
influenza virus infection [376]. Any changes in amino acid metabolism are known to implicate 
immune responses to ongoing infection and/or tissue injury [345]. Bacteria causing pneumonia 
and other lung pathogens such as P. aeruginosaare responsible for increased histidine 
biosynthesis.Histamine (a product of L-Histidine) is a major inflammatory metabolite [376, 382]. 
In our study, we observed elevated levels of L-Histidine in the lungs of unvaccinated RSV-
infected mice, while in the lung of vaccinated RSV-infected mice, the changes in the 
concentrations of this metabolite were reduced, probably due to the potential effect of ΔF/TriAdj. 
It has been previously reported that H1N1 pneumonia results in metabolomic changes in the 
concentration of amino acids in the plasma such as decreased concentration of glycine and 
threonine (probably due to the fact that these amino acids are consumed by the viruses for their 
metabolism) in H1N1-infected patients [376]. Another study also revealed serious impact of 
HIN1 influenza virus infection on amino acid metabolism in the lung [345]. In line with this, in 
the present study we also observed decreased concentration of glycine, L-Threonine and 
aminoadipic acid in the lung of unvaccinated RSV-infected mice, while in the lung of vaccinated 
RSV-infected mice, the changes in the concentrations of these metabolites by RSV infection were 
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reduced or restored (e.g. for aminoadipic acid), probably due to the potential effect of ΔF/TriAdj.  
The urea cycle via enhanced arginine metabolism is known to promote an asthmatic 
phenotype [336]. Chronic HBV infection alters the urea cycle as demonstrated by enhanced level 
of urea cycle intermediates such as citrulline and ornithine[383]. The urea cycle is related to 
aspartate-malate NADH shuttle that functions across mitochondrial membranes. Cytosolic 
aspartate binds to citrulline to form arginosucciante (a urea cycle intermediate), which gets 
converted to arginine. Arginine is a critical component of urea cycle that can be metabolized to 
ornithine and urea by the action of enzyme arginase [348, 383]. Ornithine can act as a substrate 
for the enzyme ornithine aminotransferase, which in turn is responsible for the synthesis of 
polyamines such as putrescine. Polyamines and their metabolites play an important role in cell 
proliferation and differentiation. In the present study, elevated levels of all three urea cycle 
intermediates (such as citrulline, arginine and ornithine) as well as downstream product 
(putrescine) were observed in the lung of unvaccinated RSV-infected mice, while in the lung of 
vaccinated RSV-infected mice, the changes in the concentrations of the above metabolites 
induced by RSV infection were reduced or restored (ex. for citrulline and putrescine). Therefore, 
our data suggest that ΔF/TriAdj plays an important role in controlling immunopathogenesis 
induced byRSV-mediated perturbation of pathways of arginine biosynthesis and urea 
cycle.Elevated levels of citrulline or ornithine potentially implicate attenuated aspartate transport 
and therefore, impaired aspartate-malate NADH shuttling functioning [383]. Pathway enrichment 
studies have previously revealed that the major metabolic pathways altered due to HIN1 
influenza virus infection include arginine/proline, urea cycle, glycine and histidine [345]. 
Tyrosine is the precursor amino acid for dopaminergic neurotransmitters such as Dopamine, 
Noradrenaline and Adrenaline [377]. Hydroxyphenyllactic acid and desaminotyrosine are both 
products of tyrosine metabolism (TMIC HMDB). RSV infection altered tyrosine metabolism as 
revealed by reduced levels of hydroxyphenyllactic acid and desaminotyrosine in the lung of the 
unvaccinated RSV-infected mice when compared to both healthy control mice and vaccinated 
RSV-infected mice, thereby demonstrating the ability of ΔF/TriAdj in maintaining or restoring 
tyrosine metabolism altered due to RSV infection.  
 The metabolism is increasingly being described as the crucial regulator of immune cell 
functions [261, 262];there is evidence that metabolic pathways and immune responses are heavily 
cross-regulated [377]. The use of metabolomics as an additive tool to immunological measures in 
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a vaccine response trial can have potential benefits in clinical and research settings [261]. 
Metabolites may demonstrate immunological properties via effects on cell-signaling pathways 
and receptors on various immune cells [263]. Influenza virus infection is responsible for severe 
lung inflammation due to induction of inflammatory disease markers such as IL-1β, IL-6, IL-10, 
TNF-α and IFN-γ [345]. Furthermore, influenza virus infection exerts strong effects on 
tryptophan and other amino acids and is responsible for significant alterations of lung tissue 
metabolites involved in glycophospholipid, purine, pyrimidine and amino acid pathways [345]. A 
metabolome-wide association study (MWAS) with inflammatory cytokines termed as cytokine-
MWAS (cMWAS) revealed strong association of altered lung metabolite profiles with elevated 
levels of lung cytokines such as IL-1β, IL-6, IL-10, TNF-α and IFN-γ. A few examples are cited 
here. Histidine, threonine and ornithine were the key metabolites that correlated with both IFN-γ 
and IL-6 and were associated with glycine metabolism, threonine metabolism and urea cycle 
metabolism. Similarly, tyrosine, methylseroninin, methylindoleacetate, kynurenine and citrulline 
were the key metabolites that correlated with five pro- and anti-inflammatory cytokines, 
including IL-1β, IL-6, IL-10, TNF-α and IFN-γ and were associated with tryptophan and 
arginine/proline metabolism. Urea cycle/amino group metabolism, tryptophan metabolism, 
Glycine/Serine/Alanine/Threonine metabolism, carnitine shuttle and Tyrosine metabolism are the 
significant pathways (amino acid pathways and carnitine shuttle being associated with the largest 
cytokine cluster) that were found to be associated with inflammatory cytokines [345]. 
Perturbation of the urea cycle and arginine metabolism was also correlated to inflammation-
associated metabolic changes in a mouse model of allergic asthma induced by house dust mite 
[336]. Rapid conversion of tryptophan to Kynurenine is reportedly demonstrated to correlate with 
increased levels of immune activation markers such as IFN-γ in HIV patients [377]. Other studies 
have also demonstrated that inflammatory cells and cytokines have potential biological 
associations with the metabolome profile and that the inflammatory immune responses can be 
linked to altered profiles of pulmonary metabolites [336, 345, 348]. Perturbation of the urea cycle 
and arginine metabolism is associated with neutrophil activation and function [348]. Airway 
inflammation can be linked to biologically important metabolic changes [336]. Metabolites such 
as arginine were previously strongly correlated with increased neutrophil numbers (moderate 
correlation with macrophages), while threonine was strongly correlated with neutrophil numbers 
in the BALF in rats with experimental asthma [348]. A new term known as ‘immunometabolism’ 
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has been coined to explore the role of metabolic pathways within immune cells and also to study 
how metabolic pathways regulate the immune response outcome [262]. 
The present study highlights the potential of an untargeted metabolomic approach in 
identification of key metabolic immune correlates, which in turn can promote targeted design of 
vaccine antigen, adjuvants and carrier systems so as to trigger specific key biological and 
immunological pathways that can be assessed downstream at the metabolite level [263]. Our 
untargeted CIL LC-MS-based metabolomics approach demonstrated a prominent effect of RSV 
infection on tryptophan and widespread effects on pathways including tryptophan metabolism, 
biosynthesis of amino acids, especially arginine biosynthesis and urea cycle,as well as tyrosine 
metabolism. The altered abundance of metabolites invaccinated and unvaccinated RSV-infected 
groups reflect the processes of stimulation of the mucosal immune system due to intranasal 
administration of ΔF/TriAdj and intranasal challenge with RSV [263]. The increased or 
decreased altered abundance of the above metabolites may serve as key diagnostic markers of 
RSV infection. Altered metabolites between vaccinated and unvaccinated subjects can be linked 
to the differences in immunological responses as measured by antibody production [263].  An 
elevated and sustained level of inflammatory cells and cytokines in the unvaccinated RSV-
challenged group can be linked to altered pulmonary metabolism in this group. Similarly, the role 
of ΔF/TriAdj in subsiding RSV-induced inflammatory responses and modulating or restoring 
altered metabolite profiles in the RSV-infected vaccinated group is evident from both immune 
analyses and metabolomic profiling.  
In our study, we found that ΔF/TriAdj was associated with reduced inflammatory 
responses in RSV-infected lung tissue. A combination of PCA and PLS-DA revealed distinct 
biomarkers in the lung that were induced by RSV and were corrected with ΔF/TriAdj treatment. 
In other words, ΔF/TriAdj was able to modulate the abnormal levels of these biomarkers in the 
RSV-infected mice closer to the normal levels found in untreated control mice. The lung is a 
primary site for RSV infection and replication. ΔF/TriAdj was found to exert beneficial effects on 
RSV infection in the lung by at least partially preventing or resolving the imbalance of the above 
metabolites induced by RSV infection. Combining immune analyses with metabolic profiling 
enabled us to gain a better perspective and comprehensive understanding of the potential 
immuno-metabolic interactions in the lung in response to immunization with ΔF/TriAdj [261]. 
This study also helped us to gain a better understanding of RSV pathogenesis and the role of 
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ΔF/TriAdj in ameliorating the disease outcome. The results from this study may also serve to 
identify predictive and diagnostic biomarkers for protective efficacy of ΔF/TriAdj.  
 
9.6 ACKNOWLEDGEMENTS 
 
The authors thank Laura Latimer and Amanda Galas-Wilson for their technical assistance as well 
as the animal care team at VIDO-InterVAC. This work was funded by grant MOP 42436 from 
the Canadian Institutes of Health Research (CIHR). IS was partially supported by scholarships 
from the College of Medicine, University of Saskatchewan, Canada. This is VIDO-InterVac 
manuscript number 856. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 178 
 
CHAPTER 10 
10                        GENERAL CONCLUSIONS AND DISCUSSION 
 
10.1 General conclusions  
 
The RSV vaccine candidate (ΔF/TriAdj) was delivered intranasally in a single dose and promoted 
transient and local innate immune responses in BALB/c mice.Innate immune responses were 
elicited by ΔF/TriAdj in both URT (including NALT and NALT-draining CLN) and LRT 
(including lung and lung-draining TLN). Activation of the innate immune system by ΔF/TriAdj 
was reflected in transient production of chemokines, cytokines and IFNs in the nasal tissues and 
lungs.This was followed by infiltration of DCs, macrophages and neutrophils into the NALT and 
lung. The immune cells recruited were consistent with the type of chemokines 
produced.Infiltration of DCs was also observed in the LNs draining the NALTand 
lung.Additionally, ΔF/TriAdj activated the immune cells that were recruited into the NALT, lung 
and their respective dLNs.ΔF/TriAdj also induced local mucosal immune responses via 
production of RSV ΔF-specific IgA in the nasal washes, BALF and LFCs, as well as systemic 
RSV ΔF-specific IgG responses.Finally, intranasal immunization of BALB/c mice with 
ΔF/TriAdj conferred partial protection in the URT and complete protection in the LRT when 
challenged with RSV. Both innate and adaptive immune responses were lower, when mice were 
immunized with RSV ΔF alone (i.e. in absence of any adjuvant). This further highlighted the 
importance of the TriAdj in the subunit RSV vaccine candidate in modulating the innate mucosal 
environment in both URT and LRT, contributing to robust adaptive immune responses and long-
term protective efficacy of this subunit vaccine candidate. 
ΔF/TriAdj induced upregulation of both endosomal and cytosolic PRRs in RAW264.7 
cells and BMMs, while no such effect was observed when cells were stimulated with ΔF 
alone.PRR gene expression due to ΔF/TriAdj led to secondary effector responses,namely 
induction of chemokines, pro-inflammatory cytokines as well as upregulation of MHC-II and co-
stimulatory immune markers, CD40, CD80 and CD86. TriAdj enhanced uptake of RSV ΔF 
protein by the macrophages, which is another potential mechanism responsible for the induction 
of ΔF-specific immune responses in vivo as observed previously. The JNK and ERK1/2, as well 
as CaMKII, PI3K and JAK pathways were clearly responsible for ΔF/TriAdj-mediated 
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chemokine and cytokine responses. In contrast, p38 and NF-κB pathways were minimally or not 
involved in ΔF/TriAdj-induced signaling responses.Furthermore, ΔF/TriAdj induced IFN-β, 
which in turn, was found to amplify the production of CXCL-10 via the JAK-STAT pathway. 
Blocking the JAK pathway also resulted in significant reduction in the cell surface expression of 
MHC-II and co-stimulatory immune markers. 
 RSV infection was found to alter the tryptophan metabolism (including kynurenine 
pathway) in the lung as revealed by either significantly increased (indole, L-Kynurenine and 6-
hydroxymelatonin) or significantly decreased (xanthurenic acid, serotonin and 5-
hydroxyindoleacetic acid) production of tryptophan metabolites in RSV-challenged BALB/c 
mice when compared to healthy controls. ΔF/TriAdj was predominantly found to modulate such 
alterationsin the tryptophan metabolism.In addition to the tryptophan metabolism, RSV infection 
in the lungaltered pathways involved inbiosynthesis of amino acids, including arginine 
biosynthesis, urea cycle and tyrosine metabolism. A role of ΔF/TriAdj in modulating and/or 
restoring the concentrations of the metabolites of the above pathways was also observed.Altered 
metabolic pathways in the unvaccinated RSV-challenged group may help to explain sustained 
inflammatory responses in the lung. In contrast, modulation of the alterations in the metabolic 
pathways in the vaccinated RSV-challenged group may provide a potential mechanism for 
amelioration of the inflammatory responses in this group. 
 
10.2 General discussion 
 
The disastrous outcome of the FI-RSV vaccine in 1960s was a learning lesson for the RSV 
vaccine community. First, formalin treatment to inactivate RSV resulted in alteration of the 
surface antigens on the surface of the virus that prevented development of neutralizing antibodies 
[384]. Secondly, the antibodies induced due to immunization with FI-RSV were of low avidity 
for the virus that resulted in the consequent development of ERD [385].Thirdly, the use of 
formalin in the FI-RV vaccine perhaps skewed the T cell response towards Th2 phenotype with 
an inability to prime for CD8+ T cell responsesand therefore, not resulting in induction of CTLs 
[385]. 
Since TLR activation is required for protection against RSV and in prevention of ERD, 
formulation of a killed or subunit vaccine with a TLR agonist renders the vaccine safe and 
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effective [385]. Oumouna et al reported that formulation of FI-BRSV or commercial killed 
BRSV vaccine with CpG ODN resulted in generation of effective and protective BRSV-specific 
immune response with a more Th1-type immune response and also prevented induction of 
pulmonary immunopathology [386]. In addition to TLR4 activation by RSV F protein, detection 
of RSV nucleic acids by the endosomal TLRs (ex. TLR3, TLR7) leads to activation of a large set 
of transcription factors. This is necessary and critical for antibody production and affinity 
maturation [385]. Since most TLRs share the same set of downstream effectors/mediators, in the 
context of RSV vaccine, similar effects can be accomplished by the inclusion of TLR agonists as 
adjuvants in subunit vaccines. Furthermore, combinations of TLR ligands are also used to further 
improve vaccine efficacy and safety due to the synergistic effects of multiple adjuvants. 
Association of Th2-type immune responses with vaccine-induced ERD warranted the use of 
novel adjuvants that promote a protective Th1-type or balanced immune response to RSV. 
 RSV infection occurs at the mucosal surfaces of the URT. If not contained in the URT, 
RSV can also infect the lung as it is a pneumotropic virus [102]. Secretory antibodies play a key 
role in protection against RSV. RSV-specific nasal IgA is more important than serum IgG in 
conferring protection against RSV [387]. Therefore, our goal was to develop subunit vaccine with 
an adjuvant platform that would facilitate mucosal delivery. In a study by Schulz et al, 
poly(I:C),when used as a TLR agonist,was found to promote cross-presentation that involved 
activation of DCs due to signaling through the dsRNA receptor, TLR3. This subsequently led to 
an effector cytotoxic CD8+ T cell response (cross-priming) to virus-infected cells [388]. 
Induction of a cytotoxic CD8+ T cell response is an important requirement for optimal protection 
against RSV [65]. Furthermore, Lee et al reported that vaccine-induced CD8+ T cells are 
protective against RSV. This was demonstrated by immunizing mice with a peptide representing 
an immunodominant CD8 epitope mixed with poly(I:C) and a costimulatory CD40 antibody. The 
effector anti-RSV CD8+ T cells that were induced due to vaccination were found to be protective 
against RSV infection and pathogenesis [389]. 
In the present study, we used poly(I:C) and two other adjuvants, the host defence peptide 
IDR1002, and the water-soluble polymer, PCEP, as a combination adjuvant platform (TriAdj) in 
our RSV subunit vaccine formulation (ΔF/TriAdj) containing the truncated version of the RSV 
fusion protein (ΔF) as the main protective antigen. In the field of vaccine research, there is 
considerable activity in pursuit of novel antigens that can generate robust adaptive immune 
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responses. However, in the last few years, much attention is now focussed on understanding how 
vaccines elicit innate immune responses. The two classical arms of the immune system, innate 
and adaptive, are not mutually exclusive as innate immune responses strongly dictate adaptive 
immunity. Poor induction of innate immunity by a vaccine leads to an inferior adaptive immune 
response, both qualitatively and quantitatively. The present study was undertaken to investigate 
the mechanisms by which ΔF/TriAdj promotes innate immune responses.  This provides an 
understanding of the mechanism of action of ΔF/TriAdj and explains the protective efficacy of 
this RSV subunit vaccine candidate. 
Following intranasal deposition of antigens and depending upon the extent of 
dissemination from the nasal cavity to the LRT, there may be two possible antigen uptake sites, 
one in the URT (nasal passages) and the other in the LRT (lung). The nasal passages consist of 
the nasal turbinates, septum, lateral walls and NALT. For intranasal vaccines, the NALT is 
considered to be an important inductive site of mucosal immunity to captured antigens in the 
URT [390]. While there are multiple studies on theinduction of immune responses in the lung 
upon intranasal immunization, there are relatively few studies on the initiation of immune 
responses in the URT. Intranasal administration of an antigen in combination with cholera toxin 
as a mucosal adjuvant generated antigen-specific IgA-committed B cells and memory B cells in 
the nasal passages [391]. Another study revealed that intranasal immunization with an adjuvant-
formulated influenza vaccine in mice led to IgA production in the nasal wash [270]. These 
studies suggest that the NALT and CLNs in the URT may prove to be important targets for 
intranasal immunization.  
ΔF/TriAdj significantly enhanced the mRNA expression of chemoattractants for DCs, 
macrophages and neutrophils in the nasal tissues, which in turn induced significantly higher 
influx of these cell types in the NALT. It is interesting to note that the influx of the immune cells, 
including DCs, in the NALT is an earlier event while the influx of DCs into the CLNs is a late 
event, suggesting the NALT to be more an antigen uptake site and the CLNs an inductive site. In 
contrast, the overall secretion of chemokines and pro-inflammatory cytokines induced by 
ΔF/TriAdj was considerably higher and long-lived in the lung than in the nasal tissue. The 
infiltration of immune cells into the lung also continued for a longer period of time than that in 
the NALT, possibly suggesting persistent and gradual release of vaccine components in the LRT 
when compared to the URT.  
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Similar to the CLNs, DCs also showed increased influx into the TLNs towards later time 
points, possibly to initiate adaptive immune responses. The role of ΔF/TriAdj in the activation of 
immune cells was noted in both URT and LRT. However, in contrast to the NALT, in the lung 
significant increases in the number of activated DCs were detected in the ΔF/TriAdj group at all 
time points. This suggests greater ability of the ΔF/TriAdj to activate DCs in the lung than in the 
NALT, possibly due to overall higher induction of gene expression and greater production of 
chemokines and cytokines in the lung than the nasal tissues. We observed that immunization of 
ΔF/TriAdj results in secretion of chemokines, infiltration and activation of immune cells. 
Activated immune cells also secrete pro-inflammatory cytokines. These events represent an 
interdependent positive feedback loop that leads to the co-localization of DCs, macrophages and 
neutrophils that in turn, enables cross talk between various types of cell populations.Thus 
intranasal delivery of ΔF/TriAdj induced innate immune changes in the URT as well as in the 
LRT in both similar and unique ways. Secretory mucosal IgA is an important tool in fighting off 
RSV infection in the nasal epithelium. ΔF/TriAdj elicited significantly higher IgA titres than 
ΔF/PBS or PBS in the nasal washes, BAL and LFC supernatants. Indeed, significant amounts of 
IgG1 and IgG2a were present in the serum of the ΔF/TriAdj group, suggesting that ΔF/TriAdj 
leads to a balanced Th1/Th2 immune response. Thus, intranasal delivery of ΔF/TriAdj led to the 
induction of mucosal and systemic immune responses in both URT and LRT. In summary, we 
identified three possible mechanismsby which intranasallyadministered TriAdj in formulation 
with ΔF protein exerts its adjuvanticity in the URT and LRT as follows: a) ability to induce local 
production of chemokines and pro-inflammatory cytokines, b) ability to enhance trafficking of 
DCs, macrophages and neutrophils, c) ability to activate those immune cells by inducing 
expression of co-stimulatory and activation molecules, thereby facilitating subsequent generation 
of humoral immune responses.  
 Next, we focussed on the characterization of the mode of action of ΔF/TriAdj at the 
signaling level, as it is important to know the innate immune signaling requirements of any 
vaccine. This knowledge helps us in understanding the immunological mechanisms by which 
vaccines work and also in studying the safety and immunogenicity profiles of both licensed and 
experimental vaccines [260, 300]. PRR signaling in APCs such as macrophages is involved in a 
myriad of functions, namely phagocytosis, activation and maturation of APCs, as well as 
production of chemokines, pro-inflammatory cytokines, type I IFNs and other proteins involved 
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in modulation of PRR signaling [315, 392]. In our in vivo study, we observed active infiltration 
of macrophages in the respiratory mucosal tissues in the immunized mice following intranasal 
delivery of ΔF/TriAdj [176]. ΔF/TriAdj also led to activation of the macrophages by inducing co-
stimulatory markers. Therefore, we characterized the effects of ΔF/TriAdj on a murine 
macrophage cell line, RAW264.7, and murine bone marrow-derived macrophages. A gene 
expression analysis of the putative receptors in RAW264.7 cells and BMMs revealed that 
ΔF/TriAdj induced gene expression of the endosomal TLR3 as well as the cytosolic PRRs, such 
as RIG-I, MDA5, LGP2 and NLRP3 in a spatio-temporal fashion. These results suggested an 
important role of both cytosolic and endosomal receptors in ΔF/TriAdj-mediated PRR signaling 
events. 
Downstream signaling effects mediated by these PRRs result in the induction of 
chemokines and pro-inflammatory cytokines. Upon binding to specific cell-surface receptors, 
chemokine messages are decoded and the receptors then unleash intracellular signal transduction 
events leading to various cellular responses [278]. A multi-phasic mode of induction of the 
downstream effector molecules was observed, which was consistent with the fact that PRR-
induced genes are classified into three categories: early primary response genes, late primary 
response genes and secondary response genes based on their transcriptional requirements [331]. 
Th-1 biased adaptive immunity is frequently linked to adjuvants that drive PRR activation to 
trigger production of pro-inflammatory cytokines (and increased Th1 response). Such qualities in 
any adjuvant, as we observed for TriAdj, are desirable for a better and improved RSV subunit 
vaccine [315]. 
IFN-β, regulated by the IRF7, plays a critical role in up-regulation of immune co-
stimulatory molecules on APCs and governs the induction of CD8+ T cell responses [317], [332]. 
IFN-β interacts with Type I IFN receptors in a feedback loop to cause activation of macrophages 
via up-regulation of co-stimulatory molecules [317]. After checking the ability of ΔF/TriAdj to 
mediatesecretory effector responses in macrophages, we found that ΔF/TriAdj stimulation also 
induced IRF7mRNA that in turn correlated to high induction of IFN-β. The final outcome of 
IFN-β signaling via IRF7 was also reflected in the expression of MHCII and co-stimulatory 
molecules, CD40, CD80 and CD86, demonstrating the ability of ΔF/TriAdj to activate 
macrophages.  
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PRR stimulation is also responsible for stimulating a common set of core signaling 
pathways involvingvarious signaling kinases and transcription factors [320, 331, 393]. Chemical 
inhibitors were used to identify the signal transduction pathways involved in the chemokine- and 
cytokine-inducing activity of ΔF/TriAdj due to PRR signaling. The working concentrations of 
these inhibitorswere selected based on dose titration results and their individual IC50values, and 
were well below their cytotoxic dose to avoid any non-specific or off-target effects. Use of a 
broad-spectrum kinase inhibitor clearly revealed that protein kinases indeed play a critical role in 
ΔF/TriAdj-mediated signaling events. Use of specific inhibitors against three MAPKs further 
revealed that p38 MAPK may play an important role in ΔF/TriAdj-mediated secretion of CXCL-
10 and possibly TNF-α, but not CC-chemokines. ERK1/2 signaling appeared to have a stronger 
role in ΔF/TriAdj-mediated production of chemokines and pro-inflammatory cytokines. The JNK 
MAPK pathway was found to be strongly involved in ΔF/TriAdj-mediated chemokine and pro-
inflammatory cytokine production. NF-κB pathways did not have any critical role in ΔF/TriAdj-
mediated chemokine production, while TNF-α and IL-6 production was minimally reduced by 
the use of NF-κB inhibitor. In contrast, both CaMKII and PI3K pathways were found to play a 
major role in the induction of chemokine and cytokine secretion in response to ΔF/TriAdj. IRF-7 
mediated IFN-β may trigger JAK/STAT, Raf-MEK/ERK and PI3K pathways [322]. The JAK 
pathway is also involved in transducing signals from IFN-β to upregulate the surface expression 
of immune markers. Inhibition of JAK pathway resulted in complete abrogation of ΔF/TriAdj-
mediated CCL2, CCL4, CXCL-10 an IL-6 production. Inhibition of the JAK pathway also 
resulted in significant reduction in cell surface immune markers, MHC-II, CD40, CD80 and 
CD86 induced in response to ΔF/TriAdj.  
Therefore, in this study themacrophage was found to respond directly to ΔF/TriAdj, 
which supports our previous in vivocell influx results [176]. We also found that ΔF/TriAdj is 
responsible for activation of macrophages by inducing gene expression of multiple PRRs, TLR3, 
RIG-I, MDA5, LGP2 and NLRP3. This resulted in broad chemokine and cytokine responses. 
Using specific biochemical inhibitors as probes of various signal transduction events helped to 
get an overview of the signaling requirements for ΔF/TriAdj-induced secretory responses in the 
macrophages. The results demonstrated that the JNK, ERK1/2, CaMKII, PI3K and JAK 
pathways played an important role, while the p38 and NF-κB pathways appeared to be minimally 
involved. Since no PRR gene expression or chemokine and cytokine production was observed in 
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response to ΔF/PBS, the results from this study helped to advance our understanding of the 
molecular action of TriAdj and reaffirmed the importance of formulation of ΔF with this 
combination adjuvant to promote polyvalent and synergistic immune responses.  
Subsequently, we conducted a comprehensive metabolomics study to gain a better 
understanding of the mechanism of action of ΔF/TriAdj in eliciting protectionagainst RSV. 
Metabolomics provide an important tool in the identification of metabolites, the end stage 
products of biological processes [394]. Metabolite levels can be affected by diseases or other 
perturbations due to various factors such as drugs, vaccines and other external stimuli [336, 
345].A multiplex chemokine/cytokine ELISA was performed to investigate chemokine/cytokine 
changes, while integrated LC-MS-based metabolomics was conducted to investigate metabolic 
alterations due to RSV infection. Therefore, this study helped us in gaining a comprehensive 
understanding of the inflammatory response-associated alterations in the lung metabolome profile 
in RSV-challenged mice, and modulation of lung metabolite changes in ΔF/TriAdj vaccinated 
RSV-challenged mice. 
Induction of inflammatory mediators by RSV infection was higher between days 2 and 6 
p.c. as demonstrated bytranscriptomic analysis of the RSV-infected lung tissues. Since 
metabolites represent the final downstream end products of gene expression and cellular 
activities, day 7 p.c. was selected as the later time point for all studies [263, 374]. In addition, day 
1 p.c. was also included as an earlier time point for the immunological studies to investigate the 
early effects in both ΔF/TriAdj vaccinated and unvaccinated RSV-infected mice, as well as 
healthy control mice. An analysis of the kinetics of RSV infection revealed that at day 4 p.c., 
RSV replication was at its peak, while the virus wascompletely cleared by day 8 p.c. A 
comparison of the gene expression profiles of inflammatory cytokines, chemokines and IFNs 
between RSV-infected and ΔF/TriAdj vaccinated RSV-infected mice revealed that induction of 
most of the inflammatory mediators was comparable between unvaccinated and vaccinated mice 
at day 1 p.c. However, at day 7 p.c., induction of inflammatory mediators was significantly 
higher in the RSV-infected micethan the vaccinated RSV-infected mice. Significantly higher 
influx of DCs, macrophages, neutrophils and NK cells was observed in the lungs of the RSV-
infected mice than those of the ΔF/TriAdj vaccinated RSV-infected mice at day 7 p.c., indicating 
unchecked inflammatory responses due to sustained induction of inflammatory mediators. These 
heightened inflammatory responses in the RSV-infected group at a time when the viral load has 
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substantially decreased suggestedthe contribution of host factors and/or host immune responses 
in the unchecked inflammatory responses in this group. On the other hand, ΔF/TriAdj was found 
to play a critical role in dampening or moderating excessive or heightened inflammatory 
responses in the vaccinated RSV-infected group at day 7 p.c. Furthermore, ΔF/TriAdj induced 
significantly higher influx of DCs and CD4+ T cells into the lung-dLNs, which was reflected in 
significantly elevated levels of RSV ΔF-specific IgA in the BALF and RSV ΔF-specific IgG1 
and IgG2a in the sera at day 7 p.c. in the vaccinated RSV-infected group than the RSV-infected 
group. This confirms a role of ΔF/TriAdj in inducing memory or recall responses. 
Metabolomic profiling was conducted with the lung tissues using a CIL LC-MS-based 
approach. Dansyl chloride labeling was performed to identify amine/phenol submetabolome. 
Metabolites were putatively identified by comparing their m/z masses against accurate mass 
database search using MyCompoundID library [359]. ANOVA analysis of the significantly 
altered Dansyl chloride labeled-metabolic features revealed that RSV altered tryptophan 
metabolism as evidenced by either significantly increased (indole, L-Kynurenine and 6-
hydroxymelatonin) or significantly decreased production of tryptophan metabolites (xanthurenic 
acid, serotonin and 5-hydroxyindoleacetic acid)in the RSV-infected group than thehealthy control 
group. ΔF/TriAdj played an important role in modulating RSV-induced alteration of the 
tryptophan metabolic pathway. Tryptophan is an essential amino acid. Alteration of tryptophan 
metabolism is considered as a marker of inflammation and is responsible for inflammatory 
diseases [345]. The alteration of tryptophan pathway by RSV was further evidenced by increased 
expression of IDO-1 (as well as IDO-inducers such as IFN-β, IFN-γ and IL-10) in the RSV-
infected group, while ΔF/TriAdj suppressed IDO-1 expression; this provides mechanism by 
which ΔF/TriAdj was able to modulate RSV-induced alteration of tryptophan metabolites.  
 In addition to the tryptophan pathway, RSV also altered pathways involved in amino acid 
biosynthesis, including arginine biosynthesis, urea cycle and tyrosine metabolism. Concentrations 
of all four metabolites (citrulline, arginine, ornithine and putrescine) involved in the urea cycle 
were significantly increased in the lung of RSV-infected mice. In contrast, ΔF/TriAdj was found 
to play an important role in modulating and/or restoration of the altered levels of these 
metabolites in the lung of the vaccinated RSV-infected mice. Significantly higher production of 
metabolites involved in amino acid biosynthesis (such as glycine, L-Threonine and aminoadipic 
acid) and tyrosine metabolism (such as hydroxyphenlyllactic acid and desaminotyrosine) was 
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observed in the lung of RSV-infected mice than in healthy control mice. Importantly, ΔF/TriAdj 
also modulated and/or restoredthe concentrations of the metabolites of the above pathways.In 
addition, we found alterations in lipid metabolism due to RSV infection and ΔF/TriAdj was 
found to play an important role in modulating altered lipid profile. 
Several reports have demonstrated a correlation between immunological and metabolic 
pathways.Combining immune an analysis with metabolic profiling has important implications in 
vaccine research [261, 263], because metabolites act on immune cell receptors and regulate cell-
signaling pathways[263]. Metabolites are critical regulators of immune cell functions and airway 
inflammation is often linked to altered levels of pulmonary metabolites [261, 262]. Inflammatory 
responses are also linked to altered levels of pulmonary metabolites [336, 345, 348]. The 
alteration of tryptophan metabolism, and amino acid biosynthesis, especially arginine 
biosynthesis, urea cycle and tyrosine metabolism, can be attributed to the heightened and 
sustained inflammatory responses in the lung of the RSV-infected mice, while the modulation of 
the metabolites of the above altered pathways may beresponsible for reduced inflammatory 
responses in the lung of the vaccinated RSV-infected mice. Therefore, the present study 
underscores the role of distinct metabolic pathways involved in inflammatory responses elicited 
by RSV and/or host immune responses. In parallel, this studyalso demonstrated the role of 
ΔF/TriAdj in ameliorating the outcome of such inflammatory responses by moderating/restoring 
the metabolic pathways altered due to RSV infection. 
Overall, this study shed light on the mechanism of action of this RSV vaccine candidate 
with TriAdj as a combination adjuvant platform. The adjuvanticity of TriAdj is not restricted to 
RSV only. Protective efficacy of vaccines using this combination adjuvant has been 
demonstrated against several pathogens including bovine viral diarrhea virus, bovine respiratory 
syncytial virus, porcine epidemic diarrhea virus, swine influenza and chlamydia [92, 395-399]. 
Efficacy of TriAdj has been tested in a variety of animals including cotton rats, sheep, pig, cattle 
and koalas[259, 398-400]. Strong and protective immune responses were elicited when mice and 
pigs previously immunized with pertussis toxoid from Bordetella pertussis formulated with 
TriAdj, were lethally infected with B. pertussis [400, 401]. The reason for protective efficacy of 
vaccine candidates containing TriAdj as combination adjuvant can be attributed to the fact that 
formulation of subunit vaccines with TriAdj leads to a much earlier onset of immune responses 
(due to activation of innate immunity) and long-lasting adaptive immunity [258]. At the innate 
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level, TriAdj is responsible for induction of chemokines, cytokines and IFN responses (via 
multiple signaling pathways as demonstrated ex vivo) that create an immunostimulatory 
environment, facilitating recruitment of innate immune cells. TriAdj was also responsible for 
enhanced uptake of antigen by DCs and efficient transportation of antigen-loaded DCs to the 
local draining lymph nodes for presentation to the T cells [102]. Upregulation of co-stimulatory 
immune markers (as we found for TriAdj) is critical for optimal priming and activation of CD4+ 
as well as CD8+ T cells. This indeed was reflected in induction of antigen-specific mucosal IgA, 
systemic IgG responses including affinity maturation of IgG, virus-neutralizing antibodies, 
increased number of IgA-secreting memory B cells, and antigen-specific memory CD8+ T cells 
[102, 402]. This is in line with the immunological goals of a successful RSV vaccine candidate 
requiring both humoral and cell-mediated immunity to prevent RSV infection. In this study, nasal 
innate immune responses were not as robust as those in the lung. This may be overcome by 
inclusion of a mucoadhesive compounds such as chitosan, a safe mucosal adjuvant for use in 
intranasal vaccines, having good tolerability and excellent immune stimulating properties as 
demonstrated in clinical studies [403]. Alternatively, this combination adjuvant can be designed 
into microspheres (100 nm- 2 μm) for efficient uptake by M cells in the nasal passages following 
intranasal immunization [399]. 
 
10.3 Future directions  
 
In the present study, we found that signaling events induced by the endosomal receptor 
TLR3, and the cytoplasmic receptors, RIG-I and MDA5 play an important role in macrophage 
activation and induction of effector responses by the macrophagesin vitro and ex vivo. This can 
be extended to animal studiesin vivo, where we can further elucidate the role of endosomal and 
cytoplasmic receptors in induction of adaptive immune responses in vaccinated mice. We can 
also compare the adaptive immune response in vaccinated mice with that in unvaccinated mice 
following RSV challenge. Since the downstream signaling of the endosomal and cytosolic 
receptors converge into two principal adaptors, TRIF for TLR3 and IPS-1 for RIG-I and MDA5, 
we can use TRIF-/-, IPS-1-/- and TRIF-/-IPS-1-/- double knockout mice strains. TLR3 signaling 
via TRIF is known to induce protective innate immune responses against respiratory viruses 
[404]. On the other hand, IPS-1 signaling is known to play a non-redundant role in mediating 
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antiviral responses and conferring protection against RSV [405]. In another study, it was also 
reported that both TRIF- and IPS-1-dependent signaling pathways are responsible for adjuvant-
induced antibody and CTL responses [406]. So it will be interesting to find out if TLR3 signaling 
via TRIF, or RIG-I/MDA5 signaling via IPS-1, is involved in the induction of innate, cellular and 
humoral immune responses induced by immunization with ΔF/TriAdj. Moreover, studies with 
these knockout mice strains will allow us to elucidate if endosomal TLR3 or cytosolic RLR 
signaling playsany role in conferring protection against RSV. If we find any such role, we can 
also investigate if that role is redundant or not. This will help us to understand if cooperative 
activation of endosomal TLR3 and cytosolic RNA helicases are required for the in vivo adjuvant 
activity of ΔF/TriAdj. 
 Identification of systemic biomarkers of vaccine immunogenicity and efficacy is one of 
the most important applications of metabolomics [263]. Metabolomics is employed not only to 
identify the immune pathways activated in response to vaccination but also can be used to predict 
vaccine efficacy in different target populations before actual vaccine efficacy studies [252]. Gray 
etal recently conducted differentiation of infected from vaccinated animals (DIVA) 
metabolomics to identify metabolic markers that can differentiate between vaccinated and non-
vaccinated animals[394]. Furthermore, the future of metabolomics lies in development of 
therapeutics or preventive medicine, as well as personalized medicine [407]. ΔF/TriAdj can be 
used for all these potential applications in the future. As the next step, an animal experiment can 
be designed in which mice will be vaccinated with ΔF/TriAdj, to check if there is any alteration 
of the metabolic profile. The altered profile can then be compared to the resulting immune 
responses of the vaccinated mice, such that correlations between certain metabolites and the 
subsequent magnitude and quality of the immune responses, as well as level of protection, can be 
made. This will allow us to identify early biomarkers induced by ΔF/TriAdj that are predictors of 
immunogenicity and protection. 
We also demonstrated that RSV alters tryptophan metabolism, amino acid biosynthesis, 
especially arginine biosynthesis, as well as urea cycle and tyrosine metabolism,and that 
ΔF/TriAdj was found to play an important role in modulating/restoring the altered levels of 
metabolites of the above mentioned pathways. We identified several amine/phenol-
submetabolites that were altered by RSV and modulated by ΔF/TriAdj. However, recent reports 
provide evidence that RSV also alters metabolites belonging to different classes and involved 
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inother metabolic pathways. For instance, Atzei et al first reported that compared to healthy pre-
term neonates, three metabolites, creatinine, betaine and glycine were reduced in pre-term infants 
hospitalized due to RSV bronchiolitis [408], while according to another group, 5 metabolites 
(citrate, glycine, creatine, ascorbate and 1-methylnicotinamide) were significantly decreased 
during acute RSV infection. Urinary metabolome profiling of RSV-infected infants also revealed 
alteration of leukotriene and vitamin B metabolic pathways [409]. In another study, RSV 
infection in BALB/c mice altered 11 biomarkers in plasma and 16 biomarkers in lung, 
representing metabolic pathways that involve glycerophosphocholines, sphingolipids and 
glycerolipids, and that these altered metabolites were corrected by the use of a medicinal formula 
[356]. Furthermore, metabolites involved in the citric acid cycle, such as citrate, succinate and 
trans-aconitate, are highly relevant in the context of respiratory viral infections [360]. Therefore, 
in the future, it would be very interesting to investigate the role of ΔF/TriAdj in preventing or 
correcting RSV-induced alterations (if any) of metabolites belonging to different classes, 
including carboxylic acids, bile acid, vitamins as well as glyceride, non-glyceride and complex 
lipids. Pathway analysis of these metabolites will also help us to gain a comprehensive 
understanding of the mechanism of action of ΔF/TriAdj at the level of metabolism-related 
pathways. 
In the present study, we have investigated the effect of ΔF/TriAdj only in RSV-infected 
lung tissues. Lung is the primary site of RSV replication and therefore, represents an ideal site for 
sampling to study the metabolites.However, collection of lung tissue specimens from human 
subjects is an invasive technique, and not at all suitable for the neonates, the infants and the 
elderly. An alternative approach would be to use BALF or bronchial brushings. However, these 
methods of sample collection are also uncomfortable and at times, not feasible.Plasma 
samplesprovide another alternative for metabolomic profile analyses owing to its ease in 
collection. Besides, several metabolites have been detected in plasma, which are associated with 
vaccine-induced systemic immune responses [394]. Urine is another important sample type, and 
collection of urine samples probably provides the safest and easiest approach for metabolomic 
profiling. Nuclear magnetic resonance (NMR) studies have previously established that urine is a 
rich source of metabolites and less adulterated with cellular and protein contents [360]. So as a 
future direction, we could also use BALF, plasma and urine samples to elucidate the role of 
ΔF/TriAdj in correcting/restoring any metabolic alteration induced due to RSV infection. 
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